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1. Introduction 
Overweight and obesity, commonly defined as a body mass index (BMI) of more than 
25 kg/m² according to criteria of the World Health Organization (WHO) [1], are major public 
health problems in Germany. According to a representative nationwide health survey, two 
third of the male and more than half of the female population aged 18-79 years are 
overweight or obese [2]. Longitudinal data based on this study suggests that the number of 
overweight and obese individuals may still increase within the next years or stabilizes on a 
high level, respectively [3].  
Overweight is associated with a variety of comorbidities such as hypertension and an 
increased risk for type 2 diabetes (T2D), cardiovascular disease (CVD) and several types of 
cancer [4-6]. Thus, overweight and obese people suffer more often from chronic disease 
conditions and their quality of life is markedly decreased. Based on trend calculations from 
the WHO dealing with obesity prevalence in Europe on the basis of only a moderate increase 
till 2020 [7], total expenses on obesity in Germany will increase to at least 25.7 billion € [8]. 
Thus, obesity is a risk factor with an enormous attributable risk for a lot of associated 
diseases and high attributable costs. 
Body weight gain independent of initial BMI was reported to be an independent risk 
factor for e.g. T2D [9, 10]. Even on high BMI levels, body weight gain will increase the 
chronic disease risk even more. As mentioned before, tendencies of a representative 
nationwide survey showed that prevalence of overweight and obesity will either stabilize on a 
high level or increase even more [3]. Furthermore, there are partly strong differences in 
weight-gaining individuals regarding site of body fat accumulation resulting in different body 
fat distribution phenotypes [11]. 
A lot of research has been done regarding determinants of body weight gain 
(including metabolic and hormonal determinants). Especially resting metabolic rate, 
respiratory quotient as an indirect measure of fat oxidation, insulin sensitivity, inflammatory 
markers or hormonal levels of e.g. leptin and ghrelin have been shown as being associated 
with overweight and obesity [12-14]. Those studies were focussing on body weight gain as 
their primary objective. Within the last years, evidence increased showing body fat 
distribution to be a very important risk factor for comorbidities [15-17].  
So far, the scope of metabolic determinants focused mainly on body weight gain but 
studies investigating especially future waist or hip gain are lacking, in particular using 
metabolomics approaches. The present thesis aims to to cover this lack of information. 
 Background 
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2. Background 
2.1. Definition of overweight and obesity 
Obesity is commonly defined as an excess of body fat. Individuals exceeding a BMI of 
25 kg/m² are defined as overweight wheras individuals with a BMI above 30 kg/m² are 
defined as obese [1]. In a policy paper of 2000, the WHO defined obesity as a disease due to 
its etiological, pathological and pathophysiological aspects [1]. Even the European 
parliament has requested its member states in 2006 to own the definition of obesity as a 
chronic disease. Nevertheless, the German health care system did not own this definition yet 
despite the Federal Social Court gave a verdict in 2003, that obesity is a disease based on 
German health insurance law (BSGE 59, 119 (121)). In Germany, obesity only relates to an 
excess of body fat whereas most people are aware of the associated conditions. 
 
2.2. Obesity and body fat distribution 
An excess deposition of body fat on the trunk/abdomen is called upper body, 
abdominal or android obesity; whereas an excess deposition of body fat in the gluteofemoral 
region arround the limbs and buttocks is called lower body, peripheral or gynoid obesity 
(Figure 1) [18]. The French physician Jean Vague was the first to describe these two 
different phenotypes of body fat distribution [11]. He noted differences in the distribution of 
adipose tissue between men and women and implemented the terms ‘android’ to describe 
abdominal body fat accumulation and ‘gynoid’ for the gluteofemoral body fat accumulation. 
Furthermore, he was the first to describe divergent associations of those two phenotypes 
with several diseases like diabetes mellitus, coronary heart disease and gout showing 
android body fat accumulation to be higher associated with these diseases. As mentioned 
before, the android phenotype of body fat distribution is reported to be more common in men 
and the gynoid phenotype to be more common in women. Nonetheless, either phenotype 
appears within each sex [11].  
 
Figure 1 Schematic illustration of gynoid and android body fat distribution (modified from 
Vitaleben GmbH [19]) 
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In general, there are two different types of adipose tissue which consists of 
adipocytes. Visceral adipose tissue is internal abdominal fat and located inside the peritoneal 
cavity surrounding the internal organs. It accounts for 10-20% of total fat in men and 5-8% of 
total fat in women and is characterized by rich blood supply through higher vascularization 
[20]. Subcutaneous adipose tissue accounts for approximately 80% of total body fat mass 
and is located under the layer of skin [21]. Abdominal obesity is often accompanied by whole 
body obesity. These two different types of adipose tissue differ in their structure and cell size 
(between 20 – 200 µm). Adipocytes are the main storage of energy in the human body in 
form of triglyceride depots. Newly built adipocytes are smaller and have a higher ability of 
absorbing free fatty acids and triglycerides from the circulatory system. When adipocytes 
become larger, they become dysfunctional e.g. insulin-resistant and hyperlipolytic [20]. 
Largest adipocytes can be found in the abdominal area, smallest adipocytes in the 
gluteofemoral area [20].  
Today, the gold-standard to assess the different types of adipose tissue would be the 
use of Computer Tomography (CT) and Magnetic Resonance Imaging (MRI) [22]. 
Unfortunately, these methods are very costly and time consuming and therefore impractical 
to use in large-scaled epidemiological studies. An alternative and the most commonly used 
measures are waist circumference or waist-to-hip ratio (WHR) to describe abdominal obesity. 
These measures are easy to perform, cheap to assess and they show good reliability in the 
assessment of abdominal and visceral adipose tissue [23-26]. There is some evidence that 
waist circumference is more suitable to assess abdominal obesity than WHR [27]. For waist 
circumference, increased risk for comorbidities is considered for values above 88 cm for 
women and 102 cm for men [28, 29]. 
Body fat distribution is strongly individual and a large variation of this distribution is to 
be explained by genetic variations [30]. At the end of the last century, the influence of 
genetics on body fat distribution was discussed and scientists were aware of these impacts. 
Since then, a lot of genes have been identified that are associated and responsible for the 
accumulation of adipose tissue in the abdominal or gluteofemoral region. Population-based 
and twin-studies estimated the influence of genes on the distribution of body fat with 20-60% 
[30-32]. The other factors mainly influencing this distribution are hormonal. This is obvious, 
because usually body shape differs noticeable between men and women. On the one hand, 
in particular oestrogen and prolactin were reported to promote the deposition of fat in the 
gluteofemoral region of the human body [33]. Age shows as well major impact on body fat 
distribution. With increasing age, both sexes tend to redistribute their body fat in the 
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abdominal region due to hormonal changes, in particular decline of oestrogen in women and 
attenuated production of androgens in men [21].  
Obesity-related metabolic consequences were shown to be stronger associated with 
android phenotype in comparison to gynoid phenotype [34-38]. Abdominal fat accumulation 
and increased visceral fat is accompanied by unfavourable metabolic changes due to its role 
as an endocrine organ [13, 21, 39], the impaired metabolic pathways are highly affected. In 
contrast, higher hip circumference represents gluteofemoral and peripheral adipose tissue 
and therefore subcutaneous, non-visceral fat [40]. There is strong evidence, that increased 
waist circumference is associated with an increased risk for the above mentioned diseases 
[9, 17, 28] but most of these studies neglect the role of hip circumference.   
There is evidence, that hip circumference has an important impact on the risk of 
overall mortality and risk of CVD, diabetes and insulin sensitivity with an adverse effect of low 
hip circumference and of even inverse risk association of these peripheral fat compartments 
[15, 34-38, 41]. 
But not only the single circumferences are of interest, especially the relation of both 
anthropometric markers to each other is reported to be a key factor of chronic disease risk. 
The negative effect of abdominal obesity on individual health status should be interpreted 
with regard to hip circumference [42-44]. Both high waist circumference and low hip 
circumference have been reported as being associated with CVD risk and Cameron et al. 
[45] reported a serious underestimation of the effect of abdominal obesity on CVD risk when 
neglecting the effect of hip circumference. 
On the other hand, high hip circumference has a suggestive protective effect on 
chronic disease risk, Heitmann et al. [43] reported the necessity to interpret the effects of hip 
circumference only with regard to waist circumference, BMI or both, too. Hip circumference 
and BMI are correlated and this may confound the true association between hip and chronic 
disease risk – resulting in a false positive association of hip circumference and disease risk. 
It has been reported that high hip circumference attenuates the risk association based on 
large waist circumference [16, 37] – thus not only the WHR – an established anthropometric 
marker of risk - but also the difference of these anthropometric markers could be a very 
interesting risk marker.  
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2.3. Overweight, obesity and their association to chronic diseases 
Overweight and obesity are associated with several chronic diseases e.g. T2D, CVD 
like myocardial infarction or stroke and several types of cancer [5, 6, 46]. With increasing 
body fat mass, people are more likely to develop metabolic consequences which result in 
increased chronic disease risk. A lot of metabolic pathways are affected, e.g. blood lipid 
metabolism with increased low density lipoprotein (LDL), decreased high density lipoprotein 
(HDL) and hypertriglyceridemia which is commonly described as dyslipidaemia [47]; impaired 
glucose metabolism with insulin resistance resulting in increased levels of fasting insulin and 
blood glucose and chronic low-grade inflammation [48, 49]. Thus, overweight and obese 
people may develop hypertension, diabetes and atherosclerosis which will put them on high 
risk for e.g. CVD (Figure 2). Statistics show that 58% of diabetes and 21% of ischemic heart 
disease are attributable to a BMI above 21 [50]. 
 Furthermore, obesity increases the risk of many types of cancer. Strong evidence 
exists especially for oesophagus, pancreas, colon and rectum, kidney, thyroid, gallbladder, 
endometrium and postmenopausal breast cancer [51]. Evidence exists that body weight, 
weight gain and obesity are responsible for approximately 20% of all cancer cases [6, 52].  
  
Figure 2 Overview for selected comorbidities and their increased risk due to obesity 
(BMI≥30) (modified according to WHO, 2000 [1]) 
Although obesity is clearly associated with metabolic and hormonal disturbances, no 
single metabolic or hormonal characteristic strongly predicts future weight gain. The literature 
underscores the complex pathophysiology of obesity and the methodological challenges 
facing epidemiologic research on metabolic risk factors and weight gain. Current evidence 
suggests that for most people, body weight gain is probably not a consequence of metabolic 
defects, but rather a result of many metabolic disturbances caused by a combination of 
behavioural and environmental factors, such as unhealthy diet and decreased physical 
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activity [53]. Nonetheless, further research is needed to understand the heterogeneity in 
metabolic responses to the obesogenic environment.  
There are numerous studies reporting distribution of body fat as a more important 
factor regarding elevated risk for those chronic diseases than weight gain [15-17]. In the 
1980s, major progress was made in terms of metabolic implications of different body shapes 
in pathophysiological pathways. Evidence of increased risk for CVD and T2D could be 
strengthened. Additionally, impaired glucose tolerance, insulin resistance and fasting 
hyperinsulinemia where pointed out as the underlying pathophysiological process. 
Hypertriglyceridemia, hypercholesterinaemia and lower HDL cholesterol accompanied with 
hypertension and increased risk for stroke and coronary heart disease were reported for 
people that tend to have a large waist circumference [48, 54-58]. 
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2.4. Causes of obesity  
The causes of obesity are multifactorial and cover endogenic and exogenic factors 
(Figure 3). Besides family history (genetic disposition) or health-related causes (e.g. Cushing 
syndrome, hypothyroidism), obesity and substantial weight gain is mostly explained with 
sedentary lifestyle factors like hypercaloric diet and physical inactivity [53]. Indeed, it is of 
interest whether people tend to gain weight at their waist or at their hip due to different 
associations with chronic disease risk. 
 
Figure 3 Selected causes of obesity (modified from DAG e.V. guidelines 2014 [59]) 
As mentioned before, obesity has major impact on the human metabolism and 
especially abdominal obesity is likely to affect several biochemical pathways due to the role 
of visceral adipose tissue as an endocrine organ. A lot of research has been done to identify 
and describe the relation of metabolic and hormonal determinants and predictors of body 
weight gain - thus in the development of obesity. A wide range has been covered including 
pro- and anti-inflammatory markers [13, 60, 61], liver enzymes, hormones and especially 
markers of insulin sensitivity [12, 62, 63]. There is no clear evidence that these factors are 
likely to favour weight gain and a lot of studies are restricted to specific populations and age 
groups. A reason could be the metabolic heterogeneity between populations, so results are 
not generalisable. 
Metabolic profiles are depending on three major influencing factors: age, sex and 
ethnicity [40]. Except of age, those factors are genetically given just like body fat distribution. 
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In these strongly varying profiles, the identification of biomarkers in terms of risk prediction is 
of major interest (metabolic biomarkers for predicting cardiovascular disease) [64, 65]. Single 
biomarker epidemiology is highly specific and sensitive, but on cost of a narrowed view on 
the metabolism. A possibility to get a deeper inside is given within the field of systems 
biology [66]. Systems biology is the study of biological systems that cannot easily be reduced 
to the sum of its single components. Therefore systems biology tries to understand 
organisms as a whole apart from single biomarker investigation. The science of 
metabolomics is one part of this systems biology approach and nowadays metabolic status 
can be efficiently determined by metabolomics. 
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2.5. Metabolomics 
Metabolomics is the fourth ‘omics’ research field besides genomics, transcriptomics 
and proteomics. Genomics covers the entity of all genes (about 25,000), transcriptomics is 
dealing with translational factors (about 10,000 mRNA), proteomics is especially dealing with 
enzymes and their activities (about 1,000,000 proteins) and last but not least the study of 
metabolomics which is about the entity of the human metabolome with all molecules below 
1500 Dalton (about 2500 metabolites) (Figure 4) [64, 67]. Within this four ‘omics’ research 
fields, the central dogma of molecular biology describes the information flow from genomic 
information (DNA) through mRNA transcripts, which are then translated to proteins and 
enzymes. These enzymes are directly influencing the 
concentrations of their substrates and products, which are 
integrated in tightly controlled metabolic pathways. Especially 
within subclasses of metabolites, different molecules may 
appear in the same metabolic pathways and could be easily 
transformed into one another via enzyme activities [68]. 
Therefore, from genomics to metabolomics, the knowledge is 
shifting from genotype to phenotype [69] according the central 
dogma of molecular biology [68].  
The study of metabolomics can be described as the 
study of metabolic profiling through systematic analysis of 
substrates and products of all biochemical pathways and aims 
to create snapshots of the human metabolome [67]. Metabolic 
profiling can be performed in nearly all biological samples, e.g. 
serum, plasma, urine or tissue samples. The comparison of 
results should be restricted on the same source of samples 
because concentration ranges of the chosen metabolites vary 
considerably in different tissues [70]. Within the field of 
metabolomics, we differentiate between targeted and 
untargeted approaches. 
2.5.1. Untargeted metabolomics 
Untargeted metabolomics aims to comprehensively measure all measurable 
metabolites of a sample and is not restricted to subclasses or specific pathways. 
Identification of many unknown metabolites after quantification is usually necessary, but this 
provides the opportunity of discovering novel metabolite species and pathways [71]. A 
Genomics 
•DNA 
Transcriptomics 
•mRNA 
Proteomics 
•Proteins  
Metabolomics 
•metabolites 
•    untargeted 
•    targeted 
Figure 4 Overview on the 
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common technique of untargeted metabolomics measurements includes the use of nuclear 
magnetic resonance (NMR) spectroscopy, but gas chromatography (GC) or liquid 
chromatography (LC) coupled with mass spectroscopy (MS) are used, too. NMR is able to 
detect a wide spectrum of metabolites. It is less sensitive than MS, but sensitive enough to 
identify metabolites in measurements of unmodified biological fluids. There is no necessity of 
an invasive and destructive sample preparation to make the metabolites measurable and is 
therefore well-suited for the use in untargeted metabolomics [66]. 
2.5.2. Targeted metabolomics 
The scope of targeted metabolomics is narrowed and quantifies pre-defined groups of 
chemically characterized metabolites - a subset of the metabolome [67]. This approach has 
the advantage that all quantified metabolites are already identified; results are more robust 
through the use of internal standards and show better comparability among each other. So, 
extensive understanding of physiological processes is possible on the basis of covered 
metabolic processes, enzyme kinetics and established pathways [67]. In comparison to 
untargeted metabolomics, data quality is improving at the expense of a narrowed view on the 
metabolome [71]. MS coupled with LC or GC (LC-MS and GC-MS) are often used to quantify 
metabolites in targeted metabolomics measurements. A key advantage of this method is its 
high sensitivity but MS requires the metabolites to be separated from the biological sample 
before detection and chemically modified to make them more volatile, especially if GC-MS is 
used. This treatment may damage unidentified metabolites and might give misleading results 
in untargeted metabolomics. So this method is more common within the field of targeted 
metabolomics where the quantification is based on already identified metabolites [66]. 
The platform reproducibility is a challenge to any targeted metabolomics experiment. 
Contributions from three sources of variance should be considered: system variance, 
variance introduced during sample preparation and the intra- and inter-individual biological 
variance. These confounders can be evaluated using a number of approaches [67]. 
Biological variance can be addressed using the coefficient of variation (CV). Either 
blood/serum or reference samples are measured multiple times on each plate or on several 
plates to get within-plate or between-plate variance, respectively. The standard deviation for 
those measures is divided by the mean value of the dataset for each metabolite to obtain the 
CV which is used with study-specific cut-offs as quality-control criteria.  
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2.5.3. Opportunities of metabolomics in obesity research 
The study of metabolomics is challenging in many ways. There are many factors 
influencing the human metabolome. Besides intrinsic factors like e.g. age, sex, genetics, 
health status and resting metabolic rate [40, 72-74] as well extrinsic factors like diet, physical 
activity, smoking, alcohol consumption and environment show identifiable impact on the 
human metabolome (Figure 5) [75-79]. All this influencing factors lead to metabolic 
phenotypes and individual metabolic profiles that can be measured using metabolomics 
approaches. 
The discovery that altered metabolite profiles are caused by certain diseases or by 
drug effects came up in the mid-1980s [66]. Since then, targeted metabolomics approaches 
have already been used to identify specific phenotypes that are prone to develop a disease 
of interest, e.g. T2D [65, 80-82] or identified altered metabolic profiles in individuals with 
prevalent diseases e.g. Parkinson´s disease, CVD or cancer [83-86].  
Furthermore, targeted metabolomics approaches have been investigated regarding 
their association to markers of body composition or anthropometric markers, respectively 
[87-91], to identify metabolic phenotypes that are associated with specific characteristics 
such as fat free mass (FFM). As described before, two different phenotypes of body fat 
distribution appear in men and women, differing in their corresponding risk for chronic 
diseases. The study of metabolomics was already applied to link metabolic profiles with 
disease risk in general but up to now, no study is published investigating the role of 
metabolic markers measured with a metabolomics approach as determinants of one of the 
body fat distribution phenotypes. 
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2.6. Objectives 
Because body fat distribution has major impact on the risk association of several 
chronic diseases with abdominal obesity and the android body fat distribution having 
worsening impacts, there are several questions that were addressed in the present thesis 
(Figure 5).  
1) The first part aims to describe changes of anthropometric markers to assess 
tendencies to a specific body fat distribution in weight-gaining individuals using data 
of three independent representative prospective German cohort studies.  
2) Based on these results, the second part aims to identify single metabolites that are 
favouring the development of either waist-gaining or a hip-gaining phenotype in 
weight-gaining men and women using data of two independent prospective German 
cohort studies.  
3) The third part of this thesis aims to compare a single metabolite and a principal 
component approach to investigate associations of targeted metabolomics profiles 
with either waist-gaining or a hip-gaining phenotype using data of one prospective 
German cohort study to address the highly complex metabolomics data in two 
different approaches and strengthen the evidence of observed results.  
  
 
 
 
 
 
 
 
 
 Figure 5 Objectives of this thesis in context to human metabolome, body fat accumulation and influencing factors 
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3. Subjects and Methods 
3.1. Study design 
The thesis is based on data of three prospective German cohort studies. Each step 
and statistical model of the following analyses was first tested and implemented in the 
European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam study. A 
standardized analysis plan based on the EPIC-Potsdam implementations was provided to 
the corresponding cohorts. All results were collected for further meta-analytical analyses and 
interpretation. No data pooling was done. 
3.1.1. European Prospective Investigation into Cancer and Nutrition Study 
The EPIC study is one of the largest ongoing multicentre cohort studies in the world 
with more than half a million (521,000) participants recruited across 10 countries all over 
Europe and coordinated by the International Agency for Research on Cancer (IARC) of the 
WHO in Lyon, France [92]. For Germany, two study centres at the German Cancer Research 
Center (DKFZ) in Heidelberg with 25,540 participants and at the German Institute of Human 
Nutrition (DIfE) in Potsdam with 27,548 participants are part of this large multi-centre cohort 
study [93, 94]. The primary aim of this cohort study was to study the associations between 
diet and cancer, but other risk factors and chronic diseases were considered additionally. 
For EPIC in Potsdam, the study region included the city of Potsdam and surrounding 
small to middle-town cities and communities. Participants mainly in the age of 35 (women) or 
40 (men) to 65 years from the study region were recruited between 1994 and 1998 based on 
general population registries, but interested people that did not match the age criteria were 
also allowed to be part of the study [94]. The participation rate for baseline examination was 
27%, participants tended to be more health conscious and higher educated than the general 
population [94]. For the present thesis, data from the fourth follow-up examination conducted 
between 2004 and 2008 was used. The study population of EPIC-Potsdam was biannually 
contacted by mail for follow-up information. Of this study population, a subcohort of 2,500 
participants aged 20-68 years at time of recruitment was randomly selected for specific 
biomarker measurement using a case-cohort design. The results of this subcohort are 
expected to be generalisable through the use of random selection and are therefore 
representative for the full EPIC cohort in Potsdam [95]. The EPIC-Potsdam study was 
conducted according to the guidelines of the Declaration of Helsinki and was approved by 
the Ethics Committee of the Medical Society of the State of Brandenburg. Individuals 
provided written informed consent prior to participation of the study 
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3.1.2. Cooperative Health Research Platform in the Region Augsburg Study 
The Cooperative Health Research Platform in the Region Augsburg, Bavaria (KORA) 
is a regional research platform for population-based surveys and subsequent follow-up 
studies and was designed to continue and expand the MONICA (Monitoring of Trends and 
Determinants of Cardiovascular Disease) project in Augsburg [96]. The study was approved 
by the local Ethic Committee of the Bavarian Medical Association. 
Individuals with German nationality were sampled in a two-step sampling procedure: 
A cluster sampling procedure was performed in Augsburg and 16 communities followed by a 
stratified random sampling in each community. Beginning in 1984, four cross-sectional 
studies were performed in a 5-year interval with follow-up studies for third and fourth survey 
conducted 7-10 years later from baseline examination. The fourth KORA survey (S4) was 
conducted between 1999 and 2001 with a 7-year follow-up period and follow-up examination 
between 2006 and 2008. The fourth survey consists of 4,261 participants of which 3,080 
individuals aged 25 to 74 also participated in the follow-up examination [97], of which again 
1,614 individuals aged 55 and older were selected as a subsample for targeted 
metabolomics measurement [87]. 
In all surveys, all participants were examined by trained medical staff including 
anthropometric and blood pressure measurements according to standardized operating 
procedures. Furthermore, standardized interviews on sociodemographic variables, several 
risk factors including e.g. smoking, alcohol consumption and physical activity, medical history 
(personal and family), medication use, and even more were performed. Each study was 
conducted according to the guidelines laid down in the Declaration of Helsinki and all 
participants gave written informed consent before participation on the study.  
The primary aim of the KORA study was to study risk factors of CVD due to its origin 
of the MONICA project, but with growing knowledge of associated diseases and 
pathophysiological processes, research topics have become broader. The KORA S4 is 
dealing with the topics of e.g. CVD, diabetes, obesity, dermatology and allergy [96]. 
  
 Subjects and Methods 
  
 
16 
 
3.1.3. National health interview and examination survey 
The German Health Interview and Examination Survey for Adults (DEGS) is part of 
the health monitoring at the Robert Koch-Institute (RKI) and was primarily designed as a 
periodically survey [98]. Study participation required permanent residence in Germany 
according to local population registries. To establish a longitudinal study within DEGS, 
participants from the survey conducted in 1998 (N=7,124) were reinvited to participate in 
2008-2011. Between 2008 and 2011, 3,959 participants from the German National Health 
Interview and Examination Survey 1998 (GNHIES98) (response rate 62 %) of whom 914 
were surveyed by means of interviewed only and 3,045 were both interviewed and examined 
[3]. 
Data collection included several questionnaires and (computer-assisted) personal 
interviews on e.g. habitual diet, assessment of current medication and medical history 
including family history. Furthermore, collection of biomaterial (urine and blood) and 
standardized physical performance tests were conducted [98]. 
Aims of the study were to analyse current health status, changes in health status, 
health risks and resources, functional capacity levels and disability in the adult German 
population. A major study objective was to estimate the prevalence of diseases and risk 
factors with high public health impact and the changes over time [98].  
The implementation of DEGS conformed to the guidelines of the Declaration of 
Helsinki [99] and to the German Federal Data Protection Act. The DEGS study protocol was 
consented with the Federal and State Commissioners for Data Protection and approved by 
the Charité-Universitätsmedizin Berlin Ethics Committee. Individuals provided written 
informed consent prior to participation of the study [98].  
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3.2. Study population 
The case-cohort subsample for specific biomarker measurement in EPIC-Potsdam 
consists of 2,500 participants from the overall EPIC-Potsdam study population [95]. The 
KORA S4 cohort consists of 4,261 participants, of which 3,080 individuals also participated in 
a follow-up examination F4 [97]. In a subsample of 1,614 participants aged 54 to 75 targeted 
metabolomics measurement was performed [87]. The national survey DEGS provided data 
of 3,045 participants who were both interviewed and examined [3]. Therefore, the 
investigated studies included a total of 7,159 participants (2,500 in EPIC-Potsdam, 1,614 in 
KORA, 3,045 in DEGS). Of these participants, 829 individuals with missing information for 
variables of interest at baseline or follow-up (299 in EPIC-Potsdam, 496 in KORA, 34 in 
DEGS) and 14 pregnant or postpartum women (DEGS) were excluded. Because of the 
particular interest in specific weight gain phenotypes, 2,193 individuals without body weight 
gain in the follow-up period (557 in EPIC-Potsdam, 526 in KORA, 1,110 in DEGS) were also 
excluded resulting in a final analytical study sample of 4,126 individuals (1,644 in EPIC-
Potsdam, 592 in KORA, 1,890 in DEGS), 1,802 men and 2,324 women (Figure 5).  
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Figure 6 Flow chart illustrating the exclusion criteria in terms of analytical study population 
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3.3. Tendencies to a specific body fat distribution in weight-gaining individuals in 
Germany (objective 1) 
3.3.1. Study population 
Data from all three population-based prospective German cohort studies (EPIC-
Potsdam, KORA, DEGS) were included in this part of the thesis. Thus, the final analytical 
study population consists of 4,126 participants, 1,802 men and 2,324 women. 
3.3.1. Variable assessment at baseline 
For baseline examination, participants were invited to the study centres and 
examined by trained staff according to study-specific standardized procedures in a standing 
position using a non-elastic flexible tape. For EPIC-Potsdam, all baseline measures were 
performed in underwear without shoes, for KORA and DEGS in light clothing without shoes. 
In EPIC-Potsdam, waist circumference (in cm) was measured at the midpoint between the 
lowest rib and the superior border of the iliac crest and on the narrowest point for KORA and 
DEGS. Hip circumference (in cm) was measured at the most sweeping point of the buttocks 
horizontal around the body in EPIC-Potsdam and at the most protrusion of the gluteal region 
between the superior border of the iliac crest and crotch in KORA and DEGS. 
For follow-up examination in EPIC-Potsdam, information on body weight, waist and 
hip circumference was collected as self-report. Participants received a letter with a 
standardized non-elastic flexible tape and a written instruction. With regard to reduce bias 
due to measurement error and underreporting, self-reported values were corrected using 
EPIC-specific equations developed to correct self-reports [100, 101]. For follow-up 
examination in study centres of DEGS, slight modification in standardized procedures was 
done measuring participants in underwear instead of light clothing at baseline. No 
modifications were done in KORA.  
For body weight, waist and hip circumference, average annual changes were 
calculated by subtracting the baseline measure from the follow-up measure divided by the 
individual follow-up time in years. The difference of average annual changes in waist 
circumference minus hip circumference was calculated for every individual. Negative values 
identified people gaining more hip circumference, positive values identified people gaining 
more waist circumference.  
Information on age, sex, smoking status (current, former, never smoker), alcohol 
consumption (in g/d) and physical activity (by sports) were assessed with study-specific 
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socio-demographic and lifestyle questionnaires. Four categories were formed in each cohort 
with available information on regular physical activity: no sports, less than 1h/week, 1-2 
h/week and more than 2h/week. Supplementary, a women-specific questionnaire assessed 
information regarding menopausal status und parity [93, 96, 98].  
Menopausal status was defined 2-categorical as pre- and postmenopausal. In EPIC-
Potsdam, postmenopausal was defined as suspended menses (non-surgical induced) for 
more than 1 year and no hormone replace therapy (HRT) or a started HRT during the last 
menses. In KORA, postmenopausal was defined as absence of menses; all other women 
were categorised as premenopausal. In DEGS, postmenopausal status included women with 
absence of menses for more than 1 year or HRT. All other women were categorised as 
premenopausal. 
Information on chronic disease status including myocardial infarction, stroke, any type 
of diabetes and malignant types of cancer was assessed via standardized questionnaires in 
each study. For EPIC-Potsdam, information on the diseases of interest included prevalent 
diseases at baseline examination or incident diseases within the follow-up period. For KORA, 
prevalent or incident disease status included the period from 1 year before baseline 
examination to the follow-up period. For DEGS, information on disease status refers to ever 
suffered from the disease of interest. 
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3.3.2. Statistical analysis 
Self-reported measures of body weight, waist and hip circumference for follow-up in 
EPIC-Potsdam were corrected using equations from Spencer et al. (Figure 7). All values and 
analyses in this thesis are based on the corrected measures. 
body weight  
men   body weight corr= 0.561 + (1.012* body weight SR) + (0.006* age FU) 
women  body weight corr= 0.444 + (1.010* body weight SR) + (0.006* age FU) 
 
waist circumference (waist) 
men    waist corr = 7.791 + (0.972* waist SR) - (0.035* age FU) 
women  waist corr= 9.022 + (0.847* waist SR) + (0.091* age FU) 
 
hip circumference (hip) 
men   hip corr  = 42.812 + (0.637* hip SR) - (0.075* age FU) 
women  hip corr  = 20.040 + (0.818* hip SR) - (0.011* age FU) 
Figure 7 EPIC-specific equations to correct self-reported body measures [96, 97] 
Abbreviations: corr=corrected, FU=follow-up, SR=self-reported 
Units: age (yr), body weight (kg), waist and hip circumference (cm) 
To investigate and describe longitudinal changes of anthropometric markers and with 
regard to different follow-up periods for each study, average annual changes in body weight, 
waist and hip circumference were calculated (Figure 8).  
 
average annual weight change (kg/yr) = 
body weight FU - body weight BL
FU time
 
 
average annual waist change (cm/yr)   = 
waist circumference FU  - waist circumference BL 
FU time
 
 
average annual hip change (cm/yr)       = 
hip circumference FU - hip circumference BL 
FU time 
 
Figure 8 Calculation of average annual changes of anthropometric markers 
Abbreviations: BL, Baseline examination; FU, follow-up;  
Units: age (yr), body weight (kg), waist and hip circumference (cm) 
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Because of the particular interest in weight-gaining individuals, all individuals with an 
average annual weight change less than or equal to zero were excluded from all analyses of 
this thesis. To describe the general tendencies of changes in body measures in weight-
gaining individuals, the difference of average annual changes of waist and hip circumference 
was calculated by subtracting average annual changes of hip and waist circumferences 
(Equation 1). Negative values identified people increasing rather hip circumference, positive 
values identified people increasing rather waist circumference. 
Equation 1 Calculation of the average annual waist-hip difference 
 
average annual waist-hip difference = average annual waist change – average annual hip change 
 
Unit: average annual changes (cm/yr) 
Descriptive data is presented as mean and standard deviation (SD) for continuous 
and absolute quantities and percentage for categorical variables. Depending on their 
variance and cell counts, paired Student’s t-test or sign-test for continuous and ² or Fishers 
exact test were applied to test for statistically significant differences between groups for 
continuous or categorical variables, respectively. According to criteria of the WHO [1] the 
BMI (in kg/m²) was calculated as body weight divided by height (in m) squared and 
individuals were classified in overweight (BMI ≥ 25 kg/m²), pre-obesity (25 ≤ BMI < 30 kg/m²) 
and obesity (BMI ≥ 30 kg/m²). Individuals were categorised as abdominally obese if men 
exceeded a waist circumference of 102 cm and women of 88 cm [28, 29]. Of the previously 
defined waist-hip difference, Student’s t-test was applied to test for differences between 
sexes. Furthermore, the relationship between this difference and average annual weight 
change was investigated in each study using Pearson correlation for men and women 
separately. To the current knowledge, no other study applied this average annual waist-hip 
difference yet, thus relationship between established anthropometric markers including waist 
and hip circumference, BMI, WHR and waist-hip difference was investigated in EPIC-
Potsdam using Pearson correlation coefficients.  
In the nationwide study DEGS, anthropometric markers assessed in the study were 
additionally corrected for deviations of the sample with regard to age, sex, region, nationality, 
type of municipality and education from the population structure as of December 31st, 1997 
[102]. 
To investigate the potential bias in the present analysis due to drop-out in the 
investigated cohorts, study-specific probabilities for reparticipation at follow-up examination 
were calculated in DEGS with the lowest response rate of 43% [3] and EPIC-Potsdam with 
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the highest response rate 92% [103]. Multivariable logistic regression models with response 
at follow-up as the dependent and potential predictors of drop-out as independent variables 
were used for the calculation of the probability of reparticipation. As long as assessed at the 
baseline examination, sociodemographic variables including age, sex, education and 
income, BMI, lifestyle variables including smoking, alcohol consumption and physical activity 
were considered as independent variables. Individuals that died within the follow-up period 
were not treated as drop-out and therefore not considered in the calculation. The calculated 
probabilities of reparticipation were then applied in a sensitivity analysis as inverse-
probability weights [104]. Again, the weighting factor for DEGS included additionally 
corrected deviations of the demographic population structure as of December 31st, 1997 
[102]. Calculations in all studies were done using statistical software SAS release 9.4 (SAS 
Institute Inc, Cary, NC, USA). 
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3.4. Identification of phenotype associated metabolites (objective 2) 
3.4.1. Study population 
Participants from EPIC-Potsdam and KORA were involved in this part of the thesis. 
1,644 weight-gaining individuals of EPIC-Potsdam and 592 weight-gaining individuals of 
KORA resulted in a total analytical study population of 2,236 participants, 918 men and 1,318 
women. 
3.4.2. Blood sample collection 
During their stay at the EPIC-Potsdam study centre for baseline examination, a total 
of 95.7% of the participants in Potsdam provided a 30ml blood sample which was drawn by 
trained medical staff. For baseline examination appointments before noon, participants were 
informed about the blood sampling and advised not to eat anything before their examination. 
All in all, the proportion of fasting blood collections was 28% [94]. Of the 30ml venous blood, 
20ml were inserted into citrate containing monovettes, other 10ml into monovettes without 
any anticoagulant and immediately fractioned into serum, plasma, buffy coat and 
erythrocytes. During withdrawal and processing exact time and room temperature were 
steadily documented. According to a standardized protocol, the samples were aliquoted into 
straws of 0.5ml resulting in 12 straws of plasma, 8 straws of serum, 4 straws of buffy coat 
and 4 straws of erythrocytes up to a total of 28 straws for each participant. This straws were 
then stored at -196°C in tanks of liquid nitrogen [93]. 
In KORA, fasting serum samples for metabolic analysis were collected during study 
centre visits. The blood drawing occurred after a period of overnight-fasting (minimum of 8 
hours) using S-MonovetteTM serum tubes (SARSTEDT AG & Co., Nümbrecht, Germany). 
Tubes were inverted two to three times, spent five minutes on the universal shaker 
(SARSTEDT AG & Co., Nümbrecht, Germany) before being allowed to rest for 40 minutes at 
4°C for total coagulation. Later on, tubes were centrifuged for 15 minutes at 2,660g, serum 
was separated and filled into synthetic straws which were stored in liquid nitrogen (-196°C) 
until analysis [105]. 
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3.4.3. Sample preparation and metabolomics measurement 
The measurements for EPIC-Potsdam and KORA were performed in the Genome 
Analysis Center at the Helmholtz Center Munich. Different high-throughput targeted 
metabolomics measurement AbsoluteIDQTM kits (Biocrates Life Sciences AG, Innsbruck, 
Austria) were used in the studies, but sample preparation and measurement procedures 
were equivalent. 
In EPIC-Potsdam, targeted metabolomics AbsoluteIDQTM p150 kit was used to 
quantify serum metabolites. The p150 kit uses a flow injection analysis mass spectroscopy 
coupled with multiple reaction monitoring scans (FIA-MS/MS) technique on an API 4000TM 
triple quadrupole mass spectrometer (ABSciex Deutschland GmbH, Darmstadt, Germany) 
equipped with an electrospray ionization source for the detection of metabolites [70].  
Sample preparation was done according to a Biocrates provided protocol and has 
been previously described in detail [70]. In brief, after centrifugation 10µl of each serum 
sample were pipetted by an automated Hamilton ML Star robotics system (Hamilton 
Bonaduz AG, Bonaduz, Switzerland) on special double-filter 96-well plates which contained 
already isotope labelled non-radioactive internal standards, blank samples and quality 
controls. After incubation, the filters were dried under nitrogen stream and amino acids (AA) 
were derivated with 5% phenylisothiocyanate reagent. Then the filters were dried again 
followed by the extraction of metabolites and internal standards with 5 mmol/l ammonium 
acetate in methanol, centrifuged through a filter membrane and then diluted with a MS 
running solvent. For all measurements, two 20µl injections (for positive and for negative 
electrospray ionization mode) were applied by the standard flow injection method [70]. 
Specific analytical software MetIDQTM (an integral part of the kit) provided by the 
manufacturer Biocrates Life Sciences AG was used for calculation of concentrations and 
evaluation. This software compares measured metabolites in a defined extracted ion count 
section to specific labelled internal standards or non-labelled non-physiological standards 
(semi-quantitative) of the 96-well plate. This method is in conformance with the “Guidance for 
Industry – Bioanalytical Method Validation” of the Food and Drug Administration, which 
implies the proof of reproducibility within a given error range [70]. Limits of Detection (LoD) 
were set to three times the values of the manufacturer provided zero samples (methanol and 
10 mmol/l phosphate buffer). Lower and upper limit of quantification were determined 
experimentally by the manufacturer.  
For KORA, targeted metabolomics AbsoluteIDQTM p180 kit (Biocrates Life Sciences 
AG, Innsbruck, Austria) was used to quantify serum metabolites. The p180 kit is an extension 
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of the p150 kit and uses the combination of FIA-MS/MS and Liquid Chromatography mass 
spectroscopy (LC-MS) on the mass spectrometer equipped with an electrospray ionization 
source for the detection of metabolites [70].  
Sample preparation was equivalent to EPIC-Potsdam described afore. Specific for the 
p180 kit, the plate was centrifuged at 100g for 2 min, with plate 1 (FIA plate) receiving about 
250µl sample. After removal of the upper plate, 150µl of each sample were transferred onto 
the LC-MS plate with additionally 150µl HPLC water. 500µl of a Biocrates solvent diluted in 
methanol as MS running solvent were added to the FIA plate. The LC-MS plate was 
measured first by scheduled multiple reaction monitoring, the FIA plate was stored at 4° and 
then measured by FIA equivalent to EPIC-Potsdam. Analogue to the p150 procedure 
concentrations were calculated and evaluated using the MetIQTM software of Biocrates Life 
Sciences AG. All concentrations are were calculated in mmol/l [106]. 
These targeted metabolomics approaches simultaneously identified and quantified 
163 metabolites (p150) or 186 metabolites (p180), including AA, acylcarnitines (AC), different 
kinds of glycerophospholipids (lyso-, diacyl-, and acyl-alkyl-phosphatidylcholines (PC)), 
sphingomyelins (SM) and hexose (H) (sum of six-carbon monosaccharides without 
distinction of isomers) and exclusively for p180 biogenic amines. The manufacturer selected 
the metabolites based on the robustness of their measurements. The uncertainty of the 
measurements was 10% for most of the metabolites. Regarding accuracy, all included 
metabolites were found in the range of 80–115% of their theoretical values [107].  
AAs were presented according to three letter abbreviations. Lipid side chains were 
abbreviated as Cx:y with x referring to the number of carbons in the side chain and y to the 
number of double bonds. PCs were additionally differentiated based on their type of bond to 
glycerol with ‘a’ for acyl and ‘e’ for alkyl bond, the prefix ‘lyso’ indicated only a single fatty 
acid side chain. Diacyl- and acyl-alkyl-PCs contain two fatty acid side chains, for example 
“PC ae C40:1” denotes a phosphatidylcholine (PC) with an acyl bond (a) and an alkyl bond 
(e) side chain. This metabolite contains 40 carbons in both side chains and a single double 
bond in one of them. Unfortunately these methods could not determine the exact distribution 
of carbons in each bonded fatty acid or the precise position of double bonds within the 
molecule. All ACs were derivates of free L-carnitine (C0) linked to one fatty acid [105]. 
Within the p180 kit, leucine and isoleucine were quantified separately whereas the 
p150 kit quantified these metabolites combined as xleucine. For the present analyses, these 
measures were not considered because of potential heterogeneity. 
For the selection of the final metabolomics dataset, EPIC-Potsdam and KORA used 
slightly different quality criteria. Serum or reference samples were measured multiple times 
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to get within-plate or between-plate variance, respectively. The standard deviation for those 
measures was divided by the mean value of the dataset for each metabolite to obtain the CV 
as a common measure of technical variation [87, 108].  
In EPIC-Potsdam, metabolites with a too large variation given by a CV (within- or 
between-plate) of greater than 50% or with the majority of values below the LoD were 
excluded from the analyses. The median analytical variance of EPIC-Potsdam samples was 
a 7.3% within-plate coefficient of variation and a 11.3% between-plates coefficient of 
variation [108].  
For KORA, metabolites with more than 5% missing values (1 metabolite) and a CV of 
greater than 25% (n=11) were excluded from the analysis. Metabolite concentrations were 
defined as outliers if values exceeded a range of mean +/- five standard deviations. In that 
case concentrations were treated as missing values and imputed using R package ‘mice’. 
Individuals with more than three metabolites exceeding this range were excluded from the 
analyses [87]. 
After study specific quality criteria, a total of 121 metabolites quantified in both kits 
were available for further analyses, including 13 AAs, 14 ACs, 80 PCs (34 diacyl-, 26 acyl-
alkyl, 10 lyso-PCs), 13 SM and the sum of hexoses. Abbreviations and full biochemical 
names of these metabolites are provided in Table 1. 
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Table 1 Abbreviations and full biochemical names of metabolites available in both Biocrates 
AbsoluteIDQTM kits p150 and p180 
Abbreviation Full biochemical name Abbreviation Full biochemical name 
Arg Arginine PC ae C30:0 Phosphatidylcholine acyl-alkyl C30:0 
Gln Glutamine PC ae C30:2 Phosphatidylcholine acyl-alkyl C30:2 
Gly Glycine PC ae C32:1 Phosphatidylcholine acyl-alkyl C32:1 
His Histidine PC ae C32:2 Phosphatidylcholine acyl-alkyl C32:2 
Met Methionine PC ae C34:0 Phosphatidylcholine acyl-alkyl C34:0 
Orn Ornithine PC ae C34:1 Phosphatidylcholine acyl-alkyl C34:1 
Phe Phenylalanine PC ae C34:2 Phosphatidylcholine acyl-alkyl C34:2 
Pro Proline PC ae C34:3 Phosphatidylcholine acyl-alkyl C34:3 
Ser Serine PC ae C36:0 Phosphatidylcholine acyl-alkyl C36:0 
Thr Threonine PC ae C36:1 Phosphatidylcholine acyl-alkyl C36:1 
Trp Tryptophan PC ae C36:2 Phosphatidylcholine acyl-alkyl C36:2 
Tyr Tyrosine PC ae C36:3 Phosphatidylcholine acyl-alkyl C36:3 
Val Valine PC ae C36:4 Phosphatidylcholine acyl-alkyl C36:4 
H1 Hexose PC ae C36:5 Phosphatidylcholine acyl-alkyl C36:5 
C0 Carnitine PC ae C38:0 Phosphatidylcholine acyl-alkyl C38:0 
C2 Acetylcarnitine PC ae C38:1 Phosphatidylcholine acyl-alkyl C38:1 
C3 Propionylcarnitine PC ae C38:2 Phosphatidylcholine acyl-alkyl C38:2 
C5-OH (C3-DC-M) 
Hydroxyvalerylcarnitine-
(Methylmalonylcarnitine) 
PC ae C38:3 Phosphatidylcholine acyl-alkyl C38:3 
C7-DC Pimelylcarnitine PC ae C38:4 Phosphatidylcholine acyl-alkyl C38:4 
C9 Nonaylcarnitine PC ae C38:5 Phosphatidylcholine acyl-alkyl C38:5 
C10 Decanoylcarnitine PC ae C38:6 Phosphatidylcholine acyl-alkyl C38:6 
C10:2 Decadienylcarnitine PC ae C40:1 Phosphatidylcholine acyl-alkyl C40:1 
C14:1 Tetradecenoylcarnitine PC ae C40:2 Phosphatidylcholine acyl-alkyl C40:2 
C14:2 Tetradecadienylcarnitine PC ae C40:3 Phosphatidylcholine acyl-alkyl C40:3 
C16 Hexadecanoylcarnitine PC ae C40:4 Phosphatidylcholine acyl-alkyl C40:4 
C18 Octadecanoylcarnitine PC ae C40:5 Phosphatidylcholine acyl-alkyl C40:5 
C18:1 Octadecenoylcarnitine PC ae C40:6 Phosphatidylcholine acyl-alkyl C40:6 
C18:2 Octadecadienylcarnitine PC ae C42:1 Phosphatidylcholine acyl-alkyl C42:1 
PC aa C28:1 Phosphatidylcholine diacyl C28:1 PC ae C42:2 Phosphatidylcholine acyl-alkyl C42:2 
PC aa C30:0 Phosphatidylcholine diacyl C30:0 PC ae C42:3 Phosphatidylcholine acyl-alkyl C42:3 
PC aa C32:0 Phosphatidylcholine diacyl C32:0 PC ae C42:4 Phosphatidylcholine acyl-alkyl C42:4 
PC aa C32:1 Phosphatidylcholine diacyl C32:1 PC ae C42:5 Phosphatidylcholine acyl-alkyl C42:5 
PC aa C32:2 Phosphatidylcholine diacyl C32:2 PC ae C44:3 Phosphatidylcholine acyl-alkyl C44:3 
PC aa C32:3 Phosphatidylcholine diacyl C32:3 PC ae C44:4 Phosphatidylcholine acyl-alkyl C44:4 
PC aa C34:1 Phosphatidylcholine diacyl C34:1 PC ae C44:5 Phosphatidylcholine acyl-alkyl C44:5 
PC aa C34:2 Phosphatidylcholine diacyl C34:2 PC ae C44:6 Phosphatidylcholine acyl-alkyl C44:6 
PC aa C34:3 Phosphatidylcholine diacyl C34:3 lysoPC a C14:0 lysoPhosphatidylcholine alkyl C14:0 
PC aa C34:4 Phosphatidylcholine diacyl C34:4 lysoPC a C16:0 lysoPhosphatidylcholine alkyl C16:0 
PC aa C36:0 Phosphatidylcholine diacyl C36:0 lysoPC a C16:1 lysoPhosphatidylcholine alkyl C16:1 
PC aa C36:1 Phosphatidylcholine diacyl C36:1 lysoPC a C17:0 lysoPhosphatidylcholine alkyl C17:0 
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Abbreviation Full biochemical name Abbreviation Full biochemical name 
PC aa C36:2 Phosphatidylcholine diacyl C36:2 lysoPC a C18:0 lysoPhosphatidylcholine alkyl C18:0 
PC aa C36:3 Phosphatidylcholine diacyl C36:3 lysoPC a C18:1 lysoPhosphatidylcholine alkyl C18:1 
PC aa C36:4 Phosphatidylcholine diacyl C36:4 lysoPC a C18:2 lysoPhosphatidylcholine alkyl C18:2 
PC aa C36:5 Phosphatidylcholine diacyl C36:5 lysoPC a C20:3 lysoPhosphatidylcholine alkyl C20:3 
PC aa C36:6 Phosphatidylcholine diacyl C36:5 lysoPC a C20:4 lysoPhosphatidylcholine alkyl C20:4 
PC aa C38:0 Phosphatidylcholine diacyl C38:0 lysoPC a C28:1 lysoPhosphatidylcholine alkyl C28:1 
PC aa C38:1 Phosphatidylcholine diacyl C38:1 SM C16:0 Sphingomyeline C16:0 
PC aa C38:3 Phosphatidylcholine diacyl C38:3 SM C16:1 Sphingomyeline C16:1 
PC aa C38:4 Phosphatidylcholine diacyl C38:4 SM C18:0 Sphingomyeline C18:0 
PC aa C38:5 Phosphatidylcholine diacyl C38:5 SM C18:1 Sphingomyeline C18:1 
PC aa C38:6 Phosphatidylcholine diacyl C38:6 SM C20:2 Sphingomyeline C20:2 
PC aa C40:2 Phosphatidylcholine diacyl C40:2 SM C24:0 Sphingomyeline C24:0 
PC aa C40:3 Phosphatidylcholine diacyl C40:3 SM C24:1 Sphingomyeline C24:1 
PC aa C40:4 Phosphatidylcholine diacyl C40:4 SM C26:1 Sphingomyeline C26:1 
PC aa C40:5 Phosphatidylcholine diacyl C40:5 SM (OH) C14:1 Hydroxysphingomyeline C14:1 
PC aa C40:6 Phosphatidylcholine diacyl C40:6 SM (OH) C16:1 Hydroxysphingomyeline C16:1 
PC aa C42:0 Phosphatidylcholine diacyl C42:0 SM (OH) C22:1 Hydroxysphingomyeline C22:1 
PC aa C42:1 Phosphatidylcholine diacyl C42:1 SM (OH) C22:2 Hydroxysphingomyeline C22:2 
PC aa C42:2 Phosphatidylcholine diacyl C42:2 SM (OH) C24:1 Hydroxysphingomyeline C24:1 
PC aa C42:4 Phosphatidylcholine diacyl C42:4   
PC aa C42:5 Phosphatidylcholine diacyl C42:5   
PC aa C42:6 Phosphatidylcholine diacyl C42:6   
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Floegel et al. [108] evaluated the reliability of metabolites measured with the 
AbsoluteIDQTM p150 kit and computed the intraclass correlation coefficient (ICC) with regard 
to changes over a 4-months period in fasting individuals. The ICC is a measure of 
reproducibility and ranges between 0 and 1 with ICC=0 indicating no reproducibility and 
ICC=1 indicating perfect reproducibility (Equation 2). For the majority of measured 
metabolites, a fair to good reliability given by an ICC above 0.4 was reported (Figure 9) [109].  
Equation 2 Interpretation of ICC (modified from Rosner (2011) [109]) 
ICC > 0.4  poor reproducibility 
0.4 ≤ ICC < 0.75 fair to good reproducibility 
ICC ≥ 0.75  excellent reproducibility  
Therefore, those metabolites are reliable over time and it was assumed that 
comparable metabolic profiles would be present at the time of body weight gain within the 
follow-up period. 
 
Figure 9 Intraclass correlation coefficients (ICCs) of 163 serum metabolites according to 
metabolite subclass measured over a 4-months period (modified according to 
Floegel et al. (2011) [108]) 
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3.4.4. Statistical analysis 
In order to increase comparability of results, metabolite concentrations were 
standardized to a mean of zero and a standard deviation of 1 for each sex separately. 
Based on the observed distribution across all studies (objective 1), two different 
weight-gaining phenotypes could be defined through categorisation of average annual waist-
hip difference in men and women: a waist-gaining (WG) and a hip-gaining (HG) phenotype. 
The lower 10% of the waist-hip difference were defined as the WG phenotype, whereas the 
upper 10% were defined as the HG phenotype. 
Multiple logistic regression models were fitted with either the WG or the HG 
phenotype as the dependent and standardized metabolite concentrations as independent 
variables, adjusted for age at time of baseline examination, baseline BMI, baseline measures 
of waist and hip circumference, smoking status (never, former, current smoker) and prevalent 
and incident chronic diseases including myocardial infarction, stroke, any type of diabetes 
and cancer. Odds ratios (OR) were calculated between the phenotype of interest and the 
reference category.  
Potential interactions were tested for the association between each metabolite and 
the covariate sex by including a multiplicative interaction term into the model. Because 
diacyl-PC C42:1, acyl-alkyl-PCs C44:3, C30:1, C32:1, C44:6 and SM C18:1 showed 
statistically significant interaction with sex, all logistic regression models were fitted sex-
specific. 
Because the logistic regression model was calculated for each metabolite, some of 
the results were expected to be false positive by chance due to type I error. Based on a 
common significance level of α=0.05, there is a 5% chance of making a wrong decision. The 
number of false positive results would therefore increase due to multiple testing, e.g. m=121 
tests with a significance level of α=0.05 would result in 6 expected false positive results 
(Equation 3).  
Equation 3 Expected false positive results without controlling for multiple testing 
 m *  α = expected overall false positive test results  
121 * 0.05 = 6.05  
A possibility to address that point is to adjust the significance level α by setting a 
lower threshold. In general, multiple testing corrections successful decreases type I error and 
the number of false positives but on cost of increasing type II error and number of false 
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negative results. A very common but conservative approach is the use of the Bonferroni 
method [110]. This procedure controls the overall experiment-wise type I error rate through 
adjusting the threshold of the significance level by dividing this level by the number of all 
performed tests. This procedure would be appropriate if all tests were independent of each 
other. The analytical metabolomics dataset includes partly highly correlated metabolites 
(Appendix 2), so that the assumption of independent tests is not appropriate. In case of 
highly correlated metabolites the number of type II error and therefore false negative results 
would increase even more when applying this method.  
An alternative approach to control the problem of multiple testing is the use of the 
Benjamini-Hochberg method [111] which controls the False Discovery Rate (FDR). This 
approach is less conservative compared to Bonferroni and type II error appears less often 
[110]. Therefore the linear step-up FDR method was chosen using MULTTEST procedure of 
SAS 9.4 (SAS Institute Inc., Cary, NY). Based on the number of tests (m=121) performed in 
this analysis, this procedure works as described in Equation 4. 
Equation 4 Benjamini-Hochberg FDR testing procedure (modified from Rosner (2011) [110]) 
(1) m = 121 separate tests with p-values p(1)… p(121) were conducted 
(2) tests are renumbered (for convenience) and raw p-values are ordered according to 
p(1) ≤ p(2) ≤ … ≤ p(n) ≤ … ≤ p(121) 
(3) raw p-values are corrected using the equation PFDR (n) = 
𝑚
𝑚−𝑛
  p(n) , e.g. 
PFDR (121)  = 
121
121
 p(121) 
PFDR (n)  = 
121
𝑛
 p(n) 
.  . 
.  . 
.  . 
PFDR (1)    = 
121
1
 p(1) 
(4) reject H0 for the hypotheses with an FDR-p ≥ 0.05 and accept H0 for remaining 
  hypotheses 
Several sensitivity analyses were performed to test the robustness of potential 
findings in a population without prevalent diseases at baseline or follow-up examination, a 
fasting population and for women in a population without menopause.  
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Subgroup analyses were performed for alcohol consumption (cut-off < 20 g/d for men 
and < 10 g/d for women), physical activity (cut-off < 1 h/week), age (cut-off ≤ 55 years) and 
abdominal obesity (waist circumference men ≥ 102 cm, women ≥ 88 cm).  
Single study results of EPIC-Potsdam and KORA were then combined in a meta-
analytical approach. The goal of a meta-analysis is to estimate a combined effect size 
through the computation of a weighted mean of the single study estimates [112].  
In a fixed-effects model one true effect size is assumed which is present in all 
investigated studies and single estimates are distributed around this true effect with a 
variation that depends primarily on the sample size for each study. So the aim of a fixed-
effects meta-analysis is to estimate this one true effect by the combination of weighted single 
study estimates [113]. Because distribution of the single study estimates around the true 
effect is largely determined by the within-study variance and large studies are in general 
more precise, each study is weighted by the inverse of its variance for the combination of 
study results [113]. 
In contrast, in a random-effects model many true effect sizes are assumed to be 
distributed across the investigated studies. So each study is estimating a different true effect 
size and the computed combined effect is a weighted mean of a distribution of true effects 
[114]. In this approach, the between-study variance is also taken into account for the 
combination of the single study results. So, the inverse of the total variance (sum of within- 
and between-study variance) is used for the combination of single study results with the goal 
of minimising both sources of variance [114]. 
For the present analysis it was assumed that both studies measure the same effect 
size with a variation that is due to the sample size for each study. Because analysis in both 
studies were functionally identical, a fixed-effects model was used to combine the single 
study estimates [115]. 
To separate between potential relevant and irrelevant metabolites and ensure that a 
combined association is not only due to a very strong effect in just one study by chance 
alone, the combined estimate had to fulfil two criteria to be regarded as true association: 1) 
single study estimates had to be consistent concerning effect direction and 2) the combined 
estimate had to be significant after multiple testing corrections.  
All calculations were done using SAS release 9.4 (SAS Institute, Cary, NC, USA) in 
all studies. Fixed-effects meta-analyses were performed using the statistical software ‘R’, 
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version 3.1.2 [116] with the R package ‘meta’, version 4.1-0 [117]. To correct for multiple 
testing, the FDR was controlled at 0.05 using the Benjamini-Hochberg method [111]. 
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3.5. Comparison of results from two approaches (objective 3) 
3.5.1. Study population 
This analysis is based on data from EPIC-Potsdam. The final analytical study 
population included 1,644 weight-gaining individuals, 1,015 women and 629 men. Detailed 
information on inclusion and exclusion criteria have been described in detail afore (chapter 
3.2). 
3.5.2. Statistical analysis 
A principal component analysis (PCA) was conducted with all quality controlled 
metabolites of EPIC-Potsdam. The PCA as an unsupervised data reduction method is 
examining the variance of the data [118] and makes use of the fact that in general many 
metabolites remain almost constant between groups and explain only little variance. Thus, 
the metabolites that are often highly correlated and explain a large variation in the dataset 
are grouped to principal components [119]. Especially within subclasses, metabolites are 
often highly correlated. In chapter 3.4.4, this dependency was addressed by using the FDR-
method as a less conservative approach of multiple testing correction instead of e.g. the 
Bonferroni method [111]. An alternative approach to address the highly correlated data is the 
use of a data reduction method such as PCA, which is also very common in the field of 
metabolomics [119]. Highly correlated metabolites are summarised and aggregated to a 
linear combination of the individual metabolites. The smaller numbers of obtained principal 
components explain in general a large amount of the between-person-variation in the 
underlying dataset, metabolites that do not differ between persons will not be considered in 
the interpretation of the principal components. Nevertheless, these metabolites are still part 
of the derived linear combination. 
PCA was only conducted on basis of EPIC-Potsdam data. Because PCA requires 
each observed variable to be normally distributed, all metabolites where standardized to a 
mean of 0 and a standard deviation of 1. The number of principal components for further 
analysis was derived through a combination of criteria: remaining principal components 
should have at least an eigenvalue of 1 and the proportion of variance accounted for by the 
number of retained components should account for the major fraction of proportion of 
variance in the targeted metabolomics dataset (at least 50%). The proportion was calculated 
according to Equation 5. 
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Equation 5 Proportion of variance accounted for by principal components 
 
proportion of variance =
proportion of the eigenvalue for the principal components
total eigenvalues of the correlation matrix
 
To obtain uncorrelated sex-specific principal components, orthogonal varimax rotation 
method was performed with the required number of components using the FACTOR 
procedure of SAS 9.4 (SAS Institute Inc, Cary, NY) for men and women, separately. With the 
varimax-rotation the explained variance of the required principal components is redistributed 
on the rotated principal components. In general, this will lead to an increased interpretability 
of components [120]. For further interpretation and identification, relevant metabolites had to 
be uniquely assignable to only one principal component with a meaningful factor loading of 
0.6. 
To investigate the association of the obtained principal components with the WG and 
HG phenotypes, sex-specific multiple logistic regression models specified in chapter 3.4.4 
were performed with the rotated principal components as independent variables. Because 
components are not 100% independent and several tests were performed, results were 
corrected for multiple testing using the FDR-method [111]. 
To investigate whether potential significant associations are caused by high loading 
metabolites of associated principal components or by metabolic constellations as a whole 
including as well low loading metabolites, simplified principal components were built. 
Therefore, only metabolites with a meaningful factor loading on the principal component of 
interest and their corresponding factor loading were used to form the corresponding 
simplified linear combinations for each principal component. The simplified principal 
components were again treated as independent variables in the multiple logistic regression 
models. Logistic regression results for original and simplified principal components were then 
compared regarding strength and direction of association. 
Finally, results from the logistic regression approaches using either single metabolites 
or principal components as independent variables were compared with each other with 
regard to strength and direction of associations.  
All statistical analyses were performed using statistical software SAS 9.4 (SAS 
Institute Inc, Cary, NY). 
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4. Results 
4.1. Characteristics of the analytical study populations of EPIC-Potsdam, KORA and 
DEGS 
Baseline characteristics and average annual changes of anthropometric measures of 
participants stratified by sex for each study are shown in Table 2.  
The majority of weight gainers in the studies were categorised as overweight 
according to their BMI with women in EPIC-Potsdam having the lowest (25.1 ± 4.4 kg/m²) 
and women in KORA having the highest average baseline BMI (28.3 ± 4.6 kg/m²). In all 
studies, men had statistically significantly higher initial body weight, waist circumference and 
WHR and consumed more alcohol compared to women (all p<.0001). Average annual weight 
change was comparable between men and women in each study ranging from 0.52 ± 0.42 
kg/yr for women in DEGS up to 0.63 ± 0.54 kg/yr for men in EPIC-Potsdam (all sex-
differences not significant). Participants of KORA had the highest level of waist 
circumference (89.1 ± 10.9 cm for women, 100.1 ± 9.1 cm for men), highest percentage of 
abdominally obese people (51% for women, 35% for men) and suffered more often from 
chronic diseases compared to participants of EPIC-Potsdam and DEGS. EPIC-Potsdam 
participants had the lowest initial measures of body weight, waist and hip circumference but 
the highest rates of average annual changes in those body measures (0.63 ± 0.54 kg/yr, 1.12 
± 0.65 cm/yr waist and 0.53 ± 0.51 cm/yr hip changes for women; 0.62 ± 0.51 kg/yr, 1.21 ± 
0.66 cm/yr waist and 0.48 ± 0.41 cm/yr hip changes for men). DEGS had the lowest rates of 
annual changes in waist circumference (0.52 ± 0.42 cm/yr for women; 0.55 ± 0.49 cm/yr for 
men) with men even showing a tendency of losing hip circumference on average (-0.11 ± 
0.37 cm/yr). 
Weight-gaining participants of DEGS had the lowest average age at baseline 
examination (43.3 ± 11.8 yr for women, 41.8 ± 12.8 yr for men, p=0.008) compared to EPIC-
Potsdam (48.2 ± 9.0 yr for women, 51.2 ± 8.0 yr for men, p<.0001) and KORA with the 
highest average age (62.8 ± 5.2 yr for men, 62.6 ± 5.2 yr for men, p=0.69). Because of the 
high mean age at baseline examination, 94.7% of women in KORA were postmenopausal. In 
contrast, the analytical study populations of EPIC-Potsdam and DEGS included 22.8% and 
39.8% postmenopausal women, respectively.  
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Lifestyle  
There is a great gap regarding alcohol consumption between men and women with 
men having on average a three times higher alcohol consumption than women in all 
investigated cohorts (all p<.0001). In EPIC-Potsdam and KORA, men were more often 
current or former smokers than women. In the national survey DEGS a different distribution 
for smoking status could be observed showing that women were more often current or former 
smoker than men (all p<.0001). 
The majority of participants were physically inactive with more than 50% of individuals 
in each cohort spending less than one hour per week with physical activities. In comparison, 
women were observed to have more moderate physical activity (1-2h/week) compared to 
men; in contrast men were slightly more active with regard to physical activity of more than 2 
hours per week.  
Phenotype characteristics 
HG and WG phenotypes were defined as described in chapter 3.4.4. HG phenotype 
in both sexes was characterized by highest initial body weight (EPIC-Potsdam: 76.7 ± 16.4 
kg for women, 78.8 ± 10.6 kg for men; KORA: 76.7 ± 11.3 kg for women, 89.9 ± 13.4 kg for 
men), largest initial waist and hip circumference (only exception hip circumference in men) 
but lowest rates of average annual body weight gain (EPIC-Potsdam: 0.49 ± 0.54 kg/yr for 
women, 0.41 ± 0.41 kg/yr for men; KORA: 0.71 ± 0.73 kg/yr for women; 0.46 ± 0.43 kg/yr for 
men). In both sexes, it could be observed that individuals with the HG phenotype had on 
average a higher WHR at baseline examination compared to the reference category or the 
WG phenotype. The WG phenotype was characterized by highest rates of weight gain and 
on average younger individuals compared to the HG phenotype.  Besides, a tendency 
towards larger increase in waist than hip circumference in the reference categories was 
observed. 
 
  
  
 
 
 
Table 2 Participant characteristics of weight-gaining individuals from EPIC-Potsdam, DEGS and KORA
a 
 DEGS
b
  EPIC-Potsdam  KORA 
Baseline characteristics 
Women 
(n=1,006) 
Men 
(n=884) 
 Women 
(n=1,015) 
Men 
(n=629)  
Women 
(n=303) 
Men 
(n=289) 
Age at recruitment (yr) 43.3 ± 11.8 41.8 ± 12.8  48.2 ± 9.0 51.5 ± 8.0  62.8 ± 5.2 62.6 ± 5.2 
Body weight (kg) 68.3 ± 12.9 83.2 ± 11.8  66.9 ± 12.3 81.1 ± 11.4  71.9 ± 12.0 84.0 ± 11.2 
Waist circumference (cm) 82.0 ± 11.4 94.9 ± 10.6  79.3 ± 11.4 93.0 ± 9.6  89.1 ± 10.9 100.1 ± 9.1 
Hip circumference  (cm) 104.0 ± 10.0 104.8 ± 6.3  100.4 ± 8.6 99.6 ± 6.0  106.9 ± 9.1 104.7 ± 6.6 
BMI (kg/m²) 25.5 ± 4.7 26.6 ± 3.5  25.1 ± 4.4 26.5 ± 3.5  28.3 ± 4.6 28.2 ± 3.5 
WHR 0.79 ± 0.06 0.90 ± 0.07  0.79 ± 0.07 0.93 ± 0.06  0.83 ± 0.06 0.96 ± 0.05 
Prevalence of abdominal 
obesity (%)
c
 
28.1 24.6  20.3 18.4  51.5 35.3 
Alcohol consumption (g/d) 4.6 ± 8.4 15.5 ± 19.4  8.6 ± 10.5 24.5 ± 27.6  7.0 ± 10.7 25.9 ± 26.6 
                     
Average changes per year                     
Weight (kg/yr) 0.52 ± 0.42 0.55 ± 0.49  0.63 ± 0.54 0.62 ± 0.51  0.56 ± 0.56 0.54 ± 0.49 
Waist circumference (cm/yr) 0.64 ± 0.52 0.51 ± 0.52  1.12 ± 0.65 1.21 ± 0.66  0.86 ± 0.71 0.77 ± 0.62 
Hip circumference (cm/yr) 0.17 ± 0.46 -0.11 ± 0.37  0.53 ± 0.51 0.48 ± 0.41  0.57 ± 0.59 0.44 ± 0.51 
                     
Smoking status                     
Never smoker 286  (28.4) 308  (34.8)  598  (58.9) 181  (28.8)  214  (70.6) 91  (31.5) 
Former smoker 166  (16.5) 234  (26.5)  237  (23.3) 287  (45.6)  67  (22.1) 147  (50.9) 
Current smoker 554  (55.1) 342  (38.6)  180  (17.7) 161  (25.6)  22  (7.3) 51  (17.7) 
                     
Physical activity                     
< 1 h/week 594  (59.1) 501  (56.8)  611  (60.1) 408  64.8  157  (51.8) 170  (58.8) 
1-2h/week 209  (20.8) 150  (16.9)  263  (25.9) 110  17.5  94  (31.0) 66  (22.8) 
> 2h/week 203  (20.1) 233  (26.3)  142  (14.0) 111  17.7  52  (17.2) 53  (18.3) 
                     
Prevalence of diseases 76  (7.6) 69  (7.8)  151  (14.9) 124  19.7  67  22.1 92  31.8 
Abbreviations: BMI, body mass index; WHR, waist-to-hip ratio 
a 
Values are mean ± SD or n (%)  
b 
DEGS is standardized to the structure of the German population at 31.12.1997 
c 
Abdominal obesity defined as waist circumference >88 cm (women) / >102 cm (men) 
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4.2. Tendencies to a specific body fat distribution in weight-gaining individuals 
(objective 1) 
4.2.1. General tendencies 
Based on the average annual waist-hip difference, it could be observed that two 
different types of weight gainers appeared. Weight-gaining individuals with the preferred 
deposition in the peripheral region with body weight gain rather increased their hip 
circumference than their waist circumference indicated by a negative value for waist-hip 
difference; individuals with the preferred deposition of body fat in the abdominal region with 
body weight gain rather increased their waist than their hip circumference indicated by a 
positive value for average annual waist-hip difference. Both weight gain types appeared in 
men as well as in women with the majority of individuals tend to increase more waist 
circumference. This clear tendency towards stronger increase of waist circumference 
compared to hip circumference could be observed in all studies independent of sex (Figure 
10). Lowest waist-hip differences appeared within KORA (0.33 cm/yr for men; 0.29 cm/yr for 
women) whereas highest waist-hip differences appeared in EPIC-Potsdam (0.73 cm/yr for 
men; 0.60 cm/yr for women) (Table 3). Comparison of men and women in each study 
showed differences in EPIC-Potsdam and DEGS (p<.0001) but not in KORA (p=0.41). When 
comparing nationwide results of DEGS with regional results from EPIC-Potsdam and KORA, 
comparable tendencies across all studies could be observed.  
Table 3 Average annual changes of waist-hip difference with corresponding 95% confidence 
intervals (CI) and their correlation with average annual weight change specific by 
study  
 
   
Waist-hip difference 
(cm/yr) 
Pearson's r  
with  
weight change 
 study N Mean (95% CI)  
Men DEGS a 884 0.62 (0.59 ; 0.65) 0.27 
 
EPIC-Potsdam 629 0.73 (0.68 ; 0.78) 0.41 
 
KORA 289 0.33 (0.26 ; 0.40) 0.29 
      Women DEGS a 1006 0.47 (0.43 ; 0.50) 0.13 
 
EPIC-Potsdam 1015 0.60 (0.56 ; 0.63) 0.10 
 
KORA 303 0.29 (0.22 ; 0.36) 0.005 
a standardized to demographic structure of the German population at 31.12.1997 
Potential bias due to drop-out was addressed in a sensitivity analysis. Inverse 
probability weights for reparticipation at follow-up were applied in EPIC-Potsdam with a high 
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reparticipation rate of 92% and in DEGS with a comparably low reparticipation rate of 47% 
[3]. Average annual waist-hip difference as the variable of interest was robust, 10th and 90th 
percentiles as cut-offs for the formation of WG and HG phenotype did not change in none of 
the studies (Appendix 1). Therefore no weighting for drop-out was performed in this analysis. 
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 Figure 10 Distribution of average annual waist-hip difference in men and women stratified by 
study 
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4.2.2. Waist-hip difference in association to established anthropometric markers 
Weight-gaining men showed a consistently stronger correlation between waist-hip 
difference and average annual weight change than women. Among men, EPIC-Potsdam 
showed the strongest correlation with r=0.41 (p<.0001) and DEGS the weakest correlation 
(r=0.27, p<.0001) (Figure 11); among women, DEGS showed the highest correlation (r=0.13, 
p<.0001) whereas KORA showed no statistically significant correlation between waist-hip 
difference and amount of body weight gain (r=0.005, p=0.9270) (Table 3 and Table 4). Thus, 
with a higher rate of average annual weight gain men tend to accumulate more body fat on 
their waists whereas women tend to accumulate body fat equally with increasing rates of 
average annual weight gain. 
Table 4 Pearson correlation coefficients of waist-hip difference and established 
anthropometric markers by sex in EPIC-Potsdam 
  
Men  
(N = 629)   
Women  
(N = 1,015) 
Average annual changes Pearson´s r P 
 
Pearson´s r P 
Body weight (kg/yr) 0.41 <.0001  0.10 <.0001 
BMI (kg/m²/yr) 0.39 <.0001 
 
0.10 0.0015 
Waist circumference (cm/yr) 0.80 <.0001 
 
0.67 <.0001 
Hip circumference (cm/yr) -0.22 <.0001 
 
-0.30 <.0001 
WHR (U/yr) 0.99 <.0001 
 
0.98 <.0001 
Abbreviations: BMI, body mass index; WHR, waist-to-hip ratio 
Exclusively in EPIC-Potsdam, additional established anthropometric markers were 
investigated regarding their association to the average annual waist-hip difference. It could 
be observed, that different correlations with this difference appeared for men and women 
(Table 4). Average annual changes of BMI and waist circumference were observed to be 
stronger positively correlated in men than in women; on the opposite women showed a 
stronger inverse correlation with average annual waist-hip difference than men. 
It could be observed that results of Pearson correlation analyses reveal a nearly 
perfect correlation between average annual waist-hip difference and average annual 
changes in WHR (r=0.99 for men, r=0.98 for women, p<.0001). Thus, the majority of variance 
of average annual waist-hip difference could be as well explained by the average annual 
change in WHR. 
Average annual changes of waist circumference showed stronger correlation with 
waist-hip difference than average changes of hip circumference in both men and women 
(Figure 11). 
 Results 
  
 
44 
 
 
 
Figure 11 Scatter Plots with linear regression line and corresponding 95% confidence limits 
by sex and study 
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4.3. Identification of phenotype associated metabolites (objective 2) 
Based on the observed distribution across all studies, two different weight-gaining 
phenotypes could be defined through categorisation of average annual waist-hip difference in 
men and women: a WG and a HG phenotype.  
The lower 10% of the waist-hip difference defined as the HG phenotype was 
characterized by a significant tendency to increase more hip circumference in comparison to 
waist circumference in all studies for both men and women (Table 5). For men, mean waist-
hip differences in the HG phenotype ranged from -0.22 cm/yr (95% Confidence Interval (CI): 
-0.29 cm/yr; -0.16 cm/yr) for DEGS to -0.77 cm/yr (95% CI: -0.90 cm/yr; -0.65 cm/yr) in 
KORA. For women, mean difference ranged from -0.45 cm/yr (95% CI: -0.52 cm/yr; -0.37 
cm/yr) in EPIC-Potsdam to -0.90 cm/yr (95% CI: -1.00 cm/yr; -0.80 cm/yr) in KORA. 
The upper 10% of the waist-hip difference defined as the WG phenotype was 
characterized by a significant tendency to increase more waist circumference in comparison 
to hip circumference. For men, mean waist-hip difference ranged from 1.32 cm/yr (95% CI: 
1.21 cm/yr; 1.43 cm/yr) in KORA to 1.88 cm/yr (95% CI: 1.79 cm/yr; 1.97 cm/yr) in EPIC-
Potsdam.  
Table 5 Waist-hip difference and corresponding 95% confidence interval (CI) for defined 
phenotypes and overall specific by study 
  DEGS 
a
 EPIC-Potsdam KORA 
Men Phenotype Mean (95% CI) Mean (95% CI) Mean (95% CI) 
All weight 
gainers 
 
0.62 (0.59 ; 0.65) 0.73 (0.68 ; 0.78) 0.33 (0.26 ; 0.40) 
 WG 1.49 (1.43; 1.56) 1.88 (1.79; 1.97) 1.32 (1.21; 1.43) 
 HG -0.22 (-0.29;-0.16) -0.30 (-0.38;-0.22) -0.77 (-0.90; -0.65) 
Women        
All weight 
gainers 
 
0.47 (0.43 ; 0.50) 0.60 (0.56 ; 0.63) 0.29 (0.22 ; 0.36) 
 WG 1.54 (1.46; 1.62) 1.65 (1.57; 1.74) 1.42 (1.32; 1.53) 
 HG -0.46 (-0.52;-0.40) -0.45 (-0.52;-0.37) -0.90 (-1.00;-0.80) 
a standardized to demographic structure of the German population at 31.12.1997 
For EPIC-Potsdam and KORA, these two phenotypes were considered as the 
endpoints of sex-specific multiple logistic regression models. Meta-analytical combination of 
single-study results from EPIC-Potsdam and KORA identified 21 metabolites to be 
independently inversely associated with the WG phenotype in women, namely one AA, and 
20 glycerophospholipids (19 PCs and 1 lysoPC).  
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4.3.1. Main results of the meta-analytical approach 
The aromatic AA tryptophan, diacyl-PCs C32:3, C36:0, C38:0, C38:1, C42:2, C42:5, 
acyl-alkyl-PCs C32:2, C34:0, C36:0, C36:1, C36:2, C38:0, C38:2, C40:1, C40:2, C40:5, 
C40:6, C42:2, C42:3 and lyso-PC C17:0 could be identified as being associated with the WG 
phenotype in women (Table 6). Each of these metabolites showed inverse associations with 
increasing concentration. All statistically significant associations are within a range of OR 
0.66-0.73 (pFDR 0.0181-0.0474) i.e. if metabolite concentration of selected metabolites 
increases per one SD the chance of belonging to the WG phenotype decreases between 27 
and 34%. The lowest ORs were observed for acyl-alkyl-PCs C40:6 (OR: 0.66, 95% CI: 0.52-
0.82, pFDR=0.0181), C42:3 (OR: 0.67, 95% CI: 0.53-0.83, pFDR=0.0181), C38:0 (OR: 0.68, 
95% CI: 0.54-0.85, pFDR=0.0196) and C42:2 (OR: 0.68, 95% CI: 0.54-0.84, pFDR=0.0181). All 
associations of WG and HG phenotypes with baseline metabolite concentrations for each 
study and combined are reported in Table 6 to Table 9. After correction for multiple testing, 
associations with the WG phenotype in women remained significant; the combined and 
study-specific estimates of these associations are shown in Figure 13.  
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4.3.2. Women 
4.3.2.1. Waist-gaining phenotype 
Results obtained from the meta-analytical combination of single study estimates 
revealed 41 metabolites as being associated with the WG phenotype in women, 38 
glycerophospholipids (15 diacyl-, 20 acyl-alkyl, three lyso-PCs), two ACs and one AA (Table 
6). 
With regard to the single study results, 32 metabolites in EPIC-Potsdam and 19 
metabolites in KORA showed associations with the WG phenotype in women. The lowest 
ORs in EPIC-Potsdam were observed for acyl-alkyl-PCs C42:2 (OR: 0.62, 95% CI: 0.49-
0.85, p=0.0017) and C40:6 (OR: 0.65, 95% CI: 0.50-0.84, p=0.0012) and diacyl-PC C42:2 
(OR: 0.64, 95% CI: 0.49-0.85, p=0.0017). The lowest ORs for KORA were observed for 
diacyl-PC C28:1 (OR: 0.39, 95% CI: 0.23-0.67, p=0.0005), acyl-alkyl-PC C30:2 (OR: 0.45, 
95% CI: 0.26-0.78, p=0.0049) and hydroxy-SM C14:1 (OR: 0.46, 95% CI: 0.27-0.79, 
p=0.0051). There was no metabolite showing a positive association to the HG phenotype, 
neither in the meta-analytical approach nor in the single study results. 
In both studies, in particular PCs showed inverse associations. 28 out of 32 
metabolites in EPIC-Potsdam and 14 out of 19 metabolites associated with the WG 
phenotype in KORA belonged to the subclass of PC showing consistent inverse associations 
with the WG phenotype. In addition, AAs in EPIC-Potsdam and SMs in KORA were as well 
inversely associated.  
Taking multiple testing into account, aromatic AA tryptophan, diacyl-PCs C38:0, 
C42:2 and acyl-alkyl-PCs C40:6, C42:2 and C42:3 remained significant in their association in 
EPIC-Potsdam; no metabolite showed significant associations in KORA (Table 6). 
4.3.2.2. Hip-gaining phenotype 
Meta-analytical results revealed four metabolites as being associated with the HG 
phenotype in women, three glycerophospholipids (two diacyl- and one acyl-alkyl-PC) and 
one SM (Table 7). 
With regard to single study results, four metabolites in EPIC-Potsdam and 16 
metabolites in KORA showed associations with the HG phenotype in women. The lowest 
ORs for EPIC-Potsdam were observed for diacyl-PC C40:6 (OR: 0.71, 95% CI: 0.55-0.93, 
p=0.0125) and SM C24:0 (OR: 0.76, 95% CI: 0.59-0.98, p=0.0328); in contrast no metabolite 
showed inverse associations with the HG phenotype in KORA. In EPIC-Potsdam, highest 
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ORs were observed for ACs nonaylcarnitine (C9, OR: 1.31, 95% CI: 1.03-1.66, p=0.0304) 
and pimelylcarnitine (C7-DC, OR: 1.27, 95% CI: 1.00-1.61, p=0.0491), highest ORs in KORA 
were observed for acyl-alkyl-PCs C42:2 (OR: 2.10, 95% CI: 1.33-3.30, p=0.0014), C34:3 
(OR: 2.09, 95% CI: 1.36-3.22, p=0.0008) and C32:2 (OR: 2.00, 95% CI: 1.32-3.03, 
p=0.0012) (Table 7). 
Unexceptionally, all associated metabolites in KORA, which mainly belonged to the 
group of acyl-alkyl-PCs, showed positive associations with the HG phenotype. 
Taking multiple testing into account none of the metabolites showed statistically 
significant associations with the HG phenotype in women, neither in the single studies nor in 
the meta-analytical approach.  
 
For the 21 metabolites with a statistically significant association to the WG phenotype 
in the meta-analytical approach in women, the associations for both endpoints were 
compared to investigate if directions of observed associations for the two phenotypes differ. 
When comparing the results of both endpoints of metabolites showing statistically significant 
associations with the WG phenotype in women, it could be observed that 17 out of 21 
showed contrasting non-significant effect directions for the HG phenotype (Figure 13). Only 
aromatic AA tryptophan, diacyl-PC C42:5 and acyl-alkyl-PCs C40:1 and C42:2 had the same 
effect direction but showed much weaker strength for association with the HG phenotype. 
 
4.3.3. Men 
4.3.3.1. Waist-gaining phenotype 
Meta-analytical results revealed eight metabolites as being associated with the WG 
phenotype in men, five glycerophospholipids (three diacyl-, two acyl-alkyl-, one lyso-PC), one 
AC and two SMs (Table 8). 
With regard to the single study results for men, 21 metabolites in EPIC-Potsdam and 
eight metabolites in KORA showed associations with the WG phenotype in men. The lowest 
ORs for EPIC-Potsdam were observed for diacyl-PCs C42:1 (OR: 0.56, 95% CI: 0.39-0.81, 
p=0.0017), C44:3 (OR: 0.60, 95% CI: 0.42-0.87, p=0.0065) and C32:1 (OR: 0.61, 95% CI: 
0.42-0.88, p=0.0087); in contrast no metabolite showed inverse associations in KORA. In 
EPIC-Potsdam, SMs C18:0 (OR: 1.37, 95% CI: 1.01-1.86, p=0.0448) and C18:1 (OR: 1.36, 
95% CI: 1.02-1.81, p=0.0352) showed positive associations with the WG phenotype in men; 
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in contrast SM C16:1 (OR: 1,77, 95% CI: 1.08-2.92, p=0.0244), AC hexadecanoylcarnitine 
(C16, OR: 1.71, 95% CI: 1.15-2,54, p=0.0079) and diacyl-PC C34:2 (OR: 1.69, 95% CI: 1.14-
2.51, p=0.0096) showed the strongest positive associations in KORA. 
In both studies, in particular PCs were associated with the WG phenotype in men. 19 
out of 21 metabolites in EPIC-Potsdam and three out of eight metabolites in KORA were part 
of this subclass of phospholipids. PCs in EPIC-Potsdam showed consistent inverse 
associations whereas PCs in KORA showed positive associations. Furthermore, SMs were 
observed to be positively associated in both studies. Additionally, majority of associations in 
KORA were positive with seven out of eight metabolites being positively associated (Table 
8).  
None of the associations between metabolites and the WG phenotype remained 
statistically significant when taking multiple testing into account, neither in the meta-analytical 
approach nor in the single study results. 
4.3.3.2. Hip-gaining phenotype 
Meta-analytical results revealed four metabolites as being associated with the HG 
phenotype in men, one diacyl-PC, one AA and two ACs (Table 9) 
With regard to single study results, four metabolites in EPIC-Potsdam and three 
metabolites in KORA were observed as being associated with the HG phenotype in men. An 
inverse association was observed for diacyl-PC C38:1 (OR: 0.67, 95% CI: 0.47-0.97, 
p=0.0326) for EPIC-Potsdam and for AAs glycine (OR: 0.47, 95% CI: 0.24-0.89, p=0.0217), 
phenylalanine (OR: 0.57, 95% CI: 0.34-0.96, p=0.0331) and valine (OR: 0.59, 95% CI: 0.36-
0.98, p=0.0414). Positive associations were observed in EPIC-Potsdam for ACs 
octadecanoylcarnitine (C18:0, OR: 1.50, 95% CI: 1.12-2.00, p=0.0063), 
octadecenoylcarnitine (C18:1, OR: 1.40, 95% CI: 1.06-1.85, p=0.0167) and diacyl-PC C28:1 
(OR: 1.35, 95% CI: 1.01-1.78, p=0.0395); in contrast no positive association could be 
observed for HG phenotype for men in KORA (Table 9). 
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4.3.4. Sensitivity and subgroup analyses 
To test whether associations of identified metabolites are robust, two sensitivity 
analyses were performed in a subsample of individuals without any prevalent disease at 
baseline or follow-up examination and in a subsample of non-menopausal women. 
In EPIC-Potsdam and KORA, sensitivity analyses showed that associations were 
independent of disease status and also appeared in the population without prevalent 
diseases (Appendix 3). Results of the subgroup analyses (without correcting for multiple 
testing) were consistent regarding strength and direction of the association compared to the 
overall analytical study population. All other results were not significant, whereas the majority 
of remaining results were as well consistent. 
Because women in KORA had a comparably high mean age and the majority of 
women were postmenopausal, sensitivity analysis with regard to menopausal status was 
exclusively performed in EPIC-Potsdam. Results within this sub-population showed 
consistent results compared to the overall analytical study population indicating that the 
identified association is independent of menopausal status (Appendix 3). 
Furthermore, several subgroup analyses were performed to investigate the 
robustness of the identified associations. Significant associations (without correction for 
multiple testing) in the subgroups of physical activity (cut-off <1h/week), age (cut-off >55 
years), abdominal obesity (cut-offs waist circumference ≥102cm for men and ≥88cm for 
women) and alcohol consumption (cut-offs <20g/d for men and <10g/d for women) showed 
consistent results concerning strength and direction of associations. For the remaining non-
significant associations in the investigated subgroups, the majority showed consistent 
strength and direction of associations (Appendix 4). 
  
 
 
Table 6 Combined fixed-effects meta-analytic and study-specific association of metabolites with the waist-gaining phenotype in women a 
 
Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p-value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p-value 
meta 
weight 
Amino Acids                 
Arginine 0.81 0.66 1.00 0.1428 
 
0.81 0.64 1.04 0.0949 75.3%   0.80 0.53 1.22 0.3026 24.7% 
Glutamine 0.87 0.71 1.07 0.3315 
 
0.81 0.64 1.02 0.0686 76.5%   1.11 0.73 1.70 0.6169 23.5% 
Glycine 0.89 0.73 1.09 0.3993 
 
0.78 0.61 1.00 0.0453 66.6%   1.17 0.83 1.66 0.3650 33.4% 
Histidine 0.94 0.77 1.15 0.6657 
 
0.92 0.72 1.16 0.4815 73.8%   1.00 0.67 1.50 0.9834 26.2% 
Methionine 0.81 0.64 1.03 0.2272 
 
0.70 0.52 0.93 0.0143 69.4%   1.14 0.74 1.77 0.5544 30.6% 
Ornithine 0.94 0.76 1.14 0.6395 
 
0.88 0.69 1.11 0.2773 71.7%   1.11 0.76 1.62 0.6060 28.3% 
Phenylalanine 0.82 0.66 1.02 0.2013 
 
0.82 0.64 1.05 0.1141 75.8%   0.83 0.53 1.29 0.4084 24.2% 
Proline 1.00 0.81 1.23 0.9995 
 
1.00 0.80 1.26 0.9943 82.6%   0.99 0.60 1.62 0.9693 17.4% 
Serine 0.88 0.71 1.08 0.3489 
 
0.75 0.59 0.97 0.0279 68.6%   1.22 0.84 1.77 0.3053 31.4% 
Threonine 0.95 0.76 1.18 0.7224 
 
0.83 0.65 1.07 0.1498 76.5%   1.43 0.92 2.24 0.1150 23.5% 
Tryptophan 0.71 0.57 0.88 0.0253* 
 
0.67 0.52 0.85 0.0013 75.8%   0.88 0.56 1.36 0.5580 24.2% 
Tyrosine 0.93 0.75 1.15 0.6229 
 
0.88 0.69 1.13 0.3076 75.3%   1.10 0.71 1.69 0.6725 24.7% 
Valine 0.91 0.71 1.15 0.5541 
 
0.83 0.62 1.10 0.1947 69.7%   1.12 0.73 1.74 0.5991 30.3% 
Hexose 
          
  
     H1 1.00 0.79 1.26 0.9995 
 
0.92 0.70 1.21 0.5631 70.4%   1.21 0.79 1.85 0.3759 29.6% 
Acylcarnitines 
          
  
     C0 1.02 0.83 1.25 0.9018 
 
0.97 0.77 1.22 0.7931 75.8%   1.20 0.80 1.81 0.3826 24.2% 
C2 0.92 0.75 1.13 0.5541 
 
0.89 0.71 1.12 0.3196 80.6%   1.05 0.66 1.67 0.8461 19.4% 
C3 1.06 0.87 1.30 0.6657 
 
1.01 0.80 1.28 0.9401 74.9%   1.25 0.83 1.87 0.2852 25.1% 
C5-OH (C3-DC-M) 1.14 0.94 1.38 0.3315 
 
1.16 0.94 1.43 0.1724 80.0%   1.07 0.70 1.64 0.7450 20.0% 
C7-DC 0.88 0.71 1.09 0.3853 
 
0.92 0.73 1.16 0.4776 86.7%   0.66 0.37 1.19 0.1714 13.3% 
C9 0.90 0.73 1.12 0.4898 
 
0.94 0.75 1.19 0.6249 83.4%   0.72 0.43 1.21 0.2148 16.6% 
C10 0.81 0.63 1.05 0.2755 
 
0.85 0.64 1.13 0.2646 82.4%   0.65 0.35 1.21 0.1749 17.6% 
C10:2 1.04 0.85 1.27 0.7788 
 
1.07 0.86 1.34 0.5337 78.3%   0.93 0.61 1.42 0.7330 21.7% 
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Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p-value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p-value 
meta 
weight 
C14:1 0.86 0.69 1.07 0.3315 
 
0.88 0.70 1.12 0.2972 81.5%   0.77 0.47 1.28 0.3165 18.5% 
C14:2 0.93 0.76 1.14 0.6039 
 
0.92 0.73 1.15 0.4503 79.2%   0.98 0.63 1.52 0.9386 20.8% 
C16 0.77 0.62 0.96 0.0815 
 
0.82 0.64 1.04 0.1041 79.4%   0.63 0.39 1.02 0.0613 20.6% 
C18 0.79 0.63 0.98 0.1102 
 
0.82 0.64 1.05 0.1175 79.7%   0.67 0.41 1.10 0.1137 20.3% 
C18:1 0.85 0.69 1.05 0.2965 
 
0.86 0.68 1.09 0.2191 79.9%   0.81 0.50 1.31 0.3902 20.1% 
C18:2 0.98 0.80 1.19 0.8721 
 
0.95 0.76 1.19 0.6415 81.2%   1.10 0.69 1.76 0.6883 18.8% 
Diacyl-Phosphatidylcholines 
        
  
     PC aa C28:1 0.79 0.63 0.98 0.1037 
 
0.91 0.72 1.15 0.4268 83.0%   0.39 0.23 0.67 0.0005 17.0% 
PC aa C30:0 0.88 0.71 1.08 0.3488 
 
0.92 0.73 1.17 0.5041 77.6%   0.73 0.47 1.13 0.1563 22.4% 
PC aa C32:0 0.84 0.68 1.05 0.2926 
 
0.82 0.64 1.05 0.1184 77.1%   0.92 0.58 1.46 0.7313 22.9% 
PC aa C32:1 0.90 0.72 1.12 0.4773 
 
0.89 0.69 1.14 0.3598 78.1%   0.91 0.57 1.47 0.7124 21.9% 
PC aa C32:2 0.85 0.69 1.06 0.2995 
 
0.93 0.73 1.18 0.5345 79.5%   0.62 0.39 0.99 0.0456 20.5% 
PC aa C32:3 0.69 0.55 0.86 0.0196* 
 
0.69 0.54 0.88 0.0034 78.4%   0.69 0.43 1.11 0.1297 21.6% 
PC aa C34:1 0.88 0.71 1.09 0.3901 
 
0.93 0.73 1.17 0.5253 80.7%   0.73 0.45 1.18 0.1974 19.3% 
PC aa C34:2 0.88 0.71 1.08 0.3594 
 
0.94 0.75 1.18 0.5856 81.5%   0.66 0.41 1.07 0.0916 18.5% 
PC aa C34:3 0.85 0.69 1.05 0.2965 
 
0.85 0.67 1.08 0.1813 76.6%   0.87 0.56 1.33 0.5173 23.4% 
PC aa C34:4 0.96 0.78 1.18 0.7788 
 
1.05 0.83 1.31 0.6993 80.2%   0.68 0.43 1.07 0.0947 19.8% 
PC aa C36:0 0.70 0.56 0.88 0.0229* 
 
0.69 0.54 0.89 0.0043 76.5%   0.74 0.47 1.16 0.1894 23.5% 
PC aa C36:1 0.87 0.71 1.07 0.3409 
 
0.90 0.71 1.15 0.3995 75.9%   0.78 0.51 1.19 0.2417 24.1% 
PC aa C36:2 0.87 0.71 1.07 0.3315 
 
0.92 0.73 1.16 0.4729 79.1%   0.70 0.45 1.09 0.1174 20.9% 
PC aa C36:3 0.91 0.74 1.12 0.5111 
 
1.00 0.80 1.26 0.9989 83.2%   0.56 0.34 0.94 0.0279 16.8% 
PC aa C36:4 1.03 0.84 1.27 0.8400 
 
1.12 0.90 1.40 0.3177 84.6%   0.66 0.39 1.11 0.1172 15.4% 
PC aa C36:5 0.85 0.66 1.08 0.3315 
 
0.84 0.64 1.12 0.2315 76.1%   0.86 0.52 1.41 0.5475 23.9% 
PC aa C36:6 0.77 0.61 0.97 0.0961 
 
0.81 0.62 1.06 0.1206 76.0%   0.65 0.41 1.05 0.0767 24.0% 
PC aa C38:0 0.69 0.56 0.86 0.0196* 
 
0.67 0.52 0.86 0.0016 76.1%   0.78 0.50 1.22 0.2796 23.9% 
PC aa C38:1 0.69 0.55 0.87 0.0229* 
 
0.73 0.56 0.95 0.0173 76.0%   0.59 0.37 0.95 0.0281 24.0% 
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Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p-value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p-value 
meta 
weight 
PC aa C38:3 0.94 0.75 1.18 0.7030 
 
1.09 0.85 1.39 0.5081 82.4%   0.48 0.28 0.82 0.0068 17.6% 
PC aa C38:4 1.00 0.81 1.23 0.9995 
 
1.10 0.87 1.38 0.4191 81.6%   0.66 0.41 1.07 0.0900 18.4% 
PC aa C38:5 0.85 0.68 1.05 0.2965 
 
0.88 0.69 1.13 0.3184 78.5%   0.74 0.46 1.18 0.2025 21.5% 
PC aa C38:6 0.76 0.61 0.94 0.0572 
 
0.81 0.63 1.04 0.0986 77.0%   0.60 0.38 0.94 0.0259 23.0% 
PC aa C40:2 0.75 0.59 0.97 0.0996 
 
0.71 0.52 0.97 0.0321 66.1%   0.85 0.55 1.30 0.4479 33.9% 
PC aa C40:3 0.76 0.60 0.95 0.0789 
 
0.75 0.58 0.99 0.0389 72.8%   0.77 0.50 1.19 0.2393 27.2% 
PC aa C40:4 0.98 0.79 1.21 0.9018 
 
1.05 0.83 1.33 0.6710 82.2%   0.70 0.43 1.17 0.1749 17.8% 
PC aa C40:5 0.85 0.68 1.07 0.3212 
 
0.91 0.71 1.18 0.4835 77.5%   0.67 0.42 1.07 0.0960 22.5% 
PC aa C40:6 0.74 0.59 0.93 0.0535 
 
0.78 0.60 1.02 0.0669 74.3%   0.63 0.40 0.99 0.0465 25.7% 
PC aa C42:0 0.79 0.64 0.98 0.1102 
 
0.72 0.56 0.92 0.0097 73.4%   1.05 0.69 1.59 0.8310 26.6% 
PC aa C42:1 0.77 0.62 0.96 0.0798 
 
0.71 0.55 0.91 0.0070 73.5%   0.99 0.65 1.51 0.9569 26.5% 
PC aa C42:2 0.72 0.56 0.91 0.0353* 
 
0.64 0.49 0.85 0.0017 73.6%   0.97 0.61 1.54 0.9040 26.4% 
PC aa C42:4 0.85 0.69 1.04 0.2646 
 
0.84 0.67 1.06 0.1455 75.3%   0.86 0.57 1.30 0.4728 24.7% 
PC aa C42:5 0.72 0.57 0.91 0.0353* 
 
0.75 0.58 0.99 0.0393 76.1%   0.62 0.38 0.99 0.0464 23.9% 
PC aa C42:6 0.76 0.61 0.95 0.0785 
 
0.78 0.60 1.00 0.0540 76.6%   0.71 0.45 1.13 0.1474 23.4% 
Acyl-alkyl-Phosphatidylcholines 
        
  
     PC ae C30:0 0.76 0.61 0.94 0.0572 
 
0.79 0.62 1.01 0.0560 78.2%   0.66 0.41 1.04 0.0723 21.8% 
PC ae C30:2 0.74 0.59 0.94 0.0572 
 
0.82 0.64 1.06 0.1306 83.2%   0.45 0.26 0.78 0.0049 16.8% 
PC ae C32:1 0.80 0.65 0.98 0.1037 
 
0.79 0.62 1.00 0.0483 74.9%   0.83 0.56 1.25 0.3827 25.1% 
PC ae C32:2 0.73 0.59 0.90 0.0307* 
 
0.72 0.57 0.92 0.0079 77.0%   0.74 0.48 1.15 0.1857 23.0% 
PC ae C34:0 0.72 0.58 0.90 0.0353* 
 
0.73 0.57 0.94 0.0150 75.9%   0.70 0.45 1.10 0.1201 24.1% 
PC ae C34:1 0.79 0.64 0.98 0.0996 
 
0.83 0.65 1.05 0.1208 77.8%   0.67 0.43 1.05 0.0797 22.2% 
PC ae C34:2 0.92 0.75 1.13 0.5541 
 
0.99 0.78 1.25 0.9054 77.8%   0.72 0.46 1.11 0.1403 22.2% 
PC ae C34:3 0.86 0.70 1.05 0.2965 
 
0.85 0.67 1.08 0.1764 74.5%   0.88 0.58 1.32 0.5259 25.5% 
PC ae C36:0 0.72 0.58 0.91 0.0353* 
 
0.71 0.55 0.91 0.0081 78.7%   0.79 0.48 1.29 0.3401 21.3% 
PC ae C36:1 0.73 0.59 0.91 0.0353* 
 
0.80 0.63 1.03 0.0781 79.7%   0.52 0.32 0.84 0.0082 20.3% 
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Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p-value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p-value 
meta 
weight 
PC ae C36:2 0.71 0.56 0.88 0.0282* 
 
0.77 0.60 0.99 0.0452 79.9%   0.49 0.30 0.82 0.0064 20.1% 
PC ae C36:3 0.89 0.73 1.09 0.3993 
 
0.95 0.75 1.19 0.6265 76.6%   0.74 0.49 1.12 0.1526 23.4% 
PC ae C36:4 1.04 0.86 1.27 0.7619 
 
1.06 0.85 1.32 0.6264 77.9%   1.00 0.66 1.52 0.9856 22.1% 
PC ae C36:5 0.91 0.74 1.11 0.5029 
 
0.90 0.72 1.13 0.3771 76.6%   0.94 0.62 1.42 0.7609 23.4% 
PC ae C38:0 0.68 0.54 0.85 0.0196* 
 
0.69 0.54 0.90 0.0053 76.5%   0.64 0.40 1.02 0.0596 23.5% 
PC ae C38:1 0.94 0.78 1.15 0.6657 
 
0.95 0.76 1.19 0.6287 75.4%   0.93 0.63 1.38 0.7321 24.6% 
PC ae C38:2 0.75 0.60 0.93 0.0474* 
 
0.77 0.61 0.99 0.0407 76.6%   0.67 0.43 1.05 0.0790 23.4% 
PC ae C38:3 0.82 0.67 1.02 0.2013 
 
0.94 0.74 1.19 0.6083 80.7%   0.48 0.29 0.77 0.0025 19.3% 
PC ae C38:4 0.90 0.73 1.10 0.4563 
 
0.95 0.76 1.20 0.6725 80.7%   0.71 0.44 1.13 0.1451 19.3% 
PC ae C38:5 0.92 0.75 1.12 0.5248 
 
0.89 0.71 1.12 0.3295 77.8%   1.00 0.65 1.53 0.9971 22.2% 
PC ae C38:6 0.78 0.63 0.96 0.0798 
 
0.78 0.61 0.99 0.0419 76.8%   0.77 0.49 1.20 0.2541 23.2% 
PC ae C40:1 0.70 0.56 0.87 0.0196* 
 
0.71 0.55 0.90 0.0058 77.2%   0.67 0.42 1.05 0.0807 22.8% 
PC ae C40:2 0.73 0.58 0.91 0.0353* 
 
0.78 0.60 1.00 0.0526 76.6%   0.59 0.37 0.93 0.0243 23.4% 
PC ae C40:3 0.78 0.63 0.96 0.0815 
 
0.83 0.65 1.05 0.1184 80.4%   0.61 0.38 0.98 0.0428 19.6% 
PC ae C40:4 0.77 0.61 0.96 0.0792 
 
0.78 0.61 1.00 0.0536 77.7%   0.72 0.45 1.14 0.1632 22.3% 
PC ae C40:5 0.73 0.58 0.91 0.0353* 
 
0.71 0.55 0.91 0.0079 76.8%   0.81 0.51 1.28 0.3605 23.2% 
PC ae C40:6 0.66 0.52 0.82 0.0181* 
 
0.65 0.50 0.84 0.0012 74.9%   0.67 0.43 1.05 0.0807 25.1% 
PC ae C42:1 0.84 0.68 1.03 0.2510 
 
0.84 0.67 1.07 0.1521 78.6%   0.83 0.53 1.30 0.4050 21.4% 
PC ae C42:2 0.68 0.54 0.84 0.0181* 
 
0.62 0.48 0.81 0.0004 70.2%   0.82 0.55 1.22 0.3276 29.8% 
PC ae C42:3 0.67 0.53 0.83 0.0181* 
 
0.67 0.52 0.86 0.0015 78.3%   0.67 0.41 1.07 0.0917 21.7% 
PC ae C42:4 0.88 0.71 1.09 0.3898 
 
0.89 0.69 1.14 0.3474 76.6%   0.86 0.55 1.34 0.5005 23.4% 
PC ae C42:5 0.84 0.68 1.05 0.2926 
 
0.81 0.63 1.04 0.0990 75.1%   0.96 0.62 1.48 0.8421 24.9% 
PC ae C44:3 0.88 0.72 1.08 0.3669 
 
0.90 0.72 1.13 0.3726 78.9%   0.82 0.53 1.27 0.3756 21.1% 
PC ae C44:4 0.87 0.71 1.07 0.3315 
 
0.85 0.67 1.07 0.1651 75.5%   0.94 0.62 1.43 0.7862 24.5% 
PC ae C44:5 0.92 0.76 1.13 0.5726 
 
0.90 0.72 1.14 0.3854 77.4%   1.00 0.65 1.53 0.9957 22.6% 
PC ae C44:6 0.91 0.74 1.12 0.5248 
 
0.85 0.67 1.07 0.1674 77.0%   1.18 0.76 1.81 0.4623 23.0% 
 
5
4
 
    
Table continued on the next page 
 
R
e
s
u
lts
 
   
  
 
 
 
Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p-value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p-value 
meta 
weight 
Lyso-Phosphatidylcholines 
        
  
     lysoPC a C14:0 0.91 0.74 1.12 0.5248 
 
0.94 0.74 1.19 0.6169 76.8%   0.82 0.53 1.26 0.3658 23.2% 
lysoPC a C16:0 0.82 0.65 1.02 0.1931 
 
0.77 0.60 0.99 0.0421 75.8%   0.98 0.62 1.52 0.9133 24.2% 
lysoPC a C16:1 0.82 0.64 1.05 0.2729 
 
0.77 0.58 1.02 0.0641 74.0%   1.00 0.62 1.60 0.9927 26.0% 
lysoPC a C17:0 0.73 0.58 0.91 0.0353* 
 
0.70 0.54 0.90 0.0062 74.3%   0.82 0.53 1.27 0.3767 25.7% 
lysoPC a C18:0 0.81 0.65 0.99 0.1188 
 
0.76 0.60 0.98 0.0302 72.1%   0.92 0.62 1.36 0.6848 27.9% 
lysoPC a C18:1 0.79 0.63 0.99 0.1188 
 
0.68 0.52 0.88 0.0037 75.9%   1.26 0.79 2.00 0.3334 24.1% 
lysoPC a C18:2 0.87 0.70 1.08 0.3409 
 
0.78 0.61 1.00 0.0476 74.8%   1.20 0.78 1.84 0.4040 25.2% 
lysoPC a C20:3 0.87 0.70 1.08 0.3488 
 
0.88 0.69 1.13 0.3071 79.5%   0.83 0.51 1.35 0.4462 20.5% 
lysoPC a C20:4 0.92 0.74 1.14 0.5851 
 
0.84 0.65 1.07 0.1506 77.5%   1.29 0.82 2.05 0.2681 22.5% 
lysoPC a C28:1 0.87 0.71 1.08 0.3447 
 
0.92 0.73 1.16 0.4767 80.9%   0.70 0.43 1.13 0.1405 19.1% 
Sphingomyelins 
          
  
     SM C16:0 1.00 0.82 1.22 0.9983 
 
1.00 0.80 1.25 0.9942 80.0%   1.02 0.66 1.59 0.9267 20.0% 
SM C16:1 0.98 0.80 1.21 0.9230 
 
1.00 0.80 1.26 0.9806 81.1%   0.91 0.57 1.45 0.6823 18.9% 
SM C18:0 1.03 0.84 1.27 0.8578 
 
1.15 0.91 1.45 0.2386 81.7%   0.63 0.39 1.03 0.0643 18.3% 
SM C18:1 0.95 0.77 1.17 0.7224 
 
1.01 0.80 1.27 0.9677 80.6%   0.74 0.46 1.20 0.2249 19.4% 
SM C20:2 0.85 0.69 1.06 0.2995 
 
0.89 0.70 1.14 0.3654 77.6%   0.73 0.46 1.14 0.1647 22.4% 
SM C24:0 1.03 0.84 1.25 0.8721 
 
1.09 0.87 1.37 0.4428 76.8%   0.83 0.55 1.26 0.3853 23.2% 
SM C24:1 1.01 0.83 1.23 0.9756 
 
1.03 0.83 1.28 0.7874 79.9%   0.93 0.60 1.43 0.7278 20.1% 
SM C26:1 1.04 0.85 1.28 0.7788 
 
1.02 0.81 1.29 0.8413 77.2%   1.10 0.72 1.69 0.6515 22.8% 
SM (OH) C14:1 0.85 0.68 1.05 0.2965 
 
0.95 0.75 1.20 0.6590 84.3%   0.46 0.27 0.79 0.0051 15.7% 
SM (OH) C16:1 0.87 0.70 1.07 0.3409 
 
0.95 0.75 1.20 0.6363 84.1%   0.55 0.32 0.94 0.0285 15.9% 
SM (OH) C22:1 0.91 0.74 1.11 0.4898 
 
0.99 0.79 1.25 0.9303 80.8%   0.62 0.39 0.99 0.0474 19.2% 
SM (OH) C22:2 0.87 0.71 1.08 0.3488 
 
0.96 0.77 1.20 0.7201 85.1%   0.52 0.30 0.89 0.0171 14.9% 
SM (OH) C24:1 0.99 0.81 1.21 0.9855   1.03 0.82 1.29 0.7889 78.2%   0.87 0.57 1.34 0.5286 21.8% 
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Abbreviations: a, acyl; ae, acyl-alkyl; aa, diacyl; PC, phosphatidylcholine; SM, sphingomyelin 
a
 Adjusted for age, baseline measures of BMI, waist and hip circumference, smoking status, prevalent and incident diseases including myocardial   
infarction, stroke, diabetes and any type of cancer 
*Statistically significant after correction for multiple testing (PFDR<0.05) 
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Table 7 Combined fixed-effects meta-analytic and study-specific association of metabolites with the hip-gaining phenotype in women a 
 
Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
Amino Acids                 
Arginine 0.85 0.68 1.06 0.8165 
 
0.91 0.71 1.16 0.4404 78.3%   0.66 0.41 1.06 0.0856 21.7% 
Glutamine 1.07 0.87 1.32 0.8277 
 
1.03 0.80 1.31 0.8368 73.9%   1.20 0.79 1.82 0.3862 26.1% 
Glycine 1.06 0.86 1.31 0.8277 
 
1.08 0.84 1.38 0.5589 72.4%   1.02 0.68 1.53 0.9257 27.6% 
Histidine 1.01 0.82 1.25 0.9697 
 
0.99 0.77 1.27 0.9132 71.6%   1.07 0.72 1.59 0.7405 28.4% 
Methionine 1.00 0.81 1.23 0.9939 
 
1.00 0.79 1.26 0.9870 76.0%   1.00 0.66 1.52 0.9885 24.0% 
Ornithine 0.90 0.73 1.12 0.8165 
 
0.93 0.72 1.19 0.5645 72.5%   0.84 0.56 1.26 0.3941 27.5% 
Phenylalanine 0.92 0.75 1.14 0.8165 
 
0.99 0.78 1.26 0.9507 76.2%   0.74 0.48 1.14 0.1679 23.8% 
Proline 1.15 0.92 1.43 0.8165 
 
1.20 0.93 1.53 0.1565 79.1%   0.99 0.61 1.60 0.9671 20.9% 
Serine 1.14 0.92 1.41 0.8165 
 
1.03 0.79 1.34 0.8318 67.0%   1.39 0.96 2.01 0.0852 33.0% 
Threonine 1.03 0.82 1.29 0.9044 
 
0.91 0.69 1.19 0.4843 69.7%   1.36 0.90 2.05 0.1430 30.3% 
Tryptophan 0.97 0.79 1.20 0.8813 
 
1.00 0.79 1.28 0.9831 76.4%   0.87 0.57 1.35 0.5415 23.6% 
Tyrosine 1.05 0.86 1.29 0.8277 
 
1.08 0.86 1.36 0.5094 76.1%   0.97 0.65 1.46 0.8979 23.9% 
Valine 1.10 0.89 1.36 0.8165 
 
1.18 0.93 1.50 0.1841 76.1%   0.89 0.58 1.37 0.6074 23.9% 
Hexose 
          
  
     H1 1.04 0.86 1.27 0.8277 
 
1.06 0.85 1.31 0.6091 81.2%   0.99 0.64 1.55 0.9748 18.8% 
Acylcarnitines 
          
  
     C0 1.22 0.98 1.53 0.8165 
 
1.18 0.91 1.53 0.2160 74.0%   1.35 0.87 2.09 0.1846 26.0% 
C2 1.09 0.87 1.35 0.8165 
 
1.08 0.83 1.39 0.5742 72.8%   1.11 0.73 1.69 0.6298 27.2% 
C3 1.15 0.93 1.42 0.8165 
 
1.12 0.88 1.44 0.3516 73.6%   1.21 0.80 1.83 0.3587 26.4% 
C5-OH (C3-DC-M) 1.07 0.88 1.31 0.8277 
 
1.12 0.89 1.41 0.3212 75.0%   0.93 0.62 1.38 0.7133 25.0% 
C7-DC 1.16 0.93 1.44 0.8165 
 
1.27 1.00 1.61 0.0491 83.3%   0.73 0.43 1.25 0.2557 16.7% 
C9 1.24 1.00 1.54 0.8165 
 
1.31 1.03 1.66 0.0304 79.9%   1.01 0.62 1.63 0.9717 20.1% 
C10 1.18 0.99 1.40 0.8165 
 
1.15 0.93 1.42 0.1868 69.9%   1.23 0.90 1.70 0.1941 30.1% 
C10:2 1.01 0.83 1.24 0.9697 
 
1.08 0.86 1.36 0.4967 80.5%   0.77 0.48 1.21 0.2572 19.5% 
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Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
C14:1 1.10 0.89 1.35 0.8165 
 
1.09 0.85 1.40 0.5168 71.4%   1.12 0.75 1.66 0.5808 28.6% 
C14:2 1.22 0.99 1.51 0.8165 
 
1.26 0.99 1.61 0.0656 74.2%   1.12 0.74 1.70 0.5892 25.8% 
C16 1.06 0.85 1.33 0.8277 
 
1.08 0.84 1.41 0.5463 74.0%   1.00 0.65 1.55 0.9945 26.0% 
C18 0.98 0.78 1.21 0.9044 
 
0.92 0.71 1.19 0.5163 73.8%   1.16 0.76 1.77 0.5015 26.2% 
C18:1 1.05 0.84 1.31 0.8277 
 
1.00 0.77 1.30 0.9929 70.6%   1.19 0.79 1.79 0.4057 29.4% 
C18:2 1.05 0.84 1.31 0.8277 
 
0.98 0.76 1.26 0.8555 76.4%   1.33 0.84 2.11 0.2251 23.6% 
Diacyl-Phosphatidylcholines 
         
  
     PC aa C28:1 1.01 0.81 1.25 0.9832 
 
0.97 0.75 1.26 0.8299 71.8%   1.10 0.73 1.66 0.6588 28.2% 
PC aa C30:0 0.93 0.75 1.16 0.8277 
 
0.94 0.73 1.21 0.6271 76.3%   0.91 0.58 1.43 0.6824 23.7% 
PC aa C32:0 0.99 0.80 1.23 0.9697 
 
0.91 0.71 1.17 0.4633 76.6%   1.30 0.83 2.03 0.2542 23.4% 
PC aa C32:1 0.92 0.74 1.14 0.8165 
 
0.93 0.73 1.19 0.5533 80.9%   0.88 0.53 1.45 0.6065 19.1% 
PC aa C32:2 0.86 0.69 1.06 0.8165 
 
0.90 0.70 1.16 0.4306 75.1%   0.73 0.47 1.12 0.1516 24.9% 
PC aa C32:3 1.04 0.84 1.29 0.8344 
 
0.95 0.74 1.22 0.7075 74.4%   1.33 0.87 2.03 0.1848 25.6% 
PC aa C34:1 0.89 0.72 1.11 0.8165 
 
0.86 0.67 1.10 0.2333 74.5%   1.01 0.66 1.55 0.9702 25.5% 
PC aa C34:2 0.91 0.74 1.12 0.8165 
 
0.85 0.67 1.09 0.1984 71.9%   1.07 0.72 1.58 0.7459 28.1% 
PC aa C34:3 0.90 0.73 1.11 0.8165 
 
0.89 0.69 1.13 0.3278 74.4%   0.95 0.63 1.44 0.8138 25.6% 
PC aa C34:4 0.89 0.72 1.10 0.8165 
 
0.95 0.74 1.22 0.6746 75.4%   0.73 0.47 1.12 0.1483 24.6% 
PC aa C36:0 1.08 0.86 1.34 0.8277 
 
0.93 0.72 1.19 0.5645 76.0%   1.71 1.10 2.67 0.0179 24.0% 
PC aa C36:1 0.83 0.67 1.03 0.8165 
 
0.82 0.64 1.05 0.1076 73.9%   0.88 0.58 1.33 0.5397 26.1% 
PC aa C36:2 0.85 0.69 1.05 0.8165 
 
0.80 0.62 1.03 0.0797 69.0%   0.97 0.67 1.41 0.8830 31.0% 
PC aa C36:3 0.92 0.75 1.14 0.8165 
 
0.92 0.72 1.17 0.4786 72.8%   0.95 0.64 1.41 0.7853 27.2% 
PC aa C36:4 0.91 0.73 1.13 0.8165 
 
0.90 0.70 1.15 0.3891 74.6%   0.95 0.62 1.46 0.8326 25.4% 
PC aa C36:5 0.97 0.79 1.19 0.8813 
 
0.90 0.71 1.14 0.3749 73.2%   1.21 0.82 1.79 0.3454 26.8% 
PC aa C36:6 0.92 0.75 1.14 0.8165 
 
0.88 0.69 1.12 0.3092 75.9%   1.07 0.70 1.63 0.7638 24.1% 
PC aa C38:0 1.04 0.83 1.30 0.8344 
 
0.86 0.66 1.12 0.2669 69.8%   1.62 1.08 2.44 0.0208 30.2% 
PC aa C38:1 1.12 0.90 1.39 0.8165 
 
1.06 0.83 1.36 0.6253 76.5%   1.33 0.85 2.07 0.2174 23.5% 
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Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
PC aa C38:3 0.84 0.68 1.05 0.8165 
 
0.86 0.67 1.11 0.2569 73.5%   0.78 0.51 1.20 0.2569 26.5% 
PC aa C38:4 0.86 0.70 1.07 0.8165 
 
0.87 0.68 1.11 0.2665 75.0%   0.84 0.55 1.29 0.4281 25.0% 
PC aa C38:5 0.94 0.76 1.16 0.8277 
 
0.89 0.70 1.14 0.3535 75.4%   1.10 0.72 1.67 0.6713 24.6% 
PC aa C38:6 0.88 0.71 1.10 0.8165 
 
0.79 0.61 1.02 0.0678 73.9%   1.21 0.79 1.87 0.3740 26.1% 
PC aa C40:2 1.04 0.84 1.28 0.8344 
 
0.99 0.77 1.27 0.9340 74.1%   1.19 0.78 1.80 0.4165 25.9% 
PC aa C40:3 1.06 0.84 1.33 0.8277 
 
0.98 0.75 1.28 0.8874 72.0%   1.28 0.83 1.96 0.2661 28.0% 
PC aa C40:4 0.86 0.70 1.06 0.8165 
 
0.91 0.72 1.15 0.4097 80.5%   0.70 0.44 1.13 0.1480 19.5% 
PC aa C40:5 0.79 0.64 0.98 0.8165 
 
0.83 0.65 1.06 0.1326 78.0%   0.67 0.42 1.07 0.0962 22.0% 
PC aa C40:6 0.79 0.63 0.99 0.8165 
 
0.71 0.55 0.93 0.0125 70.8%   1.01 0.67 1.52 0.9767 29.2% 
PC aa C42:0 1.11 0.88 1.39 0.8165 
 
1.00 0.77 1.31 0.9773 71.9%   1.42 0.93 2.17 0.1043 28.1% 
PC aa C42:1 1.05 0.84 1.32 0.8277 
 
0.97 0.74 1.27 0.8170 72.8%   1.30 0.84 2.02 0.2336 27.2% 
PC aa C42:2 1.09 0.89 1.34 0.8165 
 
0.96 0.76 1.21 0.7429 79.8%   1.79 1.13 2.84 0.0136 20.2% 
PC aa C42:4 0.91 0.73 1.14 0.8165 
 
0.81 0.62 1.06 0.1173 68.6%   1.18 0.80 1.76 0.4013 31.4% 
PC aa C42:5 0.92 0.74 1.15 0.8277 
 
0.92 0.71 1.19 0.5068 72.8%   0.95 0.62 1.44 0.7946 27.2% 
PC aa C42:6 0.95 0.77 1.17 0.8277 
 
0.93 0.73 1.18 0.5522 75.0%   1.03 0.68 1.56 0.8945 25.0% 
Acyl-alkyl-Phosphatidylcholines 
         
  
     PC ae C30:0 1.16 0.93 1.46 0.8165 
 
1.11 0.85 1.45 0.4527 73.5%   1.34 0.86 2.09 0.1983 26.5% 
PC ae C30:2 1.06 0.84 1.33 0.8277 
 
1.01 0.77 1.33 0.9441 72.3%   1.19 0.76 1.85 0.4423 27.7% 
PC ae C32:1 1.14 0.91 1.42 0.8165 
 
0.98 0.75 1.28 0.8736 70.1%   1.61 1.07 2.41 0.0211 29.9% 
PC ae C32:2 1.25 1.00 1.56 0.8165 
 
1.04 0.80 1.35 0.7749 71.5%   2.00 1.32 3.03 0.0012 28.5% 
PC ae C34:0 1.11 0.89 1.39 0.8165 
 
1.08 0.83 1.39 0.5778 74.6%   1.23 0.79 1.91 0.3521 25.4% 
PC ae C34:1 1.19 0.95 1.49 0.8165 
 
1.09 0.84 1.41 0.5432 72.9%   1.52 0.99 2.34 0.0539 27.1% 
PC ae C34:2 1.13 0.91 1.42 0.8165 
 
0.93 0.72 1.20 0.5708 75.6%   2.10 1.33 3.30 0.0014 24.4% 
PC ae C34:3 1.14 0.91 1.44 0.8165 
 
0.90 0.69 1.18 0.4482 71.6%   2.09 1.36 3.22 0.0008 28.4% 
PC ae C36:0 1.03 0.83 1.27 0.8991 
 
0.97 0.76 1.25 0.8177 75.3%   1.22 0.79 1.88 0.3751 24.7% 
PC ae C36:1 1.05 0.84 1.31 0.8277 
 
1.02 0.79 1.32 0.8952 74.2%   1.15 0.74 1.78 0.5282 25.8% 
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Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
PC ae C36:2 1.16 0.93 1.45 0.8165 
 
1.07 0.83 1.39 0.5901 74.3%   1.46 0.94 2.26 0.0940 25.7% 
PC ae C36:3 1.09 0.88 1.36 0.8165 
 
0.90 0.70 1.17 0.4419 71.5%   1.75 1.16 2.64 0.0078 28.5% 
PC ae C36:4 1.07 0.87 1.32 0.8277 
 
1.00 0.78 1.28 0.9965 71.7%   1.27 0.86 1.89 0.2314 28.3% 
PC ae C36:5 1.06 0.86 1.31 0.8277 
 
0.95 0.74 1.21 0.6673 71.6%   1.41 0.95 2.09 0.0848 28.4% 
PC ae C38:0 1.00 0.80 1.24 0.9923 
 
0.89 0.69 1.14 0.3433 75.2%   1.43 0.92 2.21 0.1119 24.8% 
PC ae C38:1 0.91 0.73 1.14 0.8165 
 
0.90 0.69 1.16 0.4033 73.5%   0.96 0.62 1.47 0.8355 26.5% 
PC ae C38:2 1.09 0.87 1.36 0.8165 
 
1.10 0.85 1.42 0.4886 73.0%   1.07 0.70 1.64 0.7455 27.0% 
PC ae C38:3 1.11 0.90 1.37 0.8165 
 
1.11 0.88 1.41 0.3853 75.7%   1.10 0.72 1.68 0.6442 24.3% 
PC ae C38:4 1.08 0.86 1.34 0.8277 
 
0.99 0.77 1.28 0.9409 73.2%   1.35 0.88 2.06 0.1650 26.8% 
PC ae C38:5 1.15 0.93 1.41 0.8165 
 
1.01 0.79 1.29 0.9353 70.6%   1.56 1.06 2.29 0.0226 29.4% 
PC ae C38:6 1.07 0.86 1.33 0.8277 
 
0.93 0.72 1.19 0.5461 74.3%   1.62 1.06 2.47 0.0270 25.7% 
PC ae C40:1 0.95 0.76 1.19 0.8277 
 
0.87 0.67 1.12 0.2730 75.1%   1.26 0.81 1.97 0.3020 24.9% 
PC ae C40:2 1.10 0.89 1.36 0.8165 
 
1.00 0.78 1.28 0.9955 73.7%   1.43 0.94 2.15 0.0917 26.3% 
PC ae C40:3 1.04 0.84 1.30 0.8344 
 
0.93 0.72 1.21 0.5957 72.2%   1.40 0.92 2.13 0.1118 27.8% 
PC ae C40:4 1.09 0.87 1.37 0.8165 
 
1.01 0.77 1.32 0.9541 71.5%   1.32 0.87 2.02 0.1932 28.5% 
PC ae C40:5 1.10 0.89 1.37 0.8165 
 
0.99 0.77 1.27 0.9304 73.9%   1.50 0.99 2.29 0.0573 26.1% 
PC ae C40:6 1.10 0.88 1.38 0.8165 
 
0.92 0.71 1.20 0.5269 72.2%   1.75 1.14 2.68 0.0099 27.8% 
PC ae C42:1 0.95 0.77 1.19 0.8277 
 
0.94 0.73 1.21 0.6037 73.3%   1.01 0.66 1.54 0.9560 26.7% 
PC ae C42:2 0.87 0.70 1.08 0.8165 
 
0.80 0.62 1.03 0.0831 74.2%   1.09 0.72 1.67 0.6795 25.8% 
PC ae C42:3 1.00 0.79 1.26 0.9939 
 
0.85 0.65 1.11 0.2269 73.4%   1.57 1.00 2.47 0.0479 26.6% 
PC ae C42:4 1.12 0.89 1.42 0.8165 
 
0.99 0.76 1.31 0.9565 72.2%   1.55 1.00 2.42 0.0508 27.8% 
PC ae C42:5 1.14 0.91 1.43 0.8165 
 
1.04 0.80 1.36 0.7701 69.4%   1.41 0.94 2.10 0.0961 30.6% 
PC ae C44:3 0.86 0.68 1.08 0.8165 
 
0.84 0.64 1.10 0.2039 68.5%   0.91 0.61 1.37 0.6541 31.5% 
PC ae C44:4 1.10 0.87 1.37 0.8165 
 
1.06 0.81 1.39 0.6698 71.0%   1.19 0.78 1.81 0.4170 29.0% 
PC ae C44:5 1.16 0.93 1.46 0.8165 
 
1.07 0.82 1.41 0.6147 69.3%   1.39 0.92 2.09 0.1148 30.7% 
PC ae C44:6 1.14 0.90 1.44 0.8165 
 
1.01 0.77 1. 33 0.9264 72.3%   1.56 1.00 2.42 0.0492 27.7% 
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Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
Lyso-Phosphatidylcholines 
         
  
     lysoPC a C14:0 0.94 0.76 1.17 0.8277 
 
1.04 0.81 1.33 0.7703 77.8%   0.68 0.43 1.07 0.0969 22.2% 
lysoPC a C16:0 0.89 0.71 1.11 0.8165 
 
0.89 0.69 1.15 0.3756 75.1%   0.88 0.56 1.38 0.5708 24.9% 
lysoPC a C16:1 0.96 0.80 1.16 0.8344 
 
0.96 0.78 1.18 0.7150 83.1%   0.98 0.62 1.55 0.9280 16.9% 
lysoPC a C17:0 1.11 0.89 1.39 0.8165 
 
1.12 0.87 1.46 0.3801 74.4%   1.07 0.69 1.67 0.7585 25.6% 
lysoPC a C18:0 0.83 0.67 1.03 0.8165 
 
0.84 0.65 1.08 0.1683 73.2%   0.81 0.54 1.22 0.3131 26.8% 
lysoPC a C18:1 0.95 0.78 1.17 0.8277 
 
0.93 0.74 1.16 0.5046 82.5%   1.10 0.67 1.79 0.7034 17.5% 
lysoPC a C18:2 0.96 0.76 1.21 0.8344 
 
0.93 0.71 1.22 0.5951 74.1%   1.04 0.66 1.64 0.8589 25.9% 
lysoPC a C20:3 0.90 0.73 1.11 0.8165 
 
0.94 0.75 1.18 0.5991 82.7%   0.73 0.44 1.20 0.2146 17.3% 
lysoPC a C20:4 0.94 0.76 1.17 0.8277 
 
0.95 0.76 1.20 0.6899 86.4%   0.85 0.47 1.53 0.5856 13.6% 
lysoPC a C28:1 0.99 0.78 1.25 0.9697 
 
0.95 0.72 1.27 0.7421 67.7%   1.06 0.71 1.60 0.7703 32.3% 
Sphingomyelins 
          
  
     SM C16:0 1.05 0.84 1.32 0.8277 
 
0.90 0.70 1.17 0.4400 73.8%   1.62 1.05 2.50 0.0307 26.2% 
SM C16:1 1.16 0.92 1.46 0.8165 
 
0.98 0.75 1.28 0.8785 72.2%   1.80 1.16 2.78 0.0084 27.8% 
SM C18:0 0.94 0.76 1.17 0.8277 
 
0.86 0.67 1.11 0.2436 73.2%   1.21 0.80 1.82 0.3753 26.8% 
SM C18:1 1.06 0.85 1.32 0.8277 
 
0.94 0.73 1.22 0.6328 71.6%   1.43 0.95 2.15 0.0901 28.4% 
SM C20:2 1.22 0.98 1.51 0.8165 
 
1.08 0.84 1.39 0.5493 72.7%   1.68 1.11 2.53 0.0138 27.3% 
SM C24:0 0.79 0.64 0.98 0.8165 
 
0.76 0.59 0.98 0.0338 72.1%   0.88 0.59 1.32 0.5388 27.9% 
SM C24:1 1.01 0.81 1.25 0.9697 
 
0.91 0.71 1.17 0.4667 71.1%   1.30 0.87 1.93 0.1980 28.9% 
SM C26:1 0.96 0.77 1.19 0.8344 
 
0.84 0.65 1.09 0.1832 72.0%   1.36 0.90 2.05 0.1468 28.0% 
SM (OH) C14:1 1.18 0.94 1.47 0.8165 
 
1.09 0.84 1.42 0.5300 71.5%   1.44 0.95 2.19 0.0860 28.5% 
SM (OH) C16:1 1.14 0.92 1.41 0.8165 
 
1.05 0.81 1.35 0.7283 73.0%   1.43 0.95 2.16 0.0893 27.0% 
SM (OH) C22:1 0.89 0.72 1.11 0.8165 
 
0.87 0.68 1.12 0.2901 74.1%   0.95 0.62 1.45 0.7975 25.9% 
SM (OH) C22:2 1.07 0.85 1.34 0.8277 
 
0.97 0.75 1.26 0.8162 74.5%   1.42 0.91 2.22 0.1222 25.5% 
SM (OH) C24:1 1.01 0.82 1.25 0.9697   0.99 0.77 1.27 0.9260 72.9%   1.08 0.72 1.62 0.7032 27.1% 
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Abbreviations: a, acyl; ae, acyl-alkyl; aa, diacyl; PC, phosphatidylcholine; SM, sphingomyelin 
a
 Adjusted for age, baseline measures of BMI, waist and hip circumference, smoking status, prevalent and incident diseases including myocardial   
infarction, stroke, diabetes and any type of cancer 
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Table 8 Combined fixed-effects meta-analytic and study-specific association of metabolites with the waist-gaining phenotype in men a 
 
Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
Amino Acids                 
Arginine 1.10 0.87 1.40 0.6891 
 
0.94 0.69 1.29 0.7113 58.0%   1.37 0.95 1.97 0.0929 42.0% 
Glutamine 1.10 0.87 1.39 0.6891 
 
0.93 0.69 1.27 0.6662 58.8%   1.39 0.96 2.01 0.0792 41.2% 
Glycine 0.91 0.68 1.22 0.7474 
 
0.93 0.66 1.31 0.6791 72.8%   0.86 0.49 1.51 0.6030 27.2% 
Histidine 1.10 0.86 1.41 0.7158 
 
0.90 0.65 1.24 0.5127 58.8%   1.47 1.00 2.16 0.0509 41.2% 
Methionine 1.03 0.80 1.31 0.8786 
 
0.85 0.61 1.18 0.3274 55.1%   1.30 0.90 1.87 0.1671 44.9% 
Ornithine 1.13 0.88 1.45 0.6891 
 
0.85 0.61 1.19 0.3439 58.9%   1.69 1.14 2.50 0.0092 41.1% 
Phenylalanine 1.12 0.88 1.43 0.6891 
 
1.07 0.79 1.46 0.6627 60.8%   1.20 0.81 1.76 0.3664 39.2% 
Proline 1.06 0.84 1.35 0.7849 
 
1.01 0.75 1.38 0.9279 59.6%   1.14 0.79 1.66 0.4777 40.4% 
Serine 0.91 0.70 1.19 0.7326 
 
0.76 0.54 1.05 0.0986 63.1%   1.25 0.81 1.94 0.3111 36.9% 
Threonine 0.79 0.60 1.04 0.6891 
 
0.71 0.49 1.02 0.0649 55.8%   0.91 0.60 1.37 0.6538 44.2% 
Tryptophan 1.06 0.83 1.36 0.7871 
 
0.92 0.68 1.26 0.6143 64.1%   1.37 0.90 2.08 0.1386 35.9% 
Tyrosine 1.07 0.84 1.36 0.7785 
 
0.91 0.66 1.24 0.5444 57.7%   1.33 0.92 1.93 0.1254 42.3% 
Valine 1.17 0.92 1.49 0.6891 
 
1.01 0.74 1.37 0.9595 64.0%   1.52 1.02 2.28 0.0413 36.0% 
Hexose 
          
  
     H1 1.29 0.98 1.68 0.5684 
 
1.33 0.97 1.84 0.0810 69.2%   1.19 0.73 1.92 0.4864 30.8% 
Acylcarnitines 
          
  
     C0 1.15 0.90 1.47 0.6891 
 
1.06 0.79 1.43 0.7051 67.4%   1.36 0.89 2.09 0.1589 32.6% 
C2 1.06 0.83 1.35 0.7871 
 
0.96 0.69 1.33 0.8036 56.6%   1.20 0.83 1.74 0.3341 43.4% 
C3 1.11 0.86 1.45 0.6891 
 
1.02 0.73 1.42 0.9145 63.5%   1.30 0.84 2.01 0.2400 36.5% 
C5-OH (C3-DC-M) 1.27 1.00 1.62 0.5556 
 
1.27 0.94 1.73 0.1225 63.4%   1.27 0.85 1.90 0.2510 36.6% 
C7-DC 1.13 0.89 1.42 0.6891 
 
1.24 0.91 1.68 0.1708 60.1%   0.98 0.67 1.42 0.8971 39.9% 
C9 1.02 0.79 1.31 0.9028 
 
0.93 0.67 1.30 0.6702 57.0%   1.15 0.78 1.69 0.4718 43.0% 
C10 1.07 0.84 1.34 0.7785 
 
1.11 0.85 1.45 0.4630 74.6%   0.96 0.60 1.51 0.8452 25.4% 
C10:2 1.06 0.83 1.34 0.7871 
 
1.07 0.78 1.46 0.6882 58.1%   1.04 0.72 1.51 0.8163 41.9% 
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Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
C14:1 1.07 0.84 1.37 0.7781 
 
1.01 0.73 1.39 0.9633 58.8%   1.17 0.80 1.72 0.4197 41.2% 
C14:2 1.06 0.83 1.35 0.7871 
 
0.99 0.72 1.36 0.9554 58.6%   1.15 0.79 1.69 0.4579 41.4% 
C16 1.13 0.88 1.46 0.6891 
 
0.86 0.62 1.19 0.3587 59.6%   1.71 1.15 2.54 0.0079 40.4% 
C18 1.39 1.09 1.79 0.3628 
 
1.26 0.92 1.72 0.1552 62.5%   1.66 1.10 2.48 0.0150 37.5% 
C18:1 1.14 0.89 1.45 0.6891 
 
0.96 0.70 1.31 0.8053 61.1%   1.47 1.00 2.17 0.0525 38.9% 
C18:2 1.02 0.80 1.29 0.8989 
 
0.86 0.63 1.18 0.3393 56.9%   1.28 0.89 1.84 0.1775 43.1% 
Diacyl-Phosphatidylcholines 
         
  
     PC aa C28:1 0.89 0.68 1.16 0.6891 
 
0.84 0.60 1.17 0.2951 65.8%   0.99 0.62 1.56 0.9516 34.2% 
PC aa C30:0 0.94 0.73 1.21 0.7871 
 
0.84 0.60 1.18 0.3198 56.0%   1.07 0.73 1.58 0.7201 44.0% 
PC aa C32:0 0.97 0.76 1.25 0.8617 
 
0.81 0.57 1.15 0.2336 51.3%   1.18 0.82 1.68 0.3736 48.7% 
PC aa C32:1 1.07 0.80 1.42 0.7871 
 
0.71 0.42 1.19 0.1947 30.4%   1.27 0.90 1.80 0.1661 69.6% 
PC aa C32:2 0.85 0.63 1.14 0.6891 
 
0.80 0.56 1.15 0.2288 67.3%   0.95 0.57 1.60 0.8552 32.7% 
PC aa C32:3 0.88 0.66 1.16 0.6891 
 
0.70 0.50 0.98 0.0375 67.6%   1.40 0.86 2.29 0.1745 32.4% 
PC aa C34:1 1.09 0.85 1.39 0.7326 
 
0.85 0.61 1.19 0.3376 56.3%   1.49 1.02 2.18 0.0377 43.7% 
PC aa C34:2 1.22 0.96 1.56 0.6891 
 
1.01 0.74 1.37 0.9451 62.6%   1.69 1.14 2.51 0.0096 37.4% 
PC aa C34:3 0.97 0.73 1.27 0.8617 
 
0.69 0.47 1.01 0.0539 51.8%   1.40 0.94 2.08 0.0995 48.2% 
PC aa C34:4 0.89 0.68 1.16 0.6891 
 
0.79 0.57 1.10 0.1666 66.8%   1.12 0.70 1.78 0.6291 33.2% 
PC aa C36:0 0.88 0.67 1.14 0.6891 
 
0.72 0.51 1.02 0.0678 57.6%   1.13 0.76 1.70 0.5462 42.4% 
PC aa C36:1 1.11 0.87 1.41 0.6891 
 
1.01 0.75 1.37 0.9395 64.5%   1.31 0.87 1.97 0.2015 35.5% 
PC aa C36:2 1.19 0.93 1.53 0.6891 
 
1.09 0.81 1.47 0.5771 68.1%   1.44 0.93 2.24 0.1015 31.9% 
PC aa C36:3 1.26 0.99 1.60 0.5556 
 
1.10 0.82 1.48 0.5332 65.7%   1.65 1.09 2.48 0.0170 34.3% 
PC aa C36:4 1.14 0.89 1.46 0.6891 
 
0.98 0.71 1.35 0.9021 59.4%   1.42 0.96 2.08 0.0768 40.6% 
PC aa C36:5 0.89 0.68 1.15 0.6891 
 
0.83 0.59 1.17 0.2887 56.7%   0.97 0.65 1.45 0.8916 43.3% 
PC aa C36:6 0.80 0.60 1.06 0.6891 
 
0.69 0.48 1.00 0.0474 59.3%   1.00 0.64 1.55 0.9937 40.7% 
PC aa C38:0 0.86 0.66 1.11 0.6891 
 
0.71 0.51 1.00 0.0486 58.9%   1.12 0.75 1.69 0.5797 41.1% 
PC aa C38:1 0.93 0.72 1.19 0.7781 
 
0.78 0.56 1.08 0.1290 58.0%   1.20 0.81 1.76 0.3663 42.0% 
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Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
PC aa C38:3 1.33 1.03 1.70 0.4518 
 
1.24 0.91 1.68 0.1697 65.7%   1.51 0.99 2.30 0.0585 34.3% 
PC aa C38:4 1.16 0.90 1.49 0.6891 
 
1.09 0.79 1.49 0.6161 63.1%   1.30 0.86 1.98 0.2135 36.9% 
PC aa C38:5 0.97 0.75 1.25 0.8617 
 
0.86 0.61 1.20 0.3593 57.5%   1.15 0.78 1.70 0.4760 42.5% 
PC aa C38:6 0.95 0.74 1.22 0.8024 
 
0.77 0.55 1.07 0.1233 54.3%   1.23 0.85 1.77 0.2718 45.7% 
PC aa C40:2 0.69 0.52 0.91 0.3628 
 
0.63 0.44 0.90 0.0102 63.7%   0.80 0.50 1.27 0.3412 36.3% 
PC aa C40:3 0.82 0.63 1.06 0.6891 
 
0.72 0.51 1.02 0.0615 59.6%   0.98 0.65 1.48 0.9147 40.4% 
PC aa C40:4 1.13 0.88 1.45 0.6891 
 
1.03 0.75 1.40 0.8755 62.4%   1.33 0.89 1.99 0.1616 37.6% 
PC aa C40:5 1.06 0.82 1.37 0.7871 
 
0.90 0.64 1.26 0.5371 55.3%   1.31 0.90 1.91 0.1651 44.7% 
PC aa C40:6 1.03 0.80 1.33 0.8617 
 
0.87 0.62 1.21 0.4087 56.6%   1.29 0.88 1.89 0.1871 43.4% 
PC aa C42:0 0.79 0.61 1.04 0.6891 
 
0.68 0.48 0.96 0.0267 60.9%   1.01 0.66 1.54 0.9702 39.1% 
PC aa C42:1 0.73 0.55 0.96 0.4518 
 
0.56 0.39 0.81 0.0017 57.6%   1.04 0.68 1.59 0.8470 42.4% 
PC aa C42:2 0.89 0.69 1.14 0.6891 
 
0.68 0.48 0.97 0.0319 51.3%   1.17 0.82 1.68 0.3875 48.7% 
PC aa C42:4 0.99 0.77 1.27 0.9452 
 
0.85 0.62 1.16 0.3008 61.9%   1.28 0.85 1.92 0.2324 38.1% 
PC aa C42:5 0.91 0.70 1.18 0.7326 
 
0.76 0.54 1.07 0.1138 56.0%   1.16 0.78 1.71 0.4581 44.0% 
PC aa C42:6 0.81 0.62 1.06 0.6891 
 
0.62 0.43 0.89 0.0098 55.8%   1.14 0.76 1.71 0.5352 44.2% 
Acyl-alkyl-Phosphatidylcholines 
         
  
     PC ae C30:0 0.83 0.63 1.10 0.6891 
 
0.73 0.51 1.05 0.0913 59.2%   1.01 0.65 1.57 0.9609 40.8% 
PC ae C30:2 0.85 0.64 1.13 0.6891 
 
0.85 0.59 1.22 0.3782 63.3%   0.85 0.53 1.37 0.5063 36.7% 
PC ae C32:1 0.76 0.57 1.00 0.5556 
 
0.61 0.42 0.88 0.0087 60.4%   1.04 0.66 1.64 0.8618 39.6% 
PC ae C32:2 0.71 0.53 0.95 0.4518 
 
0.62 0.43 0.88 0.0080 66.4%   0.93 0.56 1.55 0.7872 33.6% 
PC ae C34:0 0.88 0.67 1.15 0.6891 
 
0.80 0.57 1.12 0.1934 62.9%   1.03 0.67 1.59 0.8989 37.1% 
PC ae C34:1 0.95 0.73 1.24 0.8195 
 
0.80 0.57 1.12 0.1991 62.7%   1.27 0.82 1.96 0.2779 37.3% 
PC ae C34:2 0.92 0.70 1.22 0.7781 
 
0.88 0.63 1.24 0.4667 65.9%   1.02 0.63 1.63 0.9508 34.1% 
PC ae C34:3 0.85 0.64 1.13 0.6891 
 
0.82 0.59 1.14 0.2380 70.5%   0.93 0.56 1.56 0.7932 29.5% 
PC ae C36:0 0.84 0.64 1.10 0.6891 
 
0.70 0.48 1.03 0.0694 49.5%   1.00 0.68 1.45 0.9885 50.5% 
PC ae C36:1 0.92 0.70 1.19 0.7326 
 
0.81 0.59 1.13 0.2103 66.4%   1.16 0.73 1.84 0.5229 33.6% 
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Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
PC ae C36:2 0.96 0.72 1.28 0.8617 
 
0.85 0.60 1.20 0.3641 68.0%   1.24 0.75 2.05 0.4078 32.0% 
PC ae C36:3 1.00 0.77 1.31 0.9899 
 
0.94 0.68 1.30 0.6911 67.0%   1.15 0.72 1.83 0.5572 33.0% 
PC ae C36:4 1.06 0.83 1.36 0.7871 
 
1.01 0.74 1.38 0.9631 62.7%   1.15 0.77 1.73 0.4959 37.3% 
PC ae C36:5 0.91 0.70 1.18 0.7326 
 
0.87 0.63 1.20 0.3818 64.3%   1.01 0.65 1.56 0.9775 35.7% 
PC ae C38:0 0.83 0.63 1.08 0.6891 
 
0.67 0.47 0.96 0.0272 56.6%   1.09 0.73 1.63 0.6831 43.4% 
PC ae C38:1 0.82 0.64 1.07 0.6891 
 
0.80 0.58 1.11 0.1755 64.9%   0.87 0.56 1.34 0.5204 35.1% 
PC ae C38:2 0.86 0.65 1.13 0.6891 
 
0.69 0.49 0.98 0.0367 64.2%   1.27 0.80 2.02 0.3082 35.8% 
PC ae C38:3 1.09 0.84 1.42 0.7326 
 
0.99 0.72 1.37 0.9719 66.7%   1.33 0.84 2.10 0.2250 33.3% 
PC ae C38:4 1.16 0.90 1.50 0.6891 
 
1.07 0.78 1.48 0.6783 61.9%   1.33 0.88 2.01 0.1732 38.1% 
PC ae C38:5 1.01 0.79 1.31 0.9253 
 
0.92 0.67 1.27 0.6115 61.4%   1.19 0.79 1.78 0.4102 38.6% 
PC ae C38:6 0.85 0.66 1.10 0.6891 
 
0.77 0.56 1.07 0.1201 62.6%   0.99 0.65 1.51 0.9714 37.4% 
PC ae C40:1 0.91 0.71 1.17 0.7159 
 
0.75 0.54 1.05 0.0905 57.3%   1.18 0.80 1.73 0.4056 42.7% 
PC ae C40:2 0.90 0.69 1.17 0.6891 
 
0.84 0.61 1.17 0.3019 66.4%   1.02 0.65 1.60 0.9428 33.6% 
PC ae C40:3 0.93 0.71 1.22 0.7871 
 
0.82 0.59 1.16 0.2628 63.9%   1.17 0.74 1.83 0.5028 36.1% 
PC ae C40:4 1.09 0.84 1.42 0.7326 
 
0.95 0.68 1.32 0.7409 61.1%   1.37 0.90 2.09 0.1409 38.9% 
PC ae C40:5 0.96 0.73 1.28 0.8617 
 
0.81 0.56 1.18 0.2758 57.3%   1.21 0.79 1.86 0.3811 42.7% 
PC ae C40:6 0.84 0.64 1.11 0.6891 
 
0.67 0.48 0.95 0.0250 62.1%   1.22 0.79 1.90 0.3706 37.9% 
PC ae C42:1 0.89 0.69 1.15 0.6891 
 
0.79 0.57 1.11 0.1739 61.4%   1.07 0.70 1.62 0.7654 38.6% 
PC ae C42:2 0.86 0.66 1.13 0.6891 
 
0.72 0.50 1.02 0.0640 59.1%   1.13 0.74 1.72 0.5781 40.9% 
PC ae C42:3 0.89 0.69 1.16 0.6891 
 
0.74 0.53 1.04 0.0856 57.9%   1.15 0.77 1.72 0.4846 42.1% 
PC ae C42:4 1.12 0.87 1.45 0.6891 
 
1.02 0.73 1.43 0.8936 59.3%   1.29 0.86 1.93 0.2210 40.7% 
PC ae C42:5 0.89 0.69 1.16 0.6891 
 
0.76 0.55 1.06 0.1115 62.2%   1.16 0.76 1.78 0.4873 37.8% 
PC ae C44:3 0.81 0.62 1.06 0.6891 
 
0.60 0.42 0.87 0.0065 54.7%   1.15 0.77 1.72 0.4927 45.3% 
PC ae C44:4 1.16 0.90 1.49 0.6891 
 
1.06 0.76 1.47 0.7508 60.1%   1.33 0.89 2.00 0.1681 39.9% 
PC ae C44:5 0.95 0.74 1.22 0.8024 
 
0.79 0.57 1.10 0.1619 58.7%   1.24 0.84 1.82 0.2884 41.3% 
PC ae C44:6 0.88 0.69 1.14 0.6891 
 
0.70 0.50 0.98 0.0351 56.5%   1.20 0.82 1.77 0.3397 43.5% 
 
6
4
 
    
Table continued on the next page 
 
R
e
s
u
lts
 
   
  
 
 
 
Overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
Lyso-Phosphatidylcholines 
         
  
     lysoPC a C14:0 0.97 0.74 1.26 0.8617 
 
0.86 0.60 1.25 0.4347 53.2%   1.10 0.74 1.63 0.6442 46.8% 
lysoPC a C16:0 0.89 0.68 1.16 0.6891 
 
0.77 0.54 1.10 0.1510 55.9%   1.06 0.71 1.59 0.7720 44.1% 
lysoPC a C16:1 0.90 0.68 1.19 0.7158 
 
0.65 0.41 1.02 0.0589 39.3%   1.11 0.77 1.59 0.5738 60.7% 
lysoPC a C17:0 0.74 0.55 0.99 0.5556 
 
0.67 0.46 0.97 0.0347 62.9%   0.86 0.53 1.40 0.5491 37.1% 
lysoPC a C18:0 0.83 0.63 1.09 0.6891 
 
0.82 0.58 1.16 0.2578 64.4%   0.84 0.53 1.34 0.4736 35.6% 
lysoPC a C18:1 0.82 0.62 1.09 0.6891 
 
0.73 0.50 1.06 0.0951 56.4%   0.96 0.62 1.47 0.8416 43.6% 
lysoPC a C18:2 0.87 0.65 1.16 0.6891 
 
0.89 0.62 1.28 0.5190 63.7%   0.85 0.52 1.37 0.4956 36.3% 
lysoPC a C20:3 1.05 0.82 1.35 0.8024 
 
1.03 0.75 1.43 0.8508 60.7%   1.08 0.73 1.62 0.6944 39.3% 
lysoPC a C20:4 0.83 0.64 1.09 0.6891 
 
0.82 0.58 1.16 0.2619 58.6%   0.85 0.56 1.29 0.4536 41.4% 
lysoPC a C28:1 0.74 0.54 1.00 0.5556 
 
0.72 0.49 1.06 0.0989 61.4%   0.77 0.47 1.26 0.2990 38.6% 
Sphingomyelins 
          
  
     SM C16:0 1.22 0.95 1.57 0.6891 
 
1.08 0.79 1.49 0.6181 63.9%   1.50 0.99 2.28 0.0561 36.1% 
SM C16:1 1.29 0.99 1.67 0.5556 
 
1.14 0.84 1.55 0.4097 72.4%   1.77 1.08 2.92 0.0244 27.6% 
SM C18:0 1.35 1.06 1.73 0.4518 
 
1.37 1.01 1.86 0.0448 64.8%   1.32 0.87 2.00 0.1932 35.2% 
SM C18:1 1.41 1.10 1.80 0.3628 
 
1.36 1.02 1.81 0.0352 73.4%   1.55 0.96 2.49 0.0733 26.6% 
SM C20:2 0.92 0.69 1.22 0.7693 
 
0.82 0.57 1.17 0.2664 63.6%   1.12 0.70 1.80 0.6276 36.4% 
SM C24:0 1.18 0.92 1.51 0.6891 
 
1.22 0.90 1.65 0.1928 66.3%   1.11 0.73 1.69 0.6361 33.7% 
SM C24:1 1.16 0.91 1.48 0.6891 
 
1.06 0.78 1.44 0.7126 62.1%   1.34 0.91 1.99 0.1396 37.9% 
SM C26:1 1.13 0.89 1.42 0.6891 
 
1.13 0.84 1.52 0.4110 62.3%   1.12 0.77 1.63 0.5631 37.7% 
SM (OH) C14:1 1.04 0.79 1.36 0.8617 
 
1.05 0.76 1.46 0.7555 70.5%   1.00 0.60 1.65 0.9894 29.5% 
SM (OH) C16:1 1.13 0.87 1.47 0.6891 
 
1.14 0.83 1.55 0.4246 69.8%   1.13 0.70 1.82 0.6123 30.2% 
SM (OH) C22:1 1.14 0.88 1.48 0.6891 
 
1.17 0.86 1.59 0.3069 72.1%   1.05 0.64 1.72 0.8444 27.9% 
SM (OH) C22:2 1.12 0.86 1.46 0.6891 
 
1.15 0.85 1.56 0.3536 77.0%   1.03 0.59 1.78 0.9273 23.0% 
SM (OH) C24:1 0.95 0.74 1.23 0.8091   1.01 0.74 1. 37 0.9655 70.8%   0.83 0.52 1.34 0.4465 29.2% 
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Abbreviations: a, acyl; ae, acyl-alkyl; aa, diacyl; PC, phosphatidylcholine; SM, sphingomyelin 
a
 Adjusted for age, baseline measures of BMI, waist and hip circumference, smoking status, prevalent and incident diseases including myocardial   
infarction, stroke, diabetes and any type of cancer 
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Table 9 Combined fixed-effects meta-analytic and study-specific association of metabolites with the hip-gaining phenotype in men a 
 
overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
Amino Acids                 
Arginine 0.86 0.66 1.11 0.9943 
 
0.89 0.65 1.22 0.4737 67.5%   0.79 0.50 1.25 0.3084 32.5% 
Glutamine 0.94 0.73 1.22 0.9943 
 
0.92 0.67 1.26 0.6045 66.6%   0.98 0.63 1.53 0.9324 33.4% 
Glycine 0.87 0.65 1.16 0.9943 
 
1.02 0.74 1.40 0.9244 80.2%   0.47 0.24 0.89 0.0217 19.8% 
Histidine 0.84 0.65 1.09 0.9943 
 
0.85 0.61 1.17 0.3045 64.5%   0.84 0.54 1.29 0.4257 35.5% 
Methionine 0.79 0.61 1.03 0.9943 
 
0.85 0.61 1.19 0.3411 62.6%   0.71 0.46 1.09 0.1161 37.4% 
Ornithine 0.73 0.54 0.98 0.9943 
 
0.79 0.56 1.11 0.1785 72.3%   0.59 0.34 1.03 0.0649 27.7% 
Phenylalanine 0.88 0.68 1.13 0.9943 
 
1.01 0.75 1.36 0.9442 75.1%   0.57 0.34 0.96 0.0331 24.9% 
Proline 1.04 0.82 1.32 0.9943 
 
1.05 0.78 1.41 0.7532 66.0%   1.01 0.67 1.53 0.9480 34.0% 
Serine 0.75 0.56 1.00 0.9943 
 
0.72 0.50 1.03 0.0732 65.8%   0.81 0.49 1.33 0.4053 34.2% 
Threonine 0.83 0.64 1.08 0.9943 
 
0.76 0.54 1.07 0.1190 60.0%   0.93 0.61 1.41 0.7376 40.0% 
Tryptophan 0.85 0.66 1.09 0.9943 
 
0.82 0.60 1.11 0.1981 64.5%   0.92 0.61 1.40 0.7092 35.5% 
Tyrosine 0.87 0.67 1.13 0.9943 
 
0.96 0.69 1.33 0.8022 64.9%   0.73 0.47 1.13 0.1569 35.1% 
Valine 0.83 0.63 1.09 0.9943 
 
0.96 0.69 1.33 0.7936 69.9%   0.59 0.36 0.98 0.0414 30.1% 
Hexose 
          
  
     H1 1.13 0.85 1.49 0.9943 
 
1.09 0.78 1.51 0.6262 72.8%   1.26 0.74 2.15 0.4035 27.2% 
Acylcarnitines 
          
  
     C0 1.06 0.82 1.36 0.9943 
 
1.04 0.76 1.41 0.8165 67.3%   1.11 0.71 1.73 0.6436 32.7% 
C2 1.04 0.83 1.29 0.9943 
 
1.01 0.78 1.30 0.9455 75.8%   1.13 0.72 1.77 0.5830 24.2% 
C3 1.09 0.85 1.40 0.9943 
 
1.23 0.92 1.65 0.1680 70.6%   0.82 0.52 1.29 0.3796 29.4% 
C5-OH (C3-DC-M) 1.05 0.83 1.32 0.9943 
 
1.07 0.81 1.42 0.6369 66.2%   1.00 0.67 1.48 0.9842 33.8% 
C7-DC 1.04 0.82 1.31 0.9943 
 
1.05 0.78 1.40 0.7591 65.9%   1.02 0.68 1.53 0.9332 34.1% 
C9 1.05 0.82 1.33 0.9943 
 
1.03 0.77 1.39 0.8400 66.1%   1.08 0.71 1.64 0.7169 33.9% 
C10 0.95 0.75 1.22 0.9943 
 
0.91 0.67 1.22 0.5173 66.6%   1.05 0.69 1.60 0.8109 33.4% 
C10:2 0.91 0.71 1.17 0.9943 
 
0.83 0.61 1.13 0.2303 64.1%   1.09 0.72 1.65 0.6842 35.9% 
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overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
C14:1 1.02 0.80 1.29 0.9943 
 
0.99 0.73 1.34 0.9301 60.5%   1.06 0.73 1.55 0.7476 39.5% 
C14:2 0.98 0.78 1.23 0.9943 
 
0.86 0.63 1.17 0.3361 56.7%   1.15 0.81 1.64 0.4246 43.3% 
C16 1.08 0.84 1.38 0.9943 
 
1.07 0.80 1.44 0.6552 69.5%   1.11 0.71 1.73 0.6530 30.5% 
C18 1.33 1.04 1.69 0.9943 
 
1.50 1.12 2.00 0.0063 69.5%   1.02 0.66 1.57 0.9448 30.5% 
C18:1 1.30 1.04 1.63 0.9943 
 
1.40 1.06 1.85 0.0167 65.8%   1.12 0.76 1.65 0.5586 34.2% 
C18:2 1.16 0.92 1.47 0.9943 
 
1.26 0.95 1.66 0.1072 69.9%   0.97 0.63 1.48 0.8728 30.1% 
Diacyl-Phosphatidylcholines 
         
  
     PC aa C28:1 1.17 0.91 1.50 0.9943 
 
1.35 1.01 1.78 0.0395 76.4%   0.75 0.45 1.24 0.2555 23.6% 
PC aa C30:0 1.01 0.79 1.29 0.9943 
 
1.14 0.86 1.51 0.3545 76.8%   0.68 0.41 1.13 0.1352 23.2% 
PC aa C32:0 1.00 0.78 1.28 0.9958 
 
1.03 0.75 1.41 0.8500 62.9%   0.95 0.63 1.43 0.7973 37.1% 
PC aa C32:1 0.94 0.73 1.21 0.9943 
 
1.01 0.72 1.42 0.9564 57.3%   0.85 0.57 1.26 0.4121 42.7% 
PC aa C32:2 1.10 0.86 1.40 0.9943 
 
1.20 0.92 1.58 0.1814 81.9%   0.72 0.41 1.28 0.2615 18.1% 
PC aa C32:3 0.98 0.75 1.29 0.9943 
 
0.96 0.70 1.32 0.8040 72.7%   1.04 0.62 1.75 0.8913 27.3% 
PC aa C34:1 0.95 0.74 1.22 0.9943 
 
0.94 0.69 1.28 0.7102 64.2%   0.96 0.63 1.45 0.8454 35.8% 
PC aa C34:2 1.04 0.81 1.34 0.9943 
 
0.98 0.71 1.34 0.8846 63.1%   1.17 0.77 1.76 0.4578 36.9% 
PC aa C34:3 1.00 0.77 1.30 0.9943 
 
1.06 0.78 1.45 0.7123 69.2%   0.89 0.55 1.41 0.6113 30.8% 
PC aa C34:4 1.04 0.80 1.35 0.9943 
 
1.18 0.87 1.59 0.2923 73.8%   0.73 0.44 1.22 0.2328 26.2% 
PC aa C36:0 0.97 0.75 1.25 0.9943 
 
0.96 0.70 1.33 0.8218 66.0%   0.98 0.63 1.52 0.9198 34.0% 
PC aa C36:1 0.92 0.71 1.19 0.9943 
 
0.96 0.70 1.30 0.7764 69.7%   0.85 0.53 1.36 0.4934 30.3% 
PC aa C36:2 1.03 0.80 1.33 0.9943 
 
0.95 0.70 1.31 0.7649 65.9%   1.20 0.77 1.85 0.4252 34.1% 
PC aa C36:3 1.09 0.85 1.40 0.9943 
 
1.07 0.79 1.46 0.6617 63.7%   1.12 0.75 1.69 0.5754 36.3% 
PC aa C36:4 1.06 0.84 1.34 0.9943 
 
1.11 0.83 1.50 0.4864 61.8%   0.98 0.67 1.44 0.9346 38.2% 
PC aa C36:5 0.90 0.68 1.18 0.9943 
 
1.00 0.73 1.37 0.9996 73.8%   0.66 0.39 1.13 0.1326 26.2% 
PC aa C36:6 0.97 0.74 1.27 0.9943 
 
1.11 0.81 1.51 0.5226 75.2%   0.66 0.38 1.13 0.1290 24.8% 
PC aa C38:0 0.87 0.66 1.15 0.9943 
 
0.85 0.61 1.20 0.3630 66.2%   0.90 0.56 1.45 0.6674 33.8% 
PC aa C38:1 0.74 0.56 0.98 0.9943 
 
0.67 0.47 0.97 0.0326 59.9%   0.86 0.55 1.34 0.5098 40.1% 
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overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
PC aa C38:3 1.07 0.82 1.38 0.9943 
 
1.09 0.79 1.52 0.5946 62.0%   1.03 0.68 1.56 0.9017 38.0% 
PC aa C38:4 1.05 0.83 1.33 0.9943 
 
1.09 0.81 1.47 0.5726 63.4%   0.99 0.67 1.47 0.9759 36.6% 
PC aa C38:5 0.99 0.78 1.26 0.9943 
 
1.05 0.78 1.42 0.7479 64.1%   0.89 0.60 1.33 0.5736 35.9% 
PC aa C38:6 0.97 0.76 1.24 0.9943 
 
0.98 0.72 1.34 0.8940 62.9%   0.96 0.64 1.44 0.8290 37.1% 
PC aa C40:2 0.78 0.59 1.04 0.9943 
 
0.72 0.50 1.03 0.0751 61.7%   0.89 0.56 1.40 0.6048 38.3% 
PC aa C40:3 0.85 0.65 1.13 0.9943 
 
0.70 0.48 1.04 0.0739 51.5%   1.05 0.71 1.57 0.8009 48.5% 
PC aa C40:4 1.10 0.88 1.38 0.9943 
 
1.07 0.79 1.44 0.6698 58.3%   1.16 0.82 1.65 0.4098 41.7% 
PC aa C40:5 1.06 0.84 1.34 0.9943 
 
1.11 0.83 1.49 0.4919 63.1%   0.99 0.68 1.46 0.9752 36.9% 
PC aa C40:6 0.96 0.75 1.24 0.9943 
 
0.99 0.72 1.36 0.9374 62.6%   0.92 0.61 1.40 0.7005 37.4% 
PC aa C42:0 1.05 0.80 1.36 0.9943 
 
1.10 0.80 1.51 0.5509 70.1%   0.93 0.57 1.51 0.7653 29.9% 
PC aa C42:1 1.16 0.90 1.49 0.9943 
 
1.26 0.94 1.70 0.1211 73.5%   0.91 0.56 1.49 0.7031 26.5% 
PC aa C42:2 1.07 0.83 1.37 0.9943 
 
1.07 0.79 1.45 0.6633 65.3%   1.06 0.70 1.61 0.7900 34.7% 
PC aa C42:4 0.84 0.65 1.10 0.9943 
 
0.90 0.66 1.23 0.5118 68.8%   0.73 0.46 1.17 0.1917 31.2% 
PC aa C42:5 0.86 0.66 1.13 0.9943 
 
0.77 0.54 1.09 0.1438 57.8%   1.01 0.67 1.53 0.9627 42.2% 
PC aa C42:6 1.08 0.84 1.38 0.9943 
 
1.14 0.83 1.55 0.4230 62.6%   0.99 0.66 1.48 0.9607 37.4% 
Acyl-alkyl-Phosphatidylcholines 
        
  
     PC ae C30:0 1.05 0.82 1.35 0.9943 
 
1.18 0.89 1.56 0.2531 81.7%   0.64 0.35 1.15 0.1339 18.3% 
PC ae C30:2 1.23 0.97 1.55 0.9943 
 
1.27 0.96 1.68 0.0914 71.2%   1.12 0.72 1.74 0.6040 28.8% 
PC ae C32:1 0.91 0.71 1.19 0.9943 
 
0.97 0.72 1.32 0.8670 72.4%   0.78 0.47 1.27 0.3131 27.6% 
PC ae C32:2 0.88 0.67 1.15 0.9943 
 
0.91 0.67 1.26 0.5764 73.7%   0.79 0.46 1.34 0.3803 26.3% 
PC ae C34:0 1.03 0.80 1.32 0.9943 
 
1.16 0.86 1.55 0.3323 75.5%   0.71 0.43 1.19 0.1970 24.5% 
PC ae C34:1 1.00 0.77 1.29 0.9943 
 
1.08 0.81 1.44 0.6054 78.5%   0.75 0.43 1.30 0.3069 21.5% 
PC ae C34:2 0.93 0.72 1.22 0.9943 
 
1.02 0.75 1.38 0.9033 76.7%   0.70 0.40 1.21 0.1998 23.3% 
PC ae C34:3 0.92 0.69 1.21 0.9943 
 
0.97 0.70 1.34 0.8494 73.7%   0.78 0.45 1.35 0.3710 26.3% 
PC ae C36:0 0.82 0.64 1.06 0.9943 
 
0.84 0.61 1.15 0.2635 63.1%   0.80 0.53 1.21 0.2925 36.9% 
PC ae C36:1 1.06 0.82 1.37 0.9943 
 
1.20 0.90 1.60 0.2207 77.6%   0.70 0.41 1.21 0.2025 22.4% 
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Table continued on the next page 
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lts
 
   
  
 
 
 
overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
PC ae C36:2 1.02 0.78 1.34 0.9943 
 
1.05 0.77 1.43 0.7470 76.1%   0.93 0.54 1.62 0.7993 23.9% 
PC ae C36:3 0.88 0.67 1.16 0.9943 
 
0.94 0.69 1.29 0.6982 74.9%   0.73 0.42 1.25 0.2476 25.1% 
PC ae C36:4 1.00 0.78 1.27 0.9943 
 
1.07 0.80 1.44 0.6422 68.3%   0.85 0.56 1.31 0.4720 31.7% 
PC ae C36:5 0.94 0.74 1.21 0.9943 
 
1.00 0.74 1.37 0.9826 63.8%   0.85 0.56 1.28 0.4391 36.2% 
PC ae C38:0 0.94 0.73 1.22 0.9943 
 
1.01 0.74 1.38 0.9693 68.5%   0.82 0.52 1.31 0.4044 31.5% 
PC ae C38:1 0.99 0.78 1.27 0.9943 
 
1.00 0.75 1.34 0.9874 70.1%   0.98 0.63 1.53 0.9402 29.9% 
PC ae C38:2 0.98 0.75 1.28 0.9943 
 
0.95 0.70 1.30 0.7550 74.5%   1.06 0.62 1.81 0.8321 25.5% 
PC ae C38:3 1.11 0.86 1.43 0.9943 
 
1.25 0.94 1.67 0.1291 76.0%   0.76 0.45 1.27 0.2906 24.0% 
PC ae C38:4 1.00 0.78 1.28 0.9943 
 
1.06 0.79 1.42 0.7105 68.9%   0.89 0.57 1.38 0.6082 31.1% 
PC ae C38:5 0.96 0.75 1.23 0.9943 
 
0.97 0.71 1.31 0.8177 66.1%   0.94 0.62 1.44 0.7890 33.9% 
PC ae C38:6 0.89 0.68 1.16 0.9943 
 
0.94 0.68 1.30 0.6966 68.3%   0.79 0.49 1.28 0.3356 31.7% 
PC ae C40:1 0.95 0.75 1.22 0.9943 
 
0.99 0.73 1.34 0.9606 66.0%   0.89 0.58 1.35 0.5722 34.0% 
PC ae C40:2 0.97 0.75 1.25 0.9943 
 
1.05 0.77 1.42 0.7666 72.1%   0.79 0.48 1.28 0.3297 27.9% 
PC ae C40:3 1.01 0.78 1.31 0.9943 
 
1.11 0.83 1.49 0.4823 76.0%   0.76 0.45 1.28 0.2963 24.0% 
PC ae C40:4 0.94 0.73 1.21 0.9943 
 
0.96 0.71 1.30 0.7930 70.1%   0.89 0.56 1.42 0.6335 29.9% 
PC ae C40:5 0.96 0.74 1.24 0.9943 
 
0.95 0.70 1.31 0.7688 68.3%   0.96 0.60 1.53 0.8646 31.7% 
PC ae C40:6 0.96 0.73 1.25 0.9943 
 
0.99 0.72 1.36 0.9295 70.5%   0.90 0.55 1.47 0.6758 29.5% 
PC ae C42:1 1.15 0.91 1.45 0.9943 
 
1.12 0.84 1.50 0.4314 64.3%   1.19 0.80 1.75 0.3937 35.7% 
PC ae C42:2 1.02 0.79 1.31 0.9943 
 
1.10 0.82 1.49 0.5287 71.4%   0.83 0.52 1.33 0.4403 28.6% 
PC ae C42:3 0.95 0.74 1.23 0.9943 
 
0.98 0.71 1.35 0.8960 65.5%   0.90 0.58 1.40 0.6473 34.5% 
PC ae C42:4 1.01 0.79 1.29 0.9943 
 
1.06 0.78 1.42 0.7200 70.1%   0.90 0.57 1.43 0.6670 29.9% 
PC ae C42:5 0.93 0.71 1.22 0.9943 
 
0.93 0.68 1.29 0.6758 71.2%   0.92 0.56 1.52 0.7384 28.8% 
PC ae C44:3 1.13 0.88 1.45 0.9943 
 
1.30 0.97 1.74 0.0830 71.6%   0.81 0.51 1.29 0.3653 28.4% 
PC ae C44:4 0.96 0.74 1.23 0.9943 
 
0.98 0.72 1.32 0.8870 69.7%   0.91 0.58 1.44 0.6917 30.3% 
PC ae C44:5 1.00 0.77 1.28 0.9943 
 
1.01 0.75 1.36 0.9644 70.3%   0.97 0.61 1.54 0.9015 29.7% 
PC ae C44:6 1.06 0.82 1.37 0.9943 
 
1.16 0.85 1.57 0.3547 70.0%   0.87 0.55 1.39 0.5695 30.0% 
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Table continued on the next page 
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overall 
 
EPIC-Potsdam 
 
KORA 
 
OR LCL UCL PFDR 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
 
OR LCL UCL 
uncorrected  
p value 
meta 
weight 
Lyso-Phosphatidylcholines 
         
  
     lysoPC a C14:0 0.93 0.75 1.15 0.9943 
 
1.00 0.79 1.27 0.9973 79.7%   0.70 0.43 1.13 0.1407 20.3% 
lysoPC a C16:0 0.90 0.70 1.15 0.9943 
 
0.96 0.72 1.30 0.8094 69.1%   0.77 0.50 1.20 0.2521 30.9% 
lysoPC a C16:1 0.93 0.74 1.18 0.9943   1.05 0.78 1.42 0.7313 63.9%   0.76 0.51 1.12 0.1646 36.1% 
lysoPC a C17:0 1.03 0.80 1.34 0.9943 
 
1.13 0.84 1.52 0.4161 74%  0.80 0.49 1.33 0.3889 26% 
lysoPC a C18:0 0.92 0.71 1.20 0.9943 
 
0.97 0.71 1.33 0.8523 69.1%  0.82 0.51 1.32 0.4192 30.9% 
lysoPC a C18:1 0.90 0.71 1.15 0.9943 
 
0.93 0.68 1.27 0.6606 62.7%  0.85 0.57 1.27 0.4372 37.3% 
lysoPC a C18:2 0.99 0.75 1.30 0.9943 
 
1.05 0.76 1.45 0.7629 70.5%  0.85 0.52 1.40 0.5292 29.5% 
lysoPC a C20:3 1.02 0.80 1.30 0.9943 
 
1.18 0.87 1.60 0.2810 65.1%  0.77 0.51 1.16 0.2075 34.9% 
lysoPC a C20:4 0.98 0.78 1.25 0.9943 
 
1.07 0.80 1.45 0.6376 64%  0.84 0.57 1.25 0.4002 36% 
lysoPC a C28:1 1.05 0.83 1.32 0.9943 
 
1.07 0.82 1.39 0.6207 75.4%  1.00 0.63 1.59 0.9871 24.6% 
Sphingomyelins 
          
 
     SM C16:0 0.95 0.74 1.22 0.9943 
 
0.93 0.69 1.26 0.6437 69.4%  0.99 0.64 1.56 0.9824 30.6% 
SM C16:1 1.05 0.81 1.36 0.9943 
 
1.06 0.78 1.43 0.7190 74.5%  1.02 0.61 1.71 0.9415 25.5% 
SM C18:0 0.98 0.76 1.26 0.9943 
 
0.94 0.69 1.28 0.7107 66.2%  1.05 0.69 1.62 0.8131 33.8% 
SM C18:1 0.99 0.75 1.29 0.9943 
 
0.91 0.66 1.26 0.5727 69.2%  1.17 0.73 1.90 0.5141 30.8% 
SM C20:2 0.90 0.67 1.21 0.9943 
 
0.81 0.56 1.18 0.2757 63.1%  1.06 0.65 1.73 0.8140 36.9% 
SM C24:0 0.90 0.67 1.21 0.9943 
 
1.08 0.81 1.44 0.6147 69.7%  0.72 0.46 1.11 0.1388 30.3% 
SM C24:1 0.95 0.75 1.21 0.9943 
 
0.85 0.62 1.16 0.3075 66.2%  1.01 0.65 1.56 0.9617 33.8% 
SM C26:1 0.90 0.70 1.16 0.9943 
 
0.98 0.71 1.34 0.8888 66.5%  0.83 0.53 1.29 0.4101 33.5% 
SM (OH) C14:1 0.93 0.72 1.20 0.9943 
 
1.18 0.89 1.57 0.2455 78.0%  0.73 0.43 1.24 0.2456 22.0% 
SM (OH) C16:1 1.06 0.83 1.37 0.9943 
 
1.03 0.76 1.38 0.8668 72.4%  0.93 0.57 1.50 0.7532 27.6% 
SM (OH) C22:1 1.00 0.78 1.28 0.9943 
 
1.09 0.82 1.47 0.5464 74.6%  0.65 0.39 1.08 0.0942 25.4% 
SM (OH) C22:2 0.96 0.74 1.23 0.9943 
 
1.07 0.79 1.46 0.6519 77.1%  0.69 0.39 1.22 0.2048 22.9% 
SM (OH) C24:1 0.97 0.74 1.27 0.9943 
 
1.19 0.89 1.59 0.2454 75.0%  0.62 0.38 1.03 0.0636 25.0% 
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Abbreviations: a, acyl; ae, acyl-alkyl; aa, diacyl; PC, phosphatidylcholine; SM, sphingomyelin 
a
 Adjusted for age, baseline measures of BMI, waist and hip circumference, smoking status, prevalent and incident diseases including myocardial   
infarction, stroke, diabetes and any type of cancer 
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Figure 12 Forest plot of metabolites showing statistically significant 
combined association with WG phenotype in women 
 
  
 
 
 
Figure 13 Combined estimates and corresponding confidence limits of selected metabolites with waist and hip-gaining phenotypes in women 
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4.3.5. Correlations between metabolites and anthropometric measures 
The majority of quality-controlled metabolites showed different correlations with cross-
sectional anthropometric measures compared to longitudinal changes of these measures. In 
general, correlations were weak in both sexes. Strongest negative correlations between 
anthropometric markers and metabolite concentrations were observed between baseline BMI 
and lysoPC C18:2 in men (r=-0.31, p<.0001) and baseline WHR with acyl-alkyl-PC C34:3 in 
women (r=-0.34, p<.0001). Strongest positive correlations were observed between baseline 
BMI and diacyl-PC C38:3 in men (r=0.34, p<.0001) and baseline waist circumference with 
the same metabolite in women (r=0.37, p<.0001). All other metabolites showed correlations 
within this range. 
Metabolites that showed statistically significant associations with the WG phenotype 
in women are shown in Figure 14. For these metabolites, values ranged from r=-0.28 
(p<.0001) for acyl-alkyl-PC C42:3 with baseline waist circumference to r=0.13 (p<.0001) for 
the same metabolite with average annual change in waist circumference; for men values 
ranged from r=-0.23 (p<.0001) for lysoPC C17:0 with baseline waist circumference to r=0.15 
(p<.0001) for diacyl-PC C42:5 with baseline waist circumference. For these selected 
metabolites, women showed in general stronger correlations compared to men, but 
comparable directions in their correlation.  
Most of the PCs showed inverse cross-sectional correlations with anthropometric 
markers at baseline indicated by a blue colour in the corresponding heat map whereas the 
average annual changes of those measures showed positive associations indicated by a red 
colour in the corresponding heat map (Figure 14). 
Aromatic AA tryptophan showed comparable results in both sexes for both 
perspectives. Cross-sectional and longitudinal anthropometric measures did not show 
statistically significant correlations (range r=-0.01 to r=0.03). 
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Figure 14 Heat Map showing cross-sectional and longitudinal anthropometric markers and 
their correlation to selected metabolites for men and women 
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4.4. Comparing the results of two different approaches (objective 3) 
After conducting sex-specific PCA with the metabolite data, five principal components 
for men and four principal components for women were required to account for the majority 
of explained variance. The five derived principal components in men explained 55.0% of the 
total variance for men; the four principal components in women explained 50.1% of the total 
variance for women (Figure 15). After orthogonal varimax rotation, rotated components 
accounted for 14.3%, 14.3%, 12.1%, 8.0% and 6.3% of the total variance in men; rotated 
components accounted for 17.1%, 15.3%, 10.0% and 7.8% of the total variance in women.  
 
Figure 15 Cumulative variance explained by increasing number of principal components  
The composition for each principal component regarding metabolites with meaningful 
factor loadings was comparable for men and women (Table 10 & Table 11). Two principal 
components contained mostly PCs, one component contained AAs and another component 
in the main SMs. For men, an additional component with ACs was derived. Factor loadings 
were as well comparable between sexes for most components. Complete rotated factor 
patterns are shown in supplemental Appendix 6 and Appendix 7. 
No metabolite showed meaningful factor loadings on more than one principal 
component and was uniquely assignable. For both sexes, principal components 1 and 2 
contained mostly PCs but were interchanged in their structure (principal component 1 for 
women was comparable with principal component 2 in men). In general, components were 
similar but showed small differences e.g. principal component 4 in men contained threonine 
and serine whereas principal component 4 in women contained proline instead. 
  
  
 
Table 10 Principal components including metabolites with meaningful factor loadings derived from 127 metabolites measured with 
targeted metabolomics approach in men in EPIC-Potsdam 
PComp 1 
Factor 
loading 
 
PComp 2 
Factor 
loading 
 
PComp 3 
Factor 
loading 
 
PComp 4 
Factor 
loading 
 
PComp 5 
Factor 
loading 
lysoPC a C16:1 75  PC aa C36:0 69  PC aa C28:1 68  Arginine 63  C14:1 70 
PC aa C30:0 74  PC aa C38:0 80  PC ae C30:0 61  Glutamine 68  C14:2 76 
PC aa C32:0 73  PC aa C40:2 71  PC ae C36:1 64  Histidine 76  C16:2 65 
PC aa C32:1 82  PC aa C40:3 68  PC ae C38:3 62  Methionine 79  C18:1 63 
PC aa C32:2 75  PC aa C42:0 84  PC ae C40:2 63  Ornithine 70  C18:2 61 
PC aa C34:1 84  PC aa C42:1 81  SM  (OH) C14:1 85  Phenylalanine 75  C5-DC / C6-OH 63 
PC aa C34:3 78  PC aa C42:2 74  SM  (OH) C16:1 89  Serine 63  C7-DC 69 
PC aa C34:4 83  PC ae C32:2 62  SM  (OH) C22:1 84  Threonine 65    
PC aa C36:1 82  PC ae C38:0 64  SM  (OH) C22:2 84  Tryptophan 77    
PC aa C36:3 75  PC ae C38:6 73  SM  (OH) C24:1 80  Tyrosine 67    
PC aa C36:4 68  PC ae C40:1 63  SM C16:0 75  Valine 72    
PC aa C36:6 64  PC ae C40:5 73  SM C16:1 66  xLeucine 77   
 PC aa C38:3 71  PC ae C40:6 77  SM C18:0 73      
 PC aa C38:4 62  PC ae C42:2 65  SM C18:1 68      
 PC aa C38:5 76  PC ae C42:3 79  SM C24:0 62      
 PC aa C40:4 74  PC ae C42:5 70  SM C26:0 69      
 PC aa C40:5 81  PC ae C44:6 69         
 PC aa C42:6 62            
 Abbreviations: PComp, Principal Component; PC, phosphatidylcholine; a, acyl; e,-alkyl; SM, sphingomyelin   
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Table 11 Principal components including metabolites with meaningful factor loadings derived from 127 
metabolites measured with targeted metabolomics approach in women in EPIC-Potsdam 
PComp1 
Factor 
loading 
 
PComp 2 
Factor 
loading 
 
PComp 3 
Factor 
loading 
 
PComp 4 
Factor 
loading 
 PC aa C36:0 67  PC aa C30:0 77  C14:1 70  Arginine 66  
PC aa C38:0 76  PC aa C32:0 75  C14:2 64  Glutamine 66  
PC aa C42:0 83  PC aa C32:1 80  C7-DC 61  Histidine 60  
PC aa C42:1 81  PC aa C32:2 74  SM (OH) C14:1 62  Methionine 75  
PC aa C42:2 64  PC aa C34:1 84  SM (OH) C16:1 69  Ornithine 68  
PC ae C32:1 71  PC aa C34:2 60  SM (OH) C22:1 67  Phenylalanine 74  
PC ae C32:2 71  PC aa C34:3 75  SM (OH) C22:2 68  Proline 67  
PC ae C34:3 68  PC aa C34:4 85  SM (OH) C24:1 71  Tryptophan 74  
PC ae C36:5 63  PC aa C36:1 74  SM C16:0 67  Tyrosine 68  
PC ae C38:4 63  PC aa C36:3 78  SM C16:1 69  Valine 70  
PC ae C38:5 68  PC aa C36:4 72  SM C18:0 73  xLeucine 72  
PC ae C38:6 69  PC aa C36:6 72  SM C18:1 69     
PC ae C40:1 62  PC aa C38:3 73  SM C24:0 61     
PC ae C40:3 71  PC aa C38:4 65  SM C26:0 65     
PC ae C40:4 78  PC aa C38:5 74  SM C26:1 63     
PC ae C40:5 82  PC aa C40:4 73        
PC ae C40:6 77  PC aa C40:5 68        
PC ae C42:2 61  PC ae C34:0 65        
PC ae C42:3 78  PC ae C34:1 66        
PC ae C42:4 76  PC ae C36:1 63        
PC ae C42:5 85  PC ae C38:3 61        
PC ae C44:4 63           
PC ae C44:5 73           
PC ae C44:6 82           
Abbreviations: PComp, Principal Component; PC, phosphatidylcholine; a, acyl; e,-alkyl; SM, sphingomyelin
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4.4.1. Single metabolites and their association to WG and HG phenotypes in EPIC-Potsdam 
In the single metabolite approach restricted to metabolite data from EPIC-Potsdam, 
23 metabolites showed significant associations (p<0.05), of which 19 metabolites were 
associated with the WG phenotype and four metabolites with the HG phenotype. When 
taking correction for multiple testing into account, no metabolite showed statistically 
significant associations to any of the phenotypes. In women, 36 metabolites showed 
significant associations (p<0.05), 32 metabolites with the WG phenotype and four 
metabolites with the HG phenotype. When taking multiple testing into account, six 
metabolites including aromatic AA tryptophan, diacyl-PCs C38:0, C42:2 and acyl-alkyl-PCs 
C40:6, C42:2 and lyso-PC C17:0 remained significant in their association regarding the WG 
phenotype; regarding the HG phenotype no metabolite remained significant. In general, more 
associations were found for the WG than for the HG phenotype in both sexes. This is 
consistent with the results of the meta-analytical approach (chapter 4.3.1.) 
Table 12 Metabolites showing significant associations (p<0.05) with WG or HG phenotype in 
men of EPIC-Potsdam before taking multiple testing into account 
 WG phenotype   HG phenotype 
  OR LCL UCL P PFDR 
 
  OR LCL UCL P PFDR 
Phosphatidylcholines  Acylcarnitines      
PC aa C32:3 0.70 0.50 0.98 0.04 0.2980  C18:0 1.50 1.12 2.00 0.01 0.8045 
PC aa C36:6 0.69 0.48 1.00 0.05 0.3250  C18:1 1.40 1.06 1.85 0.02 0.9996 
PC aa C38:0 0.71 0.51 1.00 0.05 0.3250  Phosphatidylcholines 
PC aa C40:2 0.63 0.44 0.90 0.01 0.2162 PC aa C28:1 1.35 1.01 1.78 0.04 0.9996 
PC aa C42:0 0.68 0.48 0.96 0.03 0.2980  PC aa C38:1 0.67 0.47 0.97 0.03 0.9996 
PC aa C42:1 0.56 0.39 0.81 0.002 0.2138        
PC aa C42:2 0.68 0.48 0.97 0.03 0.2980             
PC aa C42:6 0.62 0.43 0.89 0.01 0.2162              
PC ae C30:1 0.61 0.41 0.92 0.02 0.2980              
PC ae C32:1 0.61 0.42 0.88 0.01 0.2162              
PC ae C32:2 0.62 0.43 0.88 0.01 0.2162              
PC ae C38:0 0.67 0.47 0.96 0.03 0.2980              
PC ae C38:2 0.69 0.49 0.98 0.04 0.2980             
PC ae C40:6 0.67 0.48 0.95 0.03 0.2980              
PC ae C44:3 0.60 0.42 0.87 0.01 0.2162              
PC ae C44:6 0.70 0.50 0.98 0.04 0.2980              
Lyso-Phosphatidylcholines                
lysoPC a 
C17:0 
0.67 0.46 0.97 0.03 0.2980 
 
            
Sphingomyelins              
SM C18:0 1.37 1.01 1.86 0.04 0.3250              
SM C18:1 1.36 1.02 1.81 0.04 0.2980              
Abbreviations: PC, phosphatidylcholine; a, acyl; e,-alkyl; SM, sphingomyelin 
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Table 13 Metabolites showing significant associations (p<0.05) with WG or HG phenotype in 
women of EPIC-Potsdam before taking multiple testing into account 
 WG phenotype   HG phenotype 
  OR LCL 
UC
L 
P PFDR 
 
  OR LCL 
UC
L 
P PFDR 
Amino Acids  
 
Acylcarnitines          
Glycine 0.78 0.61 1.00 0.05 0.1904 
 
C7-DC 1.27 1.00 1.61 0.05 0.9345 
Methionine 0.70 0.52 0.93 0.01 0.1004 
 
C9 1.31 1.03 1.66 0.03 0.9345 
Serine 0.75 0.59 0.97 0.03 0.1690 
 
Phosphatidylcholines        
Tryptophan 0.67 0.52 0.85 0.001 0.0359* PC aa C40:6 0.71 0.55 0.93 0.01 0.9345 
Phosphatidylcholines  
 
Sphingomyelins          
PC aa C32:3 0.69 0.54 0.88 0.003 0.0587 
 
SM C24:0 0.76 0.59 0.98 0.03 0.9345 
PC aa C36:0 0.69 0.54 0.89 0.004 0.0610 
 
            
PC aa C38:0 0.67 0.52 0.86 0.002 0.0359*             
PC aa C38:1 0.73 0.56 0.95 0.02 0.1099 
 
            
PC aa C40:2 0.71 0.52 0.97 0.03 0.1773 
 
            
PC aa C40:3 0.75 0.58 0.99 0.04 0.1904 
 
            
PC aa C42:0 0.72 0.56 0.92 0.01 0.0728 
 
            
PC aa C42:1 0.71 0.55 0.91 0.01 0.0642 
 
            
PC aa C42:2 0.64 0.49 0.85 0.002 0.0359*             
PC aa C42:5 0.75 0.58 0.99 0.04 0.1904 
 
            
PC ae C32:1 0.79 0.62 1.00 0.05 0.1904 
 
            
PC ae C32:2 0.72 0.57 0.92 0.01 0.0642 
 
            
PC ae C34:0 0.73 0.57 0.94 0.02 0.1004 
 
            
PC ae C36:0 0.71 0.55 0.91 0.01 0.0642 
 
            
PC ae C36:2 0.77 0.60 0.99 0.05 0.1904 
 
            
PC ae C38:0 0.69 0.54 0.90 0.01 0.0642 
 
            
PC ae C38:2 0.77 0.61 0.99 0.04 0.1904 
 
            
PC ae C38:6 0.78 0.61 0.99 0.04 0.1904 
 
            
PC ae C40:1 0.71 0.55 0.90 0.01 0.0642 
 
            
PC ae C40:5 0.71 0.55 0.91 0.01 0.0642 
 
            
PC ae C40:6 0.65 0.50 0.84 0.001 0.0359*             
PC ae C42:2 0.62 0.48 0.81 0.0004 0.0359*             
PC ae C42:3 0.67 0.52 0.86 0.002 0.0359*             
lyso-Phosphatidylcholines   
 
            
lysoPC a 
C16:0 
0.77 0.60 0.99 0.04 0.1904 
 
            
lysoPC a 
C17:0 
0.70 0.54 0.90 0.01 0.0642 
 
            
lysoPC a 
C18:0 
0.76 0.60 0.98 0.03 0.1742 
 
            
lysoPC a 
C18:1 
0.68 0.52 0.88 0.004 0.0587 
 
            
lysoPC a 
C18:2 
0.78 0.61 1.00 0.05 0.1904 
 
            
* Statistically significant association after correction for multiple testing 
Abbreviations: PC, phosphatidylcholine; a, acyl; e,-alkyl; SM, sphingomyelin 
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Selected results of multiple logistic regression models for men and women of EPIC-
Potsdam are shown in Table 12 and Table 13, respectively. In both sexes, especially PCs 
(diacyl, acyl-alkyl and lyso) showed inverse associations (p<0.05) with the WG phenotype. 
For men, SMs C18:0 and C18:1 showed positive associations whereas in women AAs were 
inversely associated with the WG phenotype.  
In contrast, it could be observed that higher levels of ACs showed suggestive positive 
associations with HG phenotype for men and women. Furthermore, PCs showed inconsistent 
associations with acyl-alkyl-PC C28:1 to be positively and diacyl-PC C38:1 to be inversely 
associated. 
In summary, consistent with the results of the meta-analyses reported in chapter 4.3, 
metabolites associated with the WG phenotype in women could be identified in EPIC-
Potsdam. Six metabolites, including one AA and five PCs, remained statistically significant in 
their association with the WG phenotype in women when taking multiple testing into account. 
No metabolic predictors could be identified for the WG phenotype in men or for the HG 
phenotype in both sexes. 
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4.4.2. Principal components and their association to WG and HG phenotypes in EPIC-
Potsdam 
After correction for multiple testing, principal component 1 for women and principal 
component 2 for men, which had high loadings especially on diacyl- and acyl-alkyl-PCs, 
showed a statistically significant inverse association with the WG phenotype. All other 
principal components did not show statistically significant associations with any of the weight-
gaining phenotypes. All multiple logistic regressions results with principal components as 
independent variables for both sexes are shown in Table 14. All other factors showed no 
statistically significant associations for the WG or for the HG phenotype in men and women. 
Table 14 Associations and corresponding 95% confidence limits of metabolite principal 
components with WG and HG phenotype stratified by sex 
   WG phenotype   HG phenotype 
   OR 95% CI PFDR   OR 95% CI PFDR 
Men PComp1 0.87 0.62 1.21 0.4924  1.09 0.79 1.49 0.7666 
 PComp2 0.57 0.39 0.83 0.0143  0.87 0.62 1.24 0.7583 
 PComp3 1.23 0.89 1.68 0.4828  1.18 0.88 1.57 0.7583 
 PComp4 1.00 0.72 1.40 0.9893  0.89 0.65 1.21 0.7583 
 PComp5 1.18 0.87 1.62 0.4828  1.04 0.78 1.40 0.7858 
           
Women PComp1 0.67 0.51 0.86 0.0181  0.96 0.73 1.26 0.7625 
 PComp2 0.98 0.78 1.24 0.8751  0.86 0.67 1.10 0.7625 
 PComp3 1.03 0.81 1.31 0.8751  1.05 0.81 1.37 0.7625 
 PComp4 0.81 0.64 1.03 0.1774  1.06 0.84 1.34 0.7625 
Abbreviations: PComp – Principal Component 
Simplified principal components  
The simplified components are equivalent to the linear combinations of metabolites 
shown in Table 10 and Table 11.  
The simplified linear combinations had excellent correlations with the initial principal 
components showing that the explained variance of this component is mainly explained by 
the reduced number of metabolites. For men, Pearson correlation coefficients for the derived 
linear combinations ranged from r=0.87 for principal component 5 to r=0.94 for principal 
component 1 (all p<.0001); for women, correlation coefficients ranged from r=0.87 for 
principal component 3 to r=0.94 for component 2 (all p<.0001) (Table 15).  
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Table 15 Pearson correlation coefficients and corresponding p-values for simplified principal 
components with PCA derived principal components 
 Men  Women 
 Pearson´s r p  Pearson´s r p 
Simplified PComp1 with 
PComp1 
0.94 <.0001  0.93 <.0001 
Simplified PComp2 with 
PComp2 
0.91 <.0001  0.94 <.0001 
Simplified PComp3 with 
PComp3 
0.92 <.0001  0.87 <.0001 
Simplified PComp4 with 
PComp4 
0.91 <.0001  0.89 <.0001 
Simplified PComp5 with 
PComp5 
0.87 <.0001    
Abbreviation: PComp – Principal Component 
 
Multiple logistic regression analyses were repeated with the simplified principal 
components as independent variables (Table 16). In women, it could be observed that 
simplified principal component 1 which is based on the principal component, consisting 
mainly of PCs with a statistically significant inverse association to the WG phenotype, 
remained significantly inverse associated. The strength of the association was markedly 
attenuated in comparison to the initial principal component (OR: 0.98 95% CI: 0.96-0.99, 
pFDR=0.0304 vs. OR: 0.67, 95% CI: 0.51-0.86, pFDR=0.0181). 
A similar observation was made in men. Simplified principal component 2, based on 
the principal component consisting of PCs, was markedly attenuated in strength of the 
association and lost its significance when taking multiple testing into account.  
None of the other simplified components showed a statistically significant association 
with any of the phenotypes in men. All associations were markedly attenuated and 
approached an OR of 1 in comparison to the basic principal components. 
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Table 16 Associations of simplified principal components to WG or HG phenotype in EPIC-
Potsdam by sex 
   WG phenotype   HG phenotype 
   OR 95% CI PFDR   OR 95% CI PFDR 
Men SPComp1 0.98 0.95 1.02 0.7044  1.01 0.98 1.04 0.6926 
 SPComp2 0.95 0.92 0.99 0.0526  1.00 0.96 1.03 0.8847 
 SPComp3 1.01 0.98 1.04 0.7704  1.01 0.98 1.05 0.6926 
 SPComp4 0.98 0.93 1.03 0.7044  0.98 0.93 1.02 0.6926 
 SPComp5 0.99 0.91 1.09 0.8564  1.03 0.95 1.12 0.6926 
           
Women SPComp1 0.98 0.96 0.99 0.0304  1.00 0.98 1.02 0.7977 
 SPComp2 0.99 0.97 1.01 0.5807  0.99 0.97 1.01 0.7977 
 SPComp3 1.00 0.97 1.03 0.9167  1.00 0.96 1.03 0.7977 
 SPComp4 0.96 0.92 1.00 0.1221  1.01 0.97 1.05 0.7977 
Abbreviation: SPComp – Simplified Principal Component 
4.4.3. Comparison of results 
In the principal component approach, the two principal components showing 
significant associations with the WG phenotype in men or women, respectively, were 
characterized by high factor loadings on metabolites that showed significant associations in 
the meta-analytical single metabolite approach. With diacyl-PCs C36:0, C38:0, C42:2 and 
acyl-alkyl-PCs C32:2, C38:0, C38:6, C40:1, C40:5, C40:6, C42:2, C42:3, 10 out of 19 PCs 
with statistically significant inverse associations in the meta-analytical approach in objective 2 
(chapter 4.3) showed a meaningful factor loading of greater 0.6 on principal component 2 for 
men; with the same PCs except of acyl-alkyl-PC C38:6, 9 out of 19 PCs showed as well a 
meaningful factor loading on principal component 1 for women. 
None of the principal components showed a statistically significant association to the 
HG phenotype in any sex. This is consistent with the single-metabolite approach where no 
metabolite was statistically significantly associated with the HG phenotype when taking 
multiple testing into account. 
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5. Discussion 
In this thesis, it was possible to identify weight-gaining individuals with either a 
tendency to increase rather hip circumference or rather waist circumference in three 
independent well-described population-based prospective German cohort studies. 
Furthermore, a general tendency to increase rather waist than hip circumference 
independent of the initial circumferences was observed. On basis of these observations, two 
phenotypes of WG and HG individuals were defined with significant tendencies to increase 
rather waist or hip circumference, respectively. Metabolites of a targeted metabolomics 
approach were investigated as potential predictors of these phenotypes in two independent 
cohort studies with a meta-analytical combination of single study results afterwards. 21 
predictive metabolites could be identified to be predictive for the WG phenotype in women, 
including 20 glycerophospholipids and one aromatic AA. No predictive metabolite could be 
identified for the WG phenotype in men. For the HG phenotype, we could not identify a 
predictive metabolite out of the applied targeted metabolomics kit, neither in men nor in 
women. In a further approach to investigate the metabolites in their relation to the identified 
weight-gaining phenotypes, principal components of metabolites where investigated. For 
both sexes, a principal component containing especially glycerophospholipids was inversely 
associated with the WG phenotype. Again, no significant association was observed for the 
HG phenotype. The metabolites that have been identified in the single metabolite approach 
in women had as well high factor loadings on the principal components that showed 
significant inverse associations with the same phenotype in both sexes. 
The WG phenotype will lead to an increased waist circumference. This is associated 
with an increased amount of abdominal adipose tissue which is associated with metabolic 
consequences and increased risk for several chronic diseases. It was possible to identify 
predictive metabolites of this phenotype. 
The HG phenotype will lead to an increased hip circumference. This is associated 
with an increased amount of peripheral adipose tissue, which has been associated to have 
inverse associations to mortality and CVD events. It was not possible to identify predictive 
biomarker of this phenotype. 
To the authors´ knowledge this is the first approach to analyse metabolic predictors of 
WG and HG phenotypes that have been defined using average annual waist-hip-changes.  
The tendency towards a stronger increase of abdominal instead of peripheral body fat 
was previously reported to be present in both sexes. Mousavi et al. [121] reported a 
tendency towards stronger increase of waist circumference during a 6.6-year follow-up 
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period. Koskova et al. [122] reported an increase and a redistribution of regional body fat in 
women towards the abdominal area during a 3-year follow-up period. This is in line with the 
results of this thesis where both sexes showed a tendency to increase rather abdominal than 
peripheral body fat. Furthermore, Ebrahimi-Mameghani et al. [123] reported these changes 
to be stronger in middle-aged compared to older individuals. This is again in line with the 
results of this thesis where lowest values of waist-hip difference for men and women could 
be observed in cohort with the highest mean age (KORA). 
Lustgarten et al. [89] investigated the associations between metabolites and regional 
body fat in a cross-sectional study. They observed especially AAs, ACs and their derivates to 
show different associations regarding thigh and abdominal body fat, respectively. In this 
thesis, mainly phospholipids and not especially ACs or AAs were associated with the future 
changes in regional body fat and metabolites showed differences in their associations to 
cross-sectional and longitudinal anthropometric measures. With regard to these differences, 
cross-sectional and longitudinal results are hardly comparable. Unfortunately, no study was 
found investigating the longitudinal changes of regional body fat and their association with 
serum metabolites.  
 
5.1. Discussion of the methods 
Study design and study population 
The present thesis is based on data of three prospective German cohort studies. All 
investigated studies are well-described [93, 96, 98]. Based on the longitudinal design it was 
possible to investigate determinants and predictive metabolites of future weight gain 
phenotypes.  
The study population consists of people that gained weight during the follow-up 
period, because of the particular interest in weight gain phenotypes. Thus, the obtained 
results are not representative for the overall German population despite including the 
nationwide study of DEGS which was corrected for deviations of the sample to the 
demographic population structure of Germany as a whole [102]. Nevertheless, the study 
population for objective 1 included two local and one nationwide study and therefore it is 
possible to report a suggested informative nationwide trend for the weight-gaining population 
in Germany based on the investigated studies in this thesis. 
Differences in the general characteristics of the study population between cohorts 
may be due to differences in their age structure. KORA had a comparably high mean age at 
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baseline examination. Due to the high age, participants of KORA suffered more often from 
chronic diseases like myocardial infarction, stroke, diabetes and cancer and women were 
more often postmenopausal compared to DEGS and EPIC-Potsdam. With increasing age, 
chronic diseases appear more often, the observed differences in the characteristics of the 
cohorts are therefore plausible, but one should consider potentially altered biological effects 
due to the high age and should be aware of these differences when interpreting and 
comparing the results between studies. This potential problem was addressed with the 
comparison of results from KORA with those of EPIC-Potsdam and DEGS, which had a 
younger mean age. Independent of their age-structure, it was possible to derive consistent 
phenotypes in each study and observed general trends regarding changes in waist or hip 
circumferences were comparable. 
The analyses of objective 2 and 3 were based on the assumption, that individual 
weight gain within the follow-up period appeared on the basis of a comparable metabolic 
profile as measured at baseline examination. The human plasma metabolome is age-
dependent, and follow-up periods in KORA and EPIC-Potsdam were 7.1 and 8.6 years, 
respectively. Individual weight change is not assignable to a special period within follow-up 
and metabolic changes may have appeared [73]. This point was covered with a subgroup 
analysis for age and by including age at baseline as covariate in the analyses to proof that 
effects are not only due to physiological aging effects and corresponding associations were 
consistent.  
Variable assessment 
Possible sources of bias are the self-reported measures of body weight, waist and hip 
circumference for follow-up in EPIC-Potsdam. In order to correct potential underreporting and 
measurement errors, this possible bias was addressed with the use of EPIC-specific 
equations that have been invented in the EPIC-Oxford study [100, 101].  
As described in the introduction, the effects of waist and hip circumference should 
only be interpreted considering each other, because of potentially worsening or attenuating 
effects. This point was covered by the use of the waist-hip difference, and within the logistic 
regression models by adjusting for baseline BMI and baseline circumferences. 
There were some slight differences in the covariate assessment, e.g. menopausal 
status or for information on chronic diseases. The differences between EPIC-Potsdam and 
KORA regarding relative numbers of postmenopausal women were expected due to the 
comparably high mean age of KORA. Therefore, even with homogeneous covariate 
assessment, KORA would have had the majority of women in a postmenopausal status and 
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the heterogeneous covariate assessment was therefore expected to show only little impact. 
To proof that these variables did not show an impact on the observed results, study-specific 
sensitivity and subgroup analyses dealing with these variables were performed. The 
observed results were consistent and robust independent of differences in the covariate 
assessment.  
Fixed- vs. Random-effects model 
In the statistical analysis for objective 2, it was assumed that the combined studies of 
EPIC-Potsdam and KORA were functionally identical (share a standardized analysis plan, 
study population of German individuals, metabolite measurements performed in the same 
laboratory) and shared a common true effect size, independent of their different age 
structure. An alternative approach would have been the use of a random-effects model to 
combine the single study estimates for objective 2.  Within this approach, study weights are 
more balanced and the larger study of EPIC-Potsdam is assigned a less relative weight 
compared to KORA [115]. Weights would have included the total variance (sum of within- 
and between-study variance). The total variance can be expressed in a measure of 
heterogeneity, which means the variation in true effect sizes [124]. The observed 
heterogeneity expressed as I² and computed with the ‘DerSimonianLaird’-method [114] was 
zero for the majority of identified metabolites. In general the observed heterogeneity was low 
given by an I² of less than 50% (Table 17 and Appendix 5) [125]. Possible sources of 
heterogeneity could be due to reasons of technical and biological variation. Most of the 
metabolites with a high value for I² showed differing directions in their single study 
associations and therefore would not have met the criterion of a true effect defined in chapter 
3.4.4 at all, where both study estimates had to be consistent in their effect direction. 
Table 17 Interpretation of I² according to Higgins et al. (2003) [116] 
heterogeneity I² 
No  0% 
Low  25% 
Moderate  50% 
High  75% 
 
Analytical approaches 
A possible drawback of the newly created waist-hip difference could be that the same 
values may appear in both extrema of weight-gaining individuals, e.g. people experiencing a 
large increase in waist and hip circumference will have a similar values compared to people 
experiencing just a little increase in waist and hip circumference. Both cases might be based 
 Discussion 
 88 
 
on different initial levels of anthropometric measures and therefore represent other 
biochemical processes. Nevertheless, the aim was to identify individuals with the preferred 
deposition of body fat at specific sites. The assignment of individuals to the specific endpoint 
or reference categories was possible without any problem.  
For EPIC-Potsdam and KORA, these two phenotypes were considered as the 
endpoints of sex-specific multiple logistic regression models. Those phenotypes are based 
on study-specific cut-offs of average annual waist-hip difference. Cut-offs used to categorise 
continuous variables are in most cases arbitrary. The cut-off for categorisation in this thesis 
was chosen with the extreme deciles, because for approximately 10% of both sexes in EPIC-
Potsdam a negative value for waist-hip difference could be observed. A drawback of taking 
this relative cut-off is that in each investigated study another absolute cut-off emerged and 
comparisons across studies may be complicated because they differ in their range and 
values between studies. These cut-offs are reported in Table 5. Nevertheless, both 
phenotypes clearly represent a significant tendency of larger increase in waist or hip 
circumference, respectively, independent of their cut-offs and results are therefore 
comparable in their meaningfulness of WG or HG tendency although absolute values are 
different. 
The waist-hip difference was stronger correlated with average annual changes of 
waist circumference in comparison to average annual changes in hip circumference. So, 
changes of waist circumference showed a greater impact on this difference. This should be 
considered when interpreting the results. 
The difference of the average changes of waist and hip circumferences was used to 
form the endpoint variables of either the WG or the HG phenotype. The use of average 
changes has several drawbacks, e.g. changes in circumferences might have appeared at 
different time points within the follow-up period. Thus, an average does not consider this. 
Nevertheless, the particular interest focused on android or gynoid phenotypes. With the 
chosen statistical approach it is undoubtedly possible to identify the general tendencies of 
individuals to one of those body shapes. 
A possible drawback of the PCA is that this method creates principal components to 
explain the variance of the metabolites. Variation within a metabolome dataset is often due to 
different ages of individuals [73] and so may not explain necessarily much variation with 
regard to the outcome of interest [120].  
For the interpretation of principal components, only variables with a meaningful factor 
loading of at least 0.6 should be taken into account [120]. Factor loadings can be interpreted 
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as some kind of correlation between the original variable and the newly created principal 
component. Metabolites with high factor loadings explain a large amount of variance within 
this principal component whereas metabolites with low factor loadings explain only a little 
amount of variance. Nevertheless, the “low-loading” metabolites are part of the derived linear 
combination. With increasing number of variables, the amount of variance explained by low-
loading metabolites increases and should be considered when interpreting the results. The 
observed attenuated associations from the simplified principal components underline this 
point of view. 
 
5.2. Discussion of the results 
Description of anthropometric changes in weight-gaining individuals 
For Germany, it was observed that a gain in body weight is accompanied with a 
higher gain in waist than in hip circumference. The highest decile of the difference between 
average annual change of waist and hip circumference was labelled as the WG phenotype 
and the lowest decile as the HG phenotype.  
When comparing the average annual waist-hip difference between men and women, 
no significant difference could be observed in KORA, visual examination of the study-specific 
histograms did not reveal large differences between sexes in all studies. This was not 
expected because gynoid body fat distribution is reported to be more common in women and 
android body fat distribution is reported to be more common in men [11, 126]. Therefore, a 
clearer shift of the histograms was expected with the majority of women showing a tendency 
to increase more hip circumference in comparison to men.  
Evidence exists that metabolic disturbances which come along with body weight gain 
and abdominal body fat accumulation are not completely reversible. These unfavourable 
metabolic alterations partly remain unchanged after weight loss as well as changes of body 
composition and lean body mass [127]. For example, evidence exists that overweight or 
obese individuals with subsequent weight loss decrease their left ventricular mass which in 
turn increases their risk of suffering from CVD in the future due to decreased circulation 
ability [128, 129]. 
The majority of variance for average annual waist-hip difference could be as well 
explained be the use of average annual changes of WHR. WHR has been shown to be a 
good measure of abdominal obesity and body fat distribution in general [25], but it has the 
drawback of difficult interpretability. Thus, the newly created variable presented in this thesis 
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is able to provide the same information on changes of body fat distribution but it is easier to 
interpret because of its expression in absolute changes in cm/yr. 
The new variable showed stronger correlations with average annual waist 
circumference than with average annual hip circumference. Therefore this new variable 
covers a larger variance explanation from changes in waist circumference than from changes 
in hip circumference. This could be due to the fact that there is just a greater variation 
present within the waist variable. 
DEGS provided nationwide results and could be taken as the reference especially for 
the anthropometric results. Regional studies of EPIC-Potsdam and KORA showed 
comparable distributions of average annual waist-hip difference to DEGS, so it can be ruled 
out that the observed trend is just regional in the regions of Augsburg or Potsdam. The 
definition of weight-gaining phenotypes for each study revealed different cut-off-values for 
each study but consistent in their meaningfulness to the WG or the HG phenotype, 
respectively.  
The observed changes in anthropometric markers resulting in a general tendency to 
increase rather waist circumference than hip circumference could be an index for 
physiological aging processes. All investigated studies had a mean age of more than 40 
years and follow-up periods ranging from 7.1 years (KORA) to 11.9 years (DEGS). In 
particular EPIC-Potsdam and DEGS cover an age-range in which many hormonal changes 
appear in women as well as in men. In men, testosterone production decreases with ongoing 
age leading to lower levels of free plasma testosterone, which is reported to be cross-
sectionally and longitudinally associated with abdominal obesity and visceral fat 
accumulation [130]. In women, oestrogen is the major hormone responsible for the 
accumulation of fat in the gluteofemoral area. With menopause and the accompanied decline 
of oestrogen, strong evidence exists that women redistribute their body fat and increase 
adipose tissue in the abdominal area [40]. But not only testosterone and oestrogen are 
involved, furthermore the gonadotropins luteinizing hormone and follicle stimulating hormone 
are reported as being associated with WHR and therefore body fat distribution [25]. Thus, 
changes in hormonal balance should be considered in the interpretation of results dealing 
with anthropometric changes in these age-groups. 
Associations observed in the single metabolite approach 
In objective 2, the particular interest was whether metabolites can predict either the 
WG or the HG phenotype. The investigated studies are of an observational design, thus it is 
not possible to prove biological mechanisms. Nevertheless, the discussion of the results may 
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give some suggestive ideas about possible affected mechanisms that should be confirmed in 
experimental studies. 
Overall, it was possible to identify metabolites whose concentrations were inversely 
associated with the WG phenotype in women. In men and for the HG phenotype in women, 
no significant association could be revealed taking multiple testing into account. 
Phosphatidylcholines 
In the present thesis, it was possible to identify metabolites whose serum 
concentrations were associated with the defined phenotypes. It appears that associations 
with p<0.05 were revealed more often for the WG than for the HG and that a particular class 
of metabolites, the PCs, seems to be involved in subsequent waist gain, at least in women. 
In men and for the HG phenotype, no significant association between serum metabolite 
concentrations and subsequent gain in circumferences remained when taking multiple testing 
into account. 
PCs are the most abundant phospholipids and a frequent constituent of lipoproteins in 
human blood, especially HDL [131] typically contains a saturated fatty acid at sn-1 position 
(e.g. palmitic acid, C16:0, or stearic acid, C18:0) and a poly-unsaturated fatty acid (PUFA) at 
sn-2 position [132]. De novo synthesis of PC is based on two pathways, the 
Cytidindiphsophat-choline (CDP-choline) and the phosphatidylethanolamine N-
methyltransferase (PEMT)-pathway. The CDP-choline-pathway as the major pathway 
requires alimentary choline; the PEMT-pathway is depending on the degradation of existing 
choline containing molecules, in particular phosphatidylethanolamine (PE) [132]. 
Selected PCs were significantly inversely associated with the WG phenotype in 
women, with the majority of PCs showing suggestive inverse association in both men and 
women. Meta-analytical as well as single study results suggest that this subgroup of 
metabolites seems to be involved in biochemical pathways that lead to the preferred 
deposition of body fat in the abdominal area.  
As mentioned before, there is strong evidence that in particular altered sex-hormones 
are responsible for the development of abdominal adipose tissue in both men and women 
[40, 130, 133]. Borruel et al. reported the WHR to be significantly correlated with sexual 
steroids and gonadotropin concentrations [25]. A linkage between oestrogen, testosterone 
and altered levels of PCs has been reported in mice [134] but information for humans is 
scarce. In the rodent models, an administration of oestrogen led to an increased PEMT-
enzyme activity, whereas the enzyme activity of the CDP-choline pathway was decreased. 
On the other hand, administration of testosterone did not show an effect on enzyme activities 
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[134]. For humans, consistent observations for oestrogen were made by Fischer et al. [135] 
reporting the PEMT-pathway to be induced by this hormone in women. Therefore, this 
subgroup of metabolites seems to be involved in biochemical pathways that lead to the 
preferred deposition of body fat in the abdominal area and the suggestive linkage between 
this class of metabolites and sexual hormones may explain the observed associations in this 
thesis. In EPIC-Potsdam, no significant correlation could be observed for the majority of the 
metabolites regarding oestrogen or testosterone levels showing that age-related decline of 
these sex hormones does not play a leading role in the explanation of the observed 
metabolite-phenotype associations (Appendix 8).  
Lyso-PCs are products of hydrolysis from either diacyl- and acyl-alkyl-PCs and have 
been reported as being associated with body mass and BMI [136]. Metabolic disorders have 
been reported as being associated with a reduction in lyso-PC-levels [80, 137]. Obese 
individuals and individuals with impaired glucose tolerance were reported to have decreased 
plasma levels, with lyso-PCs C16 and C18:2 to be discriminative biomarkers for normal or 
impaired glucose tolerance [80]. This is consistent with the results of this thesis, where lyso-
PC C17:0 was associated with the WG phenotype in both sexes and remained significant in 
women when taking multiple testing into account. Additionally lyso-PCs showed e.g. inverse 
associations (p<0.05) with both endpoints in both sexes before taking multiple testing into 
account. Thus, higher levels of lyso-PCs could be an index of a better health status without 
obesity- or disease-caused metabolic alterations. 
Amino acids 
The aromatic AA tryptophan was shown to be inversely associated with the WG 
phenotype in women. Coskun et al. [63] reported lower food intake and weight loss in mice 
treated with tryptophan. As an element of the serotonin metabolism, this AA may be involved 
in appetite regulation. Subjects with the WG phenotype showed significantly higher rates of 
average annual weight change and lower levels of tryptophan. Therefore higher levels of this 
AA may have a small effect on caloric restriction and might therefore be protective against 
waist gain by restricting weight gain. 
Studies investigated cross-sectional associations of metabolites and regional body fat 
or anthropometric markers like FFMI, percent lean mass or subcutaneous adipose tissue, 
linking in particular AAs to these anthropometric markers [87-90].  
Tanaka et al. [137] reported higher levels of many AA including tryptophan in 
individuals with higher levels of visceral fat compared to individuals with lower levels of 
visceral fat. Thus, high baseline levels of waist circumference and therefore visceral fat might 
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be the reason for high tryptophan levels. Tryptophan showed comparable associations with 
baseline anthropometric markers compared to average annual changes of these markers 
(chapter 4.3.5). In comparison, individuals with the WG phenotype tended to have a lower 
baseline waist circumference in the investigated studies. Multiple logistic regression models 
were adjusted for baseline levels of waist circumference but baseline levels may affect this 
association through insufficient adjustment and residual confounding. 
As a result of the single metabolite approach, it must be emphasized that 
associations were only observed for the WG phenotype in women, when taking multiple 
testing into account. Comparing results of uncorrected single study and meta-analyses 
results, similar observations can be made with men showing less significant associations 
with the WG phenotype than women.  A previously mentioned point is the lower statistical 
power for men. Another explanation could be differing effect strengths for men and women. 
Evidence exists that there is a stronger protective effect of gluteofemoral subcutaneous 
adipose in women [42-44, 138]. An alternative explanation is that the defined weight gain 
phenotypes had different cut-offs for average annual waist-hip difference in men and in 
women which could lead to attenuated effects in men. 
Null results regarding the hip-gaining phenotype 
It was not possible to identify predictors of the HG phenotype for either sex in the 
meta-analytical approach when taking multiple testing into account. With regard to the 
uncorrected (suggestive) associations, much less metabolites were associated with the HG 
phenotype compared to the WG phenotype in both men and women. This is in line with the 
literature where the information on predictors of gluteofemoral fat mass is scarce. This may 
be due to the role of visceral adipose tissue as an endocrine organ [39] which is therefore 
more likely to find predictive metabolites due to its integration in physiological processes. 
This role might be lacking in the case of hip fat mass. 
Associations observed in the principal component approach 
It was possible to summarise similar metabolites in consistent and biologically 
plausible principal components. To cover the majority of explained variance within the 
metabolomics dataset, a different numbers of principal components were necessary. 
Nevertheless, the derived components were comparable between men and women. A 
principal component that showed a similar linear combination of metabolites in men and 
women (principal component 2 in men and principal component 1 in women, respectively) 
was associated with the WG phenotype in both sexes.  
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The majority of PCs that have been identified as being associated with the WG 
phenotype in the meta-analytic single metabolite approach reappeared in the principal 
components that showed statistically significant inverse associations with this phenotype in 
the PCA approach. So results of both approaches are consistent in a way that specific PCs 
seem to play a role in this association. To study the importance of these metabolites, 
simplified linear combinations only including metabolites with meaningful factor loadings as 
weights were computed. Results of these linear combinations as independent variables in 
the sex-specific multiple logistic regression models were compared to the results obtained 
with the use of the original principal components. The associations were strongly attenuated 
for both sexes and even lost its significance among men when taking multiple testing into 
account. This could mean that not only these metabolites are responsible for the inverse 
association but the metabolic fingerprint as a whole. As a consequence single metabolites 
identified in objective 2 should not be seen independently but in combination with each other 
and one should always consider associated pathways that are affected from these metabolic 
constellations. 
Nonetheless, PCs seem to play a major role in the deposition of body fat in the 
abdominal area, because both the single metabolite as well as the principal component 
approach underlined the role of PCs in the development of abdominal fat deposition. 
Phenotype-associated metabolites and their association to chronic disease risk 
Further research in the EPIC-Heidelberg study revealed that waist circumference is 
only moderately associated with visceral fat mass [139]. Currently it could not be ruled out 
that lower gain in waist circumference is particularly related to lower gain in visceral fat mass 
that is particularly discussed to be involved in the development of chronic diseases like 
diabetes, hypertension and CVD [65, 140]. There is some evidence that common 
pathophysiological processes are involved in the development of this chronic diseases [65, 
140] and pathways of glycerophospolipids are affected from several diseases. Floegel et al. 
[82] reported four of the associated PCs from the meta-analyses (acyl-alkyl-PCs C40:5, 
C40:6, C42:3, lyso-PC C17:0) as being associated with a decreased risk of the development 
of T2D. In line with that, Pietilainen et al. [141] reported insulin-sensitive overweight 
individuals having higher levels of PCs compared to insulin-resistant overweight individuals. 
Thus, the deposition of body fat in the abdominal area accompanied with a suggested 
increase in visceral fat may be an intermediate step linking our identified metabolites with 
predictive association to the WG phenotype to increased risk for the development for T2D.  
Insulin sensitivity and lipoprotein membrane composition are linked with each other 
especially regarding skeletal muscle tissue [141-144]. Lipoproteins consist of PCs on the 
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outer and PEs on the inner side of the membrane. With a higher degree of PUFAs in the PC-
section, bio-membranes become more fluid especially regarding GLUT4 translocation after 
insulin stimulation. 11 out of 20 of the PCs that have been identified in the single-metabolite 
approach have at least 2 double bounds and are therefore eligible for containing PUFAs. 
Thus, higher levels of these metabolites may have beneficial effects in membrane fluidity and 
increase insulin-sensitivity. 
Independent of the endogenous synthesis pathways (CDP-choline or PEMT), 
especially diacyl-PCs are necessary for the hepatic secretion of very low density lipoprotein 
(VLDL) and HDL in the liver [132]. Low levels of HDL and increased levels of VLDL are 
considered as CVD risk factors and therefore PCs are directly involved in the secretion and 
clearance of those factors.  
Acyl-alkyl-PCs were reported to protect lipoproteins from oxidation through their vinyl-
ether-bond [145] and so lower risk of CVD. In this thesis, both types of glycerophospholipids 
with comparable characteristics regarding chain length and degree of saturation showed 
negative associations with the WG phenotype. It is possible, that upregulated diacyl-PCs 
lead to the upregulation of acyl-alkyl-PCs to protect them from oxidation and may explain the 
comparable characteristics.  
Ether-PCs and ether-lipids in general were reported to be decreased in hypertensive 
compared to normotensive individuals independently of other lipid alterations that are 
induced by obesity and insulin resistance [131, 146]. In this thesis, especially acyl-alkyl-PCs 
were associated with the WG phenotype in women when taking multiple testing into account 
or showed meaningful factor loadings for the principal components which showed inverse 
associations with the WG phenotype in men and women. Hypertension is a risk factor for 
chronic diseases and appears more often with increasing BMI. In EPIC-Potsdam and KORA, 
individuals in the reference category suffered less often from chronic diseases and had lower 
baseline BMI compared to the defined phenotypes which may explain parts of the observed 
associations between ether-lipids and the WG phenotype. 
It cannot be ruled out that some kind of reverse causation is present here. Are the 
prevalent unfavourable metabolic changes causing chronic diseases or is the unfavourable 
metabolic constellation caused by prevalent chronic diseases? This needs to be investigated 
in future studies. 
Phosphatidylcholines and their relation to lifestyle 
One of the most important confounders that may influence age-related changes in 
body composition is physical activity. Visceral adipocytes are more sensitive to lipolytic 
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stimulation than subcutaneous adipocytes [147] and exercise promotes the mobilization of 
triglycerides from adipose tissues. This association may attenuate or even prevent the age-
related gain in visceral adipose tissue by restricting hyperplasia and/or hypertrophy of 
adipose tissues [148, 149]. Wientzek et al. [76] reported both subclasses of PCs, diacyl and 
acyl-alkyl, to be positively associated with cardiorespiratory fitness (CRF). 8 out of 21 
associated metabolites from the single metabolite approach (PCs diacyl C36:0, C38:0, acyl-
alkyl C38:0, C42:3, C42:2, C36:0, C40:6, C40:1) were reported to be positively associated 
with CRF. Those metabolites could be markers of processes that attenuate or prevent the 
deposition of adipose tissue in the abdominal area through increased lipolysis induced by 
higher physical activity.  
Cross-sectional results of Jourdan et al. [87] showed decreasing chain length and 
saturation of fatty acids in PCs with increasing FFMI. High levels of FFMI indicate a high 
level of lean body mass in comparison to fat mass which is in general a favourable condition. 
In this thesis, associated PCs from the single metabolite approach as well as high loading 
PCs of the significant associated principal components showed in general a lower number of 
double bonds with decreasing number of carbons. That would be in line with results from 
Jourdan et al. but on the other hand two of associated PCs (acyl-alkyl C36:2 and C42:3) 
were reported to be negatively associated with FFMI in their study. Furthermore, these 
results of Jourdan et al. [87] did not exist in obese individuals but in non-obese individuals. 
They hypothesized that a sedentary lifestyle leads to derangements of skeletal muscle 
metabolism that favours the development of obesity and metabolic diseases because 
subjects in better shaped exhibit more lipolysis than less fit subjects [150]. In this thesis, the 
reference category consists in general of non-obese individuals. Body weight gain in these 
individuals may be restricted through higher physical activity levels indicated by higher FFMI 
which was reported as being associated with increased levels of PCs. Thus, the 
hypothesized pathway of comparably higher lipolysis in more fit subjects could be partly 
explain the inverse association with the WG phenotype and the associated metabolites that 
have been reported to be positively associated may be markers of the same processes 
mentioned in the paragraph before. 
Summarising the preceding sections shows that higher levels of PCs were reported 
as being associated with a favourable health status (non-obese, insulin-sensitive, 
normotensive, higher CRF). This is in line with the observed results that higher levels of PCs 
were inversely associated with the WG phenotype. The WG phenotype has a perspective of 
increased chronic disease risk due to the increase in abdominal fat. In general, this could be 
an indication of a more health-conscious lifestyle of the reference group (e.g. higher physical 
activity).  
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5.3. Strength and limitations 
The overall strength of the present thesis was the investigation of future phenotypes 
in the frame of prospective German cohort studies. The present analyses combined up to 
three prospective population-based and well described German cohort studies, which are all 
well-described. Thus, strength of this thesis is the longitudinal design of the investigated 
studies. Based on the longitudinal design it is possible to investigate determinants and 
predictive factors of future weight gain phenotypes.  
Through the combination of two independent cohort studies it was possible to create 
a larger sample size which was able to reveal even small effect sizes. For example in the 
single-study approach it was possible to identify six metabolites to be significantly associated 
with the WG phenotype in EPIC-Potsdam whereas the meta-analytical combination revealed 
21 metabolites to be significantly associated. Furthermore it was possible to replicate the 
results in each study. Thus one can be sure that observed associations are not study-specific 
and therefore the evidence for the observed results is strengthened. 
Another strength of this thesis is the comparison of two different approaches 
regarding the metabolome dataset to strengthen the meaningfulness of the obtained results. 
Both approaches showed comparable and consisting results and strengthen the evidence for 
the observed associations. 
To the authors’ knowledge, the current thesis is the first approach of defining future 
weight-gaining phenotypes regarding subsequent body fat accumulation using an innovative 
average annual waist-hip difference. It was shown in chapter 4.2.2, that this difference is 
highly correlating with the WHR but with the clear advantage of better interpretability through 
its expression in absolute changes in cm/yr. 
It must be emphasized that associations in the single metabolite approach are only 
present in for the WG phenotype in women when taking multiple testing into account. This 
may be due to several reasons. In order to create different phenotypes, the continuous 
variable ‘waist-hip difference’ was categorised. In analyses based on epidemiological data, 
conversion of continuous variables into categorical variables by grouping values is a 
common approach. But the simplicity achieved by creating artificial groups has a cost and 
may create problems. In particular, categorisation leads to a considerable loss of power and 
eventually loss of precision of estimated odds [151]. Second, fewer men than women were 
included in the analysis. It was not possible to identify predictive metabolites for the WG 
phenotype in men in the single metabolite approach. The fact of a decreased power due to 
categorisation of waist-hip difference as well as the lower number of men in the analytical 
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study population may have led to this negative result for men. Nevertheless, the principal 
component approach revealed a similar association in men compared to women, so that 
there might be a true association which could be identified with a greater power in the 
analysis for men. 
As mentioned before, the analyses of objective 2 and 3 are based on the assumption 
that individual weight gain within the follow-up period appeared on the basis of a comparable 
metabolic profile as measured at baseline examination. There are differences in the reliability 
over time for the investigated metabolites. The assumption of time-stable metabolites is 
based on ICCs for p150 metabolites computed by Floegel et al. [108] during a 4-months 
period in fasting individuals. The follow-up periods in the present analysis are 7.1 years 
(KORA) and 8.6 years (EPIC-Potsdam) and it cannot be ruled out that metabolic changes 
appeared within this period. Thus, individual weight gain may have appeared on an 
(moderate) altered metabolic profile. It is unknown whether potential changes might affect 
the observed associations. This needs to be investigated in further studies. 
Two metabolites (PC aa C38:1, PC ae C38:2) that showed a significant association 
with the WG phenotype in women had a poor ICC of less than 0.4, all other associated 
metabolites had fair to excellent ICC with the majority of 16 metabolites having at least good 
reliability of more than 0.51 ICC (Table 18) [108]. Hankinson et al. [152] reported attenuating 
effects for identified associations with decreasing ICC where derived risk estimations are 
likely to be underestimated. Below an ICC of 0.65, attenuations are markedly, above this 
value the attenuations are reported to be moderate. So the observed associations in of 
metabolites with an ICC of less than 0.65 may be attenuated and true associations may be 
even stronger. On the other hand, a low ICC may be an index of a lower biological relevance. 
Especially in terms of long-term changes of body composition, the impact of those 
metabolites may be lower compared to those metabolites with a high ICC that are reliable 
over time. 
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Table 18 Intraclass correlation coefficients of metabolites showing a significant association 
with the WG phenotype in women after correction for multiple testing (modified from 
Floegel et al. (2011) [108]) 
Metabolite ICC  Metabolite ICC 
Amino acids   Acyl-alkyl-PCs  
Trp 0.45  PC ae C32:2 0.7 
Lyso-PCs   PC ae C34:0 0.57 
lysoPC a C17:0 0.64  PC ae C36:0 0.57 
Diacyl-PCs   PC ae C36:1 0.65 
PC aa C32:3 0.65  PC ae C36:2 0.76 
PC aa C36:0 0.56  PC ae C38:0 0.61 
PC aa C38:0 0.67  PC ae C38:2 0.29 
PC aa C38:1 0.03  PC ae C40:1 0.59 
PC aa C42:2 0.4  PC ae C40:2 0.72 
PC aa C42:5 0.42  PC ae C40:5 0.6 
   PC ae C40:6 0.69 
   PC ae C42:2 0.56 
   PC ae C42:3 0.59 
Abbreviations: ICC, intraclass correlation coefficient; Trp, tryptophan; 
PC, phosphatidylcholine; a, acyl; e, alkyl 
Most studies dealing with targeted metabolomics that have been considered in the 
discussion were cross-sectional whereas information from longitudinal studies is scarce. The 
results of this thesis are based on longitudinal data and cross-sectional associations may not 
give sufficient explanations for the observed results. Nevertheless, the considered studies in 
the discussion section give a consistent overview about potentially involved mechanisms, 
especially regarding the association to favourable lifestyle characteristics like physical 
activity. 
Last limitation to mention is that not all participants provided their blood sample in a 
fasting state; nevertheless about 30% in EPIC-Potsdam and 88% KORA were fasting. To 
address this potential bias, a sensitivity analysis in a fasting population in EPIC-Potsdam was 
performed showing that the results were independent of fasting status. 
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5.4. Conclusion and Future Prospects 
The majority of weight-gaining individuals in Germany tends to accumulate adipose 
tissue in the abdominal area. The results of this thesis support the necessity of primary 
prevention in terms of avoiding weight gain due to the increased disease risk with increasing 
abdominal adipose tissue.  
The identification of metabolites from a targeted metabolomics approach revealed 
metabolic markers that showed inverse associations for the preferred deposition of body fat 
in the abdominal area. The aromatic AA tryptophan and in particular groups of PCs (diacyl, 
acyl-alkyl and lyso) were associated with a reduced chance of belonging to the WG 
phenotype. The identified metabolites may act as a marker of physiological processes that 
lead to the deposition of adipocytes in different areas of the human body. The underlying 
effects may represent a healthy lifestyle and therefore a favourable metabolic state. The 
aforementioned factors indicating a better health status (non-obese, insulin-sensitive, 
normotensive, higher CRF) were all shown to be inversely associated with chronic disease 
risk and should have synergetic effects with regard to prevention.  
Future Prospects 
With regard to elucidating the role of the identified metabolites in terms of primary 
prevention and common pathophysiological pathways, further prospective studies are 
needed to investigate especially metabolites of the phospholipid-metabolism as determinants 
for future body fat distribution. Despite this work was not able to link sexual hormones to 
metabolic profiles that were associated with one of the defined phenotypes, there is evidence 
that especially oestrogen and testosterone are involved in the deposition of body fat in 
specific areas of the human body and the underlying effects may include alterations in sexual 
hormones. However, future studies should investigate age-dependent changes of associated 
metabolites as well as dependencies to changes in sexual hormones. 
In future studies, it would be interesting to investigate and possibly replicate the 
results obtained in this thesis in multi-level-analyses. Further analyses with summarized 
metabolite subclasses or metabolic pathways as a new level in multi-level-analysis would be 
interesting concerning the effects of clusters and/or groups of metabolites. Metabolic profiles 
are very complex and metabolites are exerting impact on each other and corresponding 
pathways. The application of PCA in this thesis was a first approach to cover the point of a 
more compact view on the metabolomics data and proposed multi-level-analysis would give 
an additional benefit in future studies when dealing with this kind of data.
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Summary 
Overweight and obesity are major public health problems in Germany. The 
associated comorbidities are highly depending on individual body fat distribution. A 
distinction is made between android and gynoid body fat distribution, which is highly 
depending on factors like age and sex. The present thesis aims to investigate general 
tendencies to one of these distributions using data from 4,126 weight-gaining individuals of 
three prospective German cohort studies. Furthermore, metabolic determinants for these 
phenotypes of body fat distribution are investigated based on targeted metabolomics data 
assessed with the Biocrates AbsoluteIDQTM kits. The difference of average annual changes 
in waist and hip circumference was calculated to assess the tendency to android or gynoid 
body fat distribution. Sex-specific extrema-deciles of these differences were used to define 
waist-gaining and hip-gaining phenotypes, all remaining individuals formed the reference 
category. Multiple sex-specific logistic regression models adjusted for potential confounders 
with standardized metabolite concentration as independent and weight-gaining phenotype as 
dependent variable were fitted. Besides the single metabolite approach, a principal 
component analysis as a data-reduction method based on quality-controlled metabolite data 
was performed; corresponding principal components were as well used as independent 
variables in the pre-described logistic regression model. Overall, a general tendency to 
increase rather waist than hip circumference could be observed in men as well as in women. 
The identification of predictive metabolites showed tryptophan, diacyl-phosphatidylcholines 
C32:2, C36:0, C38:0, C38:1, C42:2, C42:5, acyl-alkyl-phosphatidylcholines C32:2, C34:0, 
C36:0, C36:1, C36:2, C38:0, C38:2, C40:1, C40:2, C40:5, C40:6, C42:2, C42:3 and lyso-
phosphatidylcholine C17:0 to be inversely associated with the waist-gaining phenotype in 
women. For the waist-gaining phenotype in men and the hip-gaining phenotype in both 
sexes, no metabolite could be identified to be statistically significantly associated. The 
principal component analysis revealed biologically plausible principal components, of which 
one principal component mainly consisting of phosphatidylcholines was inversely associated 
with the waist-gaining phenotype in both sexes. Metabolites that have been identified to be 
inversely associated with the waist-gaining phenotype in women before all showed high 
factor loadings on the associated principal component. The identified or high-loading 
metabolites were all shown as being associated with favourable health conditions like 
increased fat free mass index, higher cardiorespiratory fitness, normotensive blood pressure 
and increased insulin-sensitivity. Weight-gaining individuals in Germany tend to increase 
abdominal body fat and especially the group of phosphatidylcholines was observed to be 
involved. Thus, future studies should investigate their role in future body fat deposition to 
increase our knowledge of associated pathophysiological pathways.  
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Zusammenfassung 
Übergewicht und Adipositas stellen in Deutschland ein großes Problem dar. Die 
hiermit assoziierten Komorbiditäten sind in starker Weise abhängig von der 
zugrundeliegenden Körperfettverteilung. Hierbei werden die androide und die gynoide 
Körperform unterschieden. Die Verteilung des Körperfetts hängt stark von Faktoren wie Alter 
und Geschlecht ab. In der vorliegenden Arbeit sollte anhand der Daten dreier prospektiver 
Deutscher Kohortenstudien die generelle Tendenz von 4,126 gewichtszunehmenden 
Studienteilnehmern im Hinblick auf eine der beiden Verteilungsformen untersucht werden. 
Des Weiteren wurde auf Basis der Daten gerichteter Metabolom-Messungen mittels 
Biocrates AbsoluteIDQTM Kits nach prädiktiven Metaboliten in gesucht, welche die 
Entstehung einer dieser beiden Phänotypen begünstigen. Für die Tendenz zu einer der 
beiden Verteilungsformen von Körperfett wurde die Differenz der durchschnittlichen 
Veränderungen von Taillen- und Hüftzunahme berechnet. Die geschlechts-spezifischen 
Extrem-Dezile dieser Differenz wurden als Taillen- bzw. Hüftzunehmer-Phänotyp definiert, 
die verbliebenen Individuen bildeten die Referenzkategorie. Für die Identifikation dieser 
prädiktiven Metabolite wurden multiple logistische Regressionsmodelle mit standardisierten 
Metabolit-Konzentrationen als unabhängige und den Phänotypen als abhängige Variable 
berechnet. Neben den Einzelmetaboliten wurde auch eine Hauptkomponentenanalyse auf 
Basis qualitätskontrollierter Metabolite durchgeführt, die Hauptkomponenten gingen ebenfalls 
als unabhängige Variablen in die logistische Regression ein. Als Ergebnis konnte eine 
eindeutige Tendenz zu einer vermehrten Zunahme an Taillenumfang im Vergleich zu 
Hüftumfang in beiden Geschlechtern beobachtet werden. Die Identifikation von prädiktiven 
Metaboliten bei Frauen lieferte Tryptophan, diacyl-Phosphatidylcholine C32:3, C36:0, C38:0, 
C38:1, C42:2, C42:5, acyl-alkyl-Phosphatidylcholine C32:2, C34:0, C36:0, C36:1, C36:2, 
C38:0, C38:2, C40:1, C40:2, C40:5, C40:6, C42:2, C42:3 und lyso-Phosphatidylcholin C17:0 
als invers mit dem Taillenzunehmer-Phänotyp assoziiert. Für den Taillenzunehmer-Phänotyp 
bei Männern bzw. die Hüftzunehmer-Phänotyp bei beiden Geschlechtern konnten keine 
prädiktiven Metabolite identifiziert werden. Die Hauptkomponentenanalyse lieferte biologisch 
plausible Hauptkomponenten, von welchen eine aus Phosphatidylcholinen bestehende 
Komponente inverse Assoziation zum Taillenzunehmer-Phänotyp in beiden Geschlechtern 
zeigte. Die zuvor als invers bei Frauen assoziierten Metaboliten zeigten hohe 
Faktorladungen für diese Hauptkomponente und stehen in Verbindung mit 
gesundheitsrelevanten Faktoren wie erhöhter fettfreier Masse Index, höherer 
cardiorespiratorischer Fitness, normotensivem Blutdruck und erhöhter Insulinsensitivität. 
Gewichtszunehmende Individuen in Deutschland nehmen vermehrt im abdominellen Bereich 
zu. Insbesondere die Gruppe der Phosphatidylcholine scheint hier eine Rolle zu spielen und 
sollte hinsichtlich zukünftiger Körperfettanlagerung weiter untersucht werden, um 
pathophysiologische Zusammenhänge besser zu verstehen und aufzuklären.
 References 
 103 
 
References 
1. WHO, Obesity: preventing and managing the global epidemic. Report of a WHO 
consultation, in World Health Organ Tech Rep Ser. 2000. p. i-xii, 1-253. 
2. Mensink, G.B., et al., [Overweight and obesity in Germany: results of the German 
Health Interview and Examination Survey for Adults (DEGS1)]. 
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2013. 56(5-6): p. 
786-94. 
3. Haftenberger, M., et al., Changes in body weight and obesity status in German adults 
– results of seven population-based prospective studies. Eur J Clin Nutr, 2016; 
70(3):300-5. 
4. Wu, C.Y., et al., Association of body mass index with all-cause and cardiovascular 
disease mortality in the elderly. PLoS One, 2014. 9(7): p. e102589. 
5. Wannamethee, S.G., A.G. Shaper, and M. Walker, Overweight and obesity and 
weight change in middle aged men: impact on cardiovascular disease and diabetes. J 
Epidemiol Community Health, 2005. 59(2): p. 134-9. 
6. De Pergola, G. and F. Silvestris, Obesity as a major risk factor for cancer. J Obes, 
2013. 2013: p. 291546. 
7. WHO, Joint WHO/FAO Expert Consultant on Diet, Nutrition and the Prevention of 
Chronic Diseases, in WHO Technical Report Series 2003, World Health Organisation: 
Geneva, Switzerland. 
8. Knoll, K.P. and H. Hauner, Kosten der Adipositas in der Bundesrepublik Deutschland 
- Eine aktuelle Krankheitskostenstudie. Adipositas – Ursachen, Folgeerkrankungen, 
Therapie, 2008. 2(4): p. 204-210. 
9. Chan, J.M., et al., Obesity, fat distribution, and weight gain as risk factors for clinical 
diabetes in men. Diabetes Care, 1994. 17(9): p. 961-9. 
10. Koh-Banerjee, P., et al., Changes in body weight and body fat distribution as risk 
factors for clinical diabetes in US men. Am J Epidemiol, 2004. 159(12): p. 1150-9. 
11. Vague, J., The degree of masculine differentiation of obesities: a factor determining 
predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J 
Clin Nutr, 1956. 4(1): p. 20-34. 
12. Ravussin, E. and J.F. Gautier, Metabolic predictors of weight gain. Int J Obes Relat 
Metab Disord, 1999. 23 Suppl 1: p. 37-41. 
13. Fogarty, A.W., et al., A prospective study of weight change and systemic 
inflammation over 9 y. Am J Clin Nutr, 2008. 87(1): p. 30-5. 
14. Hu, F.B., Metabolic and Hormonal Predictors of Obesity, in Obesity Epidemiology, 
F.B. Hu, Editor. 2008, Oxford University Press. 
15. Seidell, J.C., et al., Waist and hip circumferences have independent and opposite 
effects on cardiovascular disease risk factors: the Quebec Family Study. Am J Clin 
Nutr, 2001. 74(3): p. 315-21. 
16. Snijder, M.B., et al., Independent and opposite associations of waist and hip 
circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Int 
J Obes Relat Metab Disord., 2004. 28(3): p. 402-9. 
17. Fox, C.S., et al., Abdominal visceral and subcutaneous adipose tissue compartments: 
association with metabolic risk factors in the Framingham Heart Study. Circulation, 
2007. 116(1): p. 39-48. 
18. Hu, F.B., Measurements of Adiposity and Body Composition, in Obesity 
Epidemiology, F.B. Hu, Editor. 2008, Oxford University Press. 
19. Vitaleben GmbH, Fettverteilungsrechner - Apfel oder Birne? 2015; [cited 2015 
28.11.2015]; Available from: 
http://www.vitaleben.com/service/fettverteilungsrechner2.htm. 
20. Ibrahim, M.M., Subcutaneous and visceral adipose tissue: structural and functional 
differences. Obes Rev, 2010. 11(1): p. 11-8. 
 References 
 104 
 
21. Wajchenberg, B.L., Subcutaneous and visceral adipose tissue: their relation to the 
metabolic syndrome. Endocr Rev, 2000. 21(6): p. 697-738. 
22. Wells, J.C. and M.S. Fewtrell, Measuring body composition. Arch Dis Child, 2006. 
91(7): p. 612-7. 
23. Rimm, E.B., et al., Validity of self-reported waist and hip circumferences in men and 
women. Epidemiology, 1990. 1(6): p. 466-73. 
24. Rankinen, T., et al., The prediction of abdominal visceral fat level from body 
composition and anthropometry: ROC analysis. Int J Obes Relat Metab Disord, 1999. 
23(8): p. 801-9. 
25. Borruel, S., et al., Surrogate markers of visceral adiposity in young adults: waist 
circumference and body mass index are more accurate than waist hip ratio, model of 
adipose distribution and visceral adiposity index. PLoS One, 2014. 9(12): p. e114112. 
26. Brambilla, P., et al., Crossvalidation of anthropometry against magnetic resonance 
imaging for the assessment of visceral and subcutaneous adipose tissue in children. 
Int J Obes (Lond), 2006. 30(1): p. 23-30. 
27. Clasey, J.L., et al., The use of anthropometric and dual-energy X-ray absorptiometry 
(DXA) measures to estimate total abdominal and abdominal visceral fat in men and 
women. Obes Res, 1999. 7(3): p. 256-64. 
28. Lean, M.E., T.S. Han, and C.E. Morrison, Waist circumference as a measure for 
indicating need for weight management. BMJ, 1995. 311(6998): p. 158-61. 
29. Alberti, K.G., et al., Harmonizing the metabolic syndrome: a joint interim statement of 
the International Diabetes Federation Task Force on Epidemiology and Prevention; 
National Heart, Lung, and Blood Institute; American Heart Association; World Heart 
Federation; International Atherosclerosis Society; and International Association for 
the Study of Obesity. Circulation, 2009. 120(16): p. 1640-5. 
30. Heid, I.M., et al., Meta-analysis identifies 13 new loci associated with waist-hip ratio 
and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet, 
2010. 42(11): p. 949-60. 
31. Shungin, D., et al., New genetic loci link adipose and insulin biology to body fat 
distribution. Nature, 2015. 518(7538): p. 187-96. 
32. Randall, J.C., et al., Sex-stratified genome-wide association studies including 
270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. 
PLoS Genet, 2013. 9(6): p. e1003500. 
33. Law, J., et al., The influence of sex steroids on adipose tissue growth and function. 
Horm Mol Biol Clin Investig, 2014. 19(1): p. 13-24. 
34. Esmaillzadeh, A., et al., Larger hip circumference independently contributed to 
reduced metabolic risks in Tehranian adult women. Int J Cardiol, 2006. 108(3): p. 
338-45. 
35. Snijder, M.B., et al., Larger thigh and hip circumferences are associated with better 
glucose tolerance: the Hoorn study. Obes Res, 2003. 11(1): p. 104-11. 
36. Snijder, M.B., et al., Associations of hip and thigh circumferences independent of 
waist circumference with the incidence of type 2 diabetes: the Hoorn Study. Am J Clin 
Nutr, 2003. 77(5): p. 1192-7. 
37. Lanfer, A., et al., Does change in hip circumference predict cardiovascular disease 
and overall mortality in Danish and Swedish women? Obesity (Silver Spring), 2014. 
22(3): p. 957-63. 
38. Lissner, L., et al., Larger hip circumference independently predicts health and 
longevity in a Swedish female cohort. Obes Res, 2001. 9(10): p. 644-6. 
39. Galic, S., J.S. Oakhill, and G.R. Steinberg, Adipose tissue as an endocrine organ. 
Mol Cell Endocrinol, 2010. 316(2): p. 129-39. 
40. Geer, E.B. and W. Shen, Gender differences in insulin resistance, body composition, 
and energy balance. Gend Med, 2009. 6 Suppl 1: p. 60-75. 
41. Snijder, M.B., et al., Low subcutaneous thigh fat is a risk factor for unfavourable 
glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. 
Diabetologia, 2005. 48(2): p. 301-8. 
 References 
 105 
 
42. Heitmann, B.L., P. Frederiksen, and L. Lissner, Hip circumference and cardiovascular 
morbidity and mortality in men and women. Obes Res, 2004. 12(3): p. 482-7. 
43. Heitmann, B.L. and L. Lissner, Hip Hip Hurrah! Hip size inversely related to heart 
disease and total mortality. Obes Rev, 2011. 12(6): p. 478-81. 
44. Parker, E.D., et al., Association of hip circumference with incident diabetes and 
coronary heart disease: the Atherosclerosis Risk in Communities study. Am J 
Epidemiol, 2009. 169(7): p. 837-47. 
45. Cameron, A.J., et al., The influence of hip circumference on the relationship between 
abdominal obesity and mortality. Int J Epidemiol, 2012. 41(2): p. 484-94. 
46. Hubert, H.B., et al., Obesity as an independent risk factor for cardiovascular disease: 
a 26-year follow-up of participants in the Framingham Heart Study. Circulation, 1983. 
67(5): p. 968-77. 
47. Schulte, H., P. Cullen, and G. Assmann, Obesity, mortality and cardiovascular 
disease in the Munster Heart Study (PROCAM). Atherosclerosis, 1999. 144(1): p. 
199-209. 
48. Stern, M.P. and S.M. Haffner, Body fat distribution and hyperinsulinemia as risk 
factors for diabetes and cardiovascular disease. Arteriosclerosis, 1986. 6(2): p. 123-
30. 
49. Alexopoulos, N., D. Katritsis, and P. Raggi, Visceral adipose tissue as a source of 
inflammation and promoter of atherosclerosis. Atherosclerosis, 2014. 233(1): p. 104-
12. 
50. World Heart Federation, Cardiovascular disease risk factors - obesity. 2015  [cited 
2015 22.09.2015]; Available from: http://www.world-heart-
federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/obesity/. 
51. Calle, E.E. and R. Kaaks, Overweight, obesity and cancer: epidemiological evidence 
and proposed mechanisms. Nat Rev Cancer, 2004. 4(8): p. 579-91. 
52. Wolin, K.Y., K. Carson, and G.A. Colditz, Obesity and cancer. Oncologist, 2010. 
15(6): p. 556-65. 
53. Steffen, A., et al., Development and validation of a risk score predicting substantial 
weight gain over 5 years in middle-aged European men and women. PLoS One, 
2013. 8(7): p. e67429. 
54. Larsson, B., et al., Abdominal adipose tissue distribution, obesity, and risk of 
cardiovascular disease and death: 13 year follow up of participants in the study of 
men born in 1913. Br Med J (Clin Res Ed), 1984. 288(6428): p. 1401-4. 
55. Bjorntorp, P., Hazards in subgroups of human obesity. Eur J Clin Invest, 1984. 14(4): 
p. 239-41. 
56. Peiris, A.N., et al., Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med, 
1989. 110(11): p. 867-72. 
57. Kissebah, A.H. and A.N. Peiris, Biology of regional body fat distribution: relationship 
to non-insulin-dependent diabetes mellitus. Diabetes Metab Rev, 1989. 5(2): p. 83-
109. 
58. Despres, J.P., et al., Regional distribution of body fat, plasma lipoproteins, and 
cardiovascular disease. Arteriosclerosis, 1990. 10(4): p. 497-511. 
59. DAG e.V. guidelines, Interdisziplinäre Leitlinie der Qualität S3 zur „Prävention und 
Therapie der Adipositas“. 2014. 
60. Duncan, B.B., et al., Inflammation markers predict increased weight gain in smoking 
quitters. Obes Res, 2003. 11(11): p. 1339-44. 
61. Holz, T., et al., Markers of inflammation and weight change in middle-aged adults: 
results from the prospective MONICA/KORA S3/F3 study. Obesity (Silver Spring), 
2010. 18(12): p. 2347-53. 
62. Schwartz, M.W., et al., Reduced insulin secretion: an independent predictor of body 
weight gain. J Clin Endocrinol Metab, 1995. 80(5): p. 1571-6. 
63. Wedick, N.M., et al., Prospective investigation of metabolic characteristics in relation 
to weight gain in older adults: the Hoorn Study. Obesity (Silver Spring), 2009. 17(8): 
p. 1609-14. 
 References 
 106 
 
64. Gerszten, R.E. and T.J. Wang, The search for new cardiovascular biomarkers. 
Nature, 2008. 451(7181): p. 949-52. 
65. Herder, C., M. Karakas, and W. Koenig, Biomarkers for the prediction of type 2 
diabetes and cardiovascular disease. Clin Pharmacol Ther, 2011. 90(1): p. 52-66. 
66. Nicholson, J.K. and J.C. Lindon, Systems biology: Metabonomics. Nature, 2008. 
455(7216): p. 1054-6. 
67. Roberts, L.D., et al., Targeted metabolomics. Curr Protoc Mol Biol, 2012. Chapter 30: 
p. Unit 30 2 1-24. 
68. Crick, F., Central dogma of molecular biology. Nature, 1970. 227(5258): p. 561-3. 
69. German, J.B., B.D. Hammock, and S.M. Watkins, Metabolomics: building on a 
century of biochemistry to guide human health. Metabolomics, 2005. 1(1): p. 3-9. 
70. Römisch-Margl, W., et al., Procedure for tissue sample preparation and metabolite 
extraction for high-throughput targeted metabolomics. Metabolomics, 2012. 8(1): p. 
133-142. 
71. Vinayavekhin, N. and A. Saghatelian, Untargeted metabolomics. Curr Protoc Mol 
Biol, 2010. Chapter 30: p. Unit 30 1 1-24. 
72. Siegert, S., et al., Sex Dependency  of  Human  Metabolic  Profiles  Revisited. 
Metabolomics, 2012. 2(5): p. e1000115. 
73. Yu, Z., et al., Human serum metabolic profiles are age dependent. Aging Cell, 2012. 
11(6): p. 960-7. 
74. Suhre, K., et al., Metabolic footprint of diabetes: a multiplatform metabolomics study 
in an epidemiological setting. PLoS One, 2010. 5(11): p. e13953. 
75. Gibney, M.J., et al., Metabolomics in human nutrition: opportunities and challenges. 
Am J Clin Nutr, 2005. 82(3): p. 497-503. 
76. Wientzek, A., et al., Serum metabolites related to cardiorespiratory fitness, physical 
activity energy expenditure, sedentary time and vigorous activity. Int J Sport Nutr 
Exerc Metab, 2014. 24(2): p. 215-26. 
77. Menni, C., et al., Targeted metabolomics profiles are strongly correlated with 
nutritional patterns in women. Metabolomics, 2013. 9(2): p. 506-514. 
78. Xu, T., et al., Effects of smoking and smoking cessation on human serum metabolite 
profile: results from the KORA cohort study. BMC Med, 2013. 11(1): p. 60. 
79. Zheng, Y., et al., Metabolomic patterns and alcohol consumption in African 
Americans in the Atherosclerosis Risk in Communities Study. Am J Clin Nutr, 2014. 
99(6): p. 1470-1478. 
80. Zhao, X., et al., Metabonomic fingerprints of fasting plasma and spot urine reveal 
human pre-diabetic metabolic traits. Metabolomics, 2010. 6(3): p. 362-374. 
81. Wang-Sattler, R., et al., Novel biomarkers for pre-diabetes identified by 
metabolomics. Mol Syst Biol, 2012. 8: p. 615. 
82. Floegel, A., et al., Identification of serum metabolites associated with risk of type 2 
diabetes using a targeted metabolomic approach. Diabetes, 2013. 62(2): p. 639-48. 
83. Qiu, Y., et al., Mass spectrometry-based quantitative metabolomics revealed a 
distinct lipid profile in breast cancer patients. Int J Mol Sci, 2013. 14(4): p. 8047-61. 
84. Bogdanov, M., et al., Metabolomic profiling to develop blood biomarkers for 
Parkinson's disease. Brain, 2008. 131(Pt 2): p. 389-96. 
85. Lewis, G.D., et al., Metabolite profiling of blood from individuals undergoing planned 
myocardial infarction reveals early markers of myocardial injury. J Clin Invest, 2008. 
118(10): p. 3503-12. 
86. Sreekumar, A., et al., Metabolomic profiles delineate potential role for sarcosine in 
prostate cancer progression. Nature, 2009. 457(7231): p. 910-4. 
87. Jourdan, C., et al., Body fat free mass is associated with the serum metabolite profile 
in a population-based study. PLoS One, 2012. 7(6): p. e40009. 
88. Lustgarten, M.S., et al., Branched chain amino acids are associated with muscle 
mass in functionally limited older adults. J Gerontol A Biol Sci Med Sci, 2014. 69(6): 
p. 717-24. 
 References 
 107 
 
89. Lustgarten, M.S., et al., Serum glycine is associated with regional body fat and insulin 
resistance in functionally-limited older adults. PLoS One, 2013. 8(12): p. e84034. 
90. Lustgarten, M.S., et al., Serum Predictors of Percent Lean Mass in Young Adults. J 
Strength Cond Res, 2013. 
91. Moore, S., et al., Human metabolic correlates of body mass index. Metabolomics, 
2013: p. 1-11. 
92. Bingham, S. and E. Riboli, Diet and cancer--the European Prospective Investigation 
into Cancer and Nutrition. Nat Rev Cancer, 2004. 4(3): p. 206-15. 
93. Boeing, H., J. Wahrendorf, and N. Becker, EPIC-Germany--A source for studies into 
diet and risk of chronic diseases. European Investigation into Cancer and Nutrition. 
Ann Nutr Metab, 1999. 43(4): p. 195-204. 
94. Boeing, H., A. Korfmann, and M.M. Bergmann, Recruitment procedures of EPIC-
Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab, 1999. 
43(4): p. 205-15. 
95. Ford, E.S., et al., Liver enzymes and incident diabetes: findings from the European 
Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 
Care, 2008. 31(6): p. 1138-43. 
96. Holle, R., et al., KORA--a research platform for population based health research. 
Gesundheitswesen, 2005. 67 Suppl 1: p. S19-25. 
97. Wolfenstetter, S.B., et al., Body weight changes and outpatient medical care 
utilisation: Results of the MONICA/KORA cohorts S3/F3 and S4/F4. Psychosoc Med, 
2012. 9: p. Doc09. 
98. Scheidt-Nave, C., et al., German health interview and examination survey for adults 
(DEGS) - design, objectives and implementation of the first data collection wave. 
BMC Public Health, 2012. 12: p. 730. 
99. World Medical Association Declaration of Helsinki: ethical principles for medical 
research involving human subjects. JAMA, 2000. 284(23): p. 3043-5. 
100. Spencer, E.A., et al., Validity of self-reported height and weight in 4808 EPIC-Oxford 
participants. Public Health Nutr, 2002. 5(4): p. 561-5. 
101. Spencer, E.A., A.W. Roddam, and T.J. Key, Accuracy of self-reported waist and hip 
measurements in 4492 EPIC-Oxford participants. Public Health Nutr, 2004. 7(6): p. 
723-7. 
102. Kamtsiuris, P., et al., [The first wave of the German Health Interview and Examination 
Survey for Adults (DEGS1): sample design, response, weighting and 
representativeness]. Bundesgesundheitsblatt Gesundheitsforschung 
Gesundheitsschutz, 2013. 56(5-6): p. 620-30. 
103. Bergmann, M.M., U. Bussas, and H. Boeing, Follow-up procedures in EPIC-
Germany--data quality aspects. European Prospective Investigation into Cancer and 
Nutrition. Ann Nutr Metab, 1999. 43(4): p. 225-34. 
104. Li, L., et al., On weighting approaches for missing data. Stat Methods Med Res, 2013. 
22(1): p. 14-30. 
105. Illig, T., et al., A genome-wide perspective of genetic variation in human metabolism. 
Nat Genet, 2010. 42(2): p. 137-41. 
106. Schmerler, D., et al., Targeted metabolomics for discrimination of systemic 
inflammatory disorders in critically ill patients. J Lipid Res, 2012. 53(7): p. 1369-75. 
107. Floegel, A., Serum metabolites and their association with risk of type 2 diabetes and 
cardiovascular diseases: a targeted metabolomics approach in EPIC-Potsdam. 2013, 
Technische Universität Berlin. 
108. Floegel, A., et al., Reliability of serum metabolite concentrations over a 4-month 
period using a targeted metabolomic approach. PLoS One, 2011. 6(6): p. e21103. 
109. Rosner, B., The Intraclass Correlation Coefficient, in Fundamentals of Biostatistics. 
2011, Brooks/Cole: Bosten, MA USA. p. 568-571. 
110. Rosner, B., The False-Discovery Rate, in Fundamentals of Biostatistics. 2011, 
Brooks/Cole: Bosten, MA USA. p. 536-538. 
 References 
 108 
 
111. Benjamini, Y. and Y. Hochberg, Controlling the False Discovery Rate - a Practical 
and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society 
Series B-Methodological, 1995. 57(1): p. 289-300. 
112. Borenstein, M., et al., A basic introduction to fixed-effect and random-effects models 
for meta-analysis. Res Synth Methods, 2010. 1(2): p. 97-111. 
113. Borenstein, M., et al., Fixed-Effect Model, in Introduction to Meta-Analysis. 2009, 
John Wiley & Sons, Ltd. p. 63-67. 
114. Borenstein, M., et al., Random-Effects Model, in Introduction to Meta-Analysis. 2009, 
John Wiley & Sons, Ltd. p. 69-75. 
115. Borenstein, M., et al., Fixed-Effect Versus Random-Effects Models, in Introduction to 
Meta-Analysis. 2009, John Wiley & Sons, Ltd. p. 77-86. 
116. R Core Team, R: A Language and Environment for Statistical Computing. 2015, R 
Foundation for Statistical Computing: http://www.R-project.org. 
117. Schwarzer, G., General Package for Meta-Analysis. 2015, CRAN: http://cran.r-
project.org/web/packages/meta/index.html. 
118. Pearson, K., On lines and planes of closest fit to systems of points in space. 
Philosophical Magazine, 1901. 2: p. 559-572. 
119. Powers, B.W.a.R., Multivariate Analysis in Metabolomics. Current Metabolomics, 
2013. 1(1): p. 92-107. 
120. Bortz, J. and C. Schuster, Faktorenanalyse, in Statistik für Human- und 
Sozialwissenschaftler. 2010, Springer. 
121. Mousavi, S., et al., Changes in body mass index, waist and hip circumferences, 
waist-to-hip ratio and risk of all-cause mortality in men. Eur J Clin Nutr, 2015. 69: p. 
927-932. 
122. Koskova, I., et al., Weight, body composition and fat distribution changes of Czech 
women in the different reproductive phases: a longitudinal study. Prague Med Rep, 
2007. 108(3): p. 226-42. 
123. Ebrahimi-Mameghani, M., et al., Changes in weight and waist circumference over 9 
years in a Scottish population. Eur J Clin Nutr, 2008. 62(10): p. 1208-14. 
124. Borenstein, M., et al., Identifying and Quantifying Heterogeneity, in Introduction to 
Meta-Analysis. 2009, John Wiley & Sons, Ltd. p. 107-125. 
125. Higgins, J.P., et al., Measuring inconsistency in meta-analyses. BMJ, 2003. 
327(7414): p. 557-60. 
126. Palmer, B.F. and D.J. Clegg, The sexual dimorphism of obesity. Mol Cell Endocrinol, 
2015. 402C: p. 113-119. 
127. Vazquez, L.A., et al., Effects of changes in body weight and insulin resistance on 
inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin 
Endocrinol Metab, 2005. 90(1): p. 316-22. 
128. Lakhani, M. and S. Fein, Effects of obesity and subsequent weight reduction on left 
ventricular function. Cardiol Rev, 2011. 19(1): p. 1-4. 
129. Karason, K., et al., Effects of obesity and weight loss on left ventricular mass and 
relative wall thickness: survey and intervention study. BMJ, 1997. 315(7113): p. 912-
6. 
130. Blouin, K., A. Boivin, and A. Tchernof, Androgens and body fat distribution. J Steroid 
Biochem Mol Biol, 2008. 108(3-5): p. 272-80. 
131. Quehenberger, O. and E.A. Dennis, The human plasma lipidome. N Engl J Med, 
2011. 365(19): p. 1812-23. 
132. Cole, L.K., J.E. Vance, and D.E. Vance, Phosphatidylcholine biosynthesis and 
lipoprotein metabolism. Biochim Biophys Acta, 2012. 1821(5): p. 754-61. 
133. Mayes, J.S. and G.H. Watson, Direct effects of sex steroid hormones on adipose 
tissues and obesity. Obes Rev, 2004. 5(4): p. 197-216. 
134. Young, D.L., Estradiol- and testosterone-induced alterations in phosphatidylcholine 
and triglyceride synthesis in hepatic endoplasmic reticulum. J Lipid Res, 1971. 12(5): 
p. 590-5. 
 References 
 109 
 
135. Fischer, L.M., et al., Dietary choline requirements of women: effects of estrogen and 
genetic variation. Am J Clin Nutr, 2010. 92(5): p. 1113-9. 
136. Barber, M.N., et al., Plasma lysophosphatidylcholine levels are reduced in obesity 
and type 2 diabetes. PLoS One, 2012. 7(7): p. e41456. 
137. Tanaka, T., et al., Plasma amino acid profile is altered by visceral fat accumulation 
and is a predictor of visceral obesity in humans. 2011. 
138. Janghorbani, M., F. Momeni, and M. Dehghani, Hip circumference, height and risk of 
type 2 diabetes: systematic review and meta-analysis. Obes Rev, 2012. 13(12): p. 
1172-81. 
139. Neamat-Allah, J., et al., Validation of anthropometric indices of adiposity against 
whole-body magnetic resonance imaging--a study within the German European 
Prospective Investigation into Cancer and Nutrition (EPIC) cohorts. PLoS One, 2014. 
9(3): p. e91586. 
140. Cheung, B.M. and C. Li, Diabetes and hypertension: is there a common metabolic 
pathway? Curr Atheroscler Rep, 2012. 14(2): p. 160-6. 
141. Pietilainen, K.H., et al., Acquired obesity is associated with changes in the serum 
lipidomic profile independent of genetic effects--a monozygotic twin study. PLoS One, 
2007. 2(2): p. e218. 
142. Mayer-Davis, E.J., et al., Insulin secretion, obesity, and potential behavioral 
influences: results from the Insulin Resistance Atherosclerosis Study (IRAS). 
Diabetes Metab Res Rev, 2001. 17(2): p. 137-45. 
143. Wedick, N.M., et al., Insulin resistance precedes weight loss in adults without 
diabetes : the Rancho Bernardo Study. Am J Epidemiol, 2001. 153(12): p. 1199-205. 
144. Tijburg, L.B., M.J. Geelen, and L.M. van Golde, Regulation of the biosynthesis of 
triacylglycerol, phosphatidylcholine and phosphatidylethanolamine in the liver. 
Biochim Biophys Acta, 1989. 1004(1): p. 1-19. 
145. Wallner, S. and G. Schmitz, Plasmalogens the neglected regulatory and scavenging 
lipid species. Chem Phys Lipids, 2011. 164(6): p. 573-89. 
146. Graessler, J., et al., Top-down lipidomics reveals ether lipid deficiency in blood 
plasma of hypertensive patients. PLoS One, 2009. 4(7): p. e6261. 
147. Fried, S.K., et al., Lipolysis in intraabdominal adipose tissues of obese women and 
men. Obes Res, 1993. 1(6): p. 443-8. 
148. Scafoglieri, A., et al., Use of anthropometry for the prediction of regional body tissue 
distribution in adults: benefits and limitations in clinical practice. Aging Dis, 2014. 5(6): 
p. 373-93. 
149. Kay, S.J. and M.A. Fiatarone Singh, The influence of physical activity on abdominal 
fat: a systematic review of the literature. Obes Rev, 2006. 7(2): p. 183-200. 
150. Newby, P.K., et al., Long-term stability of food patterns identified by use of factor 
analysis among Swedish women. J Nutr, 2006. 136(3): p. 626-33. 
151. Royston, P., D.G. Altman, and W. Sauerbrei, Dichotomizing continuous predictors in 
multiple regression: a bad idea. Stat Med, 2006. 25(1): p. 127-41. 
152. Hankinson, S.E., et al., Laboratory reproducibility of endogenous hormone levels in 
postmenopausal women. Cancer Epidemiol Biomarkers Prev, 1994. 3(1): p. 51-6. 
 
 
  
 Appendix 
 110 
 
Appendix 
 
Appendix 1 Impact of weighting for drop-out on average annual weight-hip-difference* in 
EPIC-Potsdam and DEGS 
* (cm/yr) 
 not weighted for drop-out  weighted for drop-out 
 waist-hip 
difference 
(95% CI) 
cut-offs  
waist-hip difference 
(95% CI) 
cut-offs 
 p10 p90  p10 p90 
EPIC-
Potsdam 
       
men 
0.729 
(0.682-0.776) 
0.012 1.478  
0.730 
(0.683-0.777) 
0.012 1.478 
women 
0.598 
(0.561-0.635) 
-0.057 1.243  
0.597 
(0.560-0.634) 
-0.057 1.243 
DEGS        
men 
0.618 
(0.586-0.650) 
0.088 1.200  
0.635 
(0.603-0 668) 
0.088 1.200 
women 
0.466 
(0.430-0.502) 
-0.213 1.120  
0.449 
(0.413-0.486) 
-0.213 1.120 
  
  
       
Appendix 2 Pearson correlations among quality-controlled diacyl- and acyl-alkyl PCs for men and  women in EPIC-Potsdam (PCs are ordered 
by type of bond and length of side chains as shown in Table 6 and Table 9) 
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Appendix 3 Results of sensitivity analyses in women for metabolites showing significant 
associations with WG phenotype in women 
Metabolite Study 
Overall 
population 
“Healthy” 
population 
Non-
menopausal 
population 
Fasting 
population 
  
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
Tryptophan 
EPIC-
Potsdam 
0.67 
(0.52-0.85) 
0.70 
(0.54-0.90) 
0.70 
(0.54-0.90) 
1.14 
(0.61-2.12) 
 KORA 
0.88 
(0.56-1.36) 
1.00 
(0.63-1.59) 
- - 
PC aa C32:3 
EPIC-
Potsdam 
0.69 
(0.54-0.88) 
0.77 
(0.60-1.00) 
0.77 
(0.60-1.00) 
0.46 
(0.24-0.89) 
 KORA 
0.69 
(0.43-1.11) 
0.73 
(0.44-1.23) 
- - 
PC aa C36:0 
EPIC-
Potsdam 
0.69 
(0.54-0.89) 
0.80 
(0.62-1.04) 
0.80 
(0.62-1.04) 
0.67 
(0.35-1.29) 
 KORA 
0.74 
(0.47-1.16) 
0.78 
(0.49-1.24) 
- - 
PC aa C38:0 
EPIC-
Potsdam 
0.67 
(0.52-0.86) 
0.71 
(0.55-0.94) 
0.71 
(0.55-0.94) 
0.66 
(0.35-1.25) 
 KORA 
0.78 
(0.50-1.22) 
0.88 
(0.55-1.40) 
- - 
PC aa C38:1 
EPIC-
Potsdam 
0.73 
(0.56-0.95) 
0.69 
(0.52-0.91) 
0.69 
(0.52-0.91) 
0.79 
(0.42-1.47) 
 KORA 
0.59 
(0.37-0.95) 
0.57 
(0.35-0.95) 
-  
PC aa C42:2 
EPIC-
Potsdam 
0.64 
(0.49-0.85) 
0.67 
(0.50-0.89) 
0.67 
(0.50-0.89) 
0.65 
(0.33-1.28) 
 KORA 
0.97 
(0.61-1.54) 
1.12 
(0.70-1.80) 
- - 
PC aa C42:5 
EPIC-
Potsdam 
0.75 
(0.58-0.99) 
0.82 
(0.62-1.08) 
0.82 
(0.62-1.08) 
0.64 
(0.31-1.34) 
 KORA 
0.62 
(0.38-0.99) 
0.54 
(0.32-0.91) 
- - 
PC ae C32:2 
EPIC-
Potsdam 
0.72 
(0.57-0.92) 
0.80 
(0.62-1.03) 
0.80 
(0.62-1.03) 
0.62 
(0.34-1.15) 
 KORA 
0.74 
(0.48-1.15) 
0.79 
(0.49-1.25) 
- - 
PC ae C34:0 
EPIC-
Potsdam 
0.73 
(0.57-0.94) 
0.83 
(0.65-1.08) 
0.83 
(0.65-1.08) 
0.75 
(0.41-1.38) 
 KORA 
0.70 
(0.45-1.10) 
0.71 
(0.43-1.18) 
- - 
      
PC ae C36:0 
EPIC-
Potsdam 
0.71 
(0.55-0.91) 
0.69 
(0.53-0.91) 
0.69 
(0.53-0.91) 
0.65 
(0.30-1.44) 
 
KORA 
0.79 
(0.48-1.29) 
0.8 
(0.47-1.36) 
 
 
 
- - 
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Metabolite Study 
Overall 
population 
“Healthy” 
population 
Non-
menopausal 
population 
Fasting 
population 
  
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
PC ae C36:1 
EPIC-
Potsdam 
0.80 
(0.63-1.03) 
0.89 
(0.69-1.15) 
0.89 
(0.69-1.15) 
0.84 
(0.44-1.60) 
 KORA 
0.52 
(0.32-0.84) 
0.49 
(0.29-0.85) 
- - 
PC ae C36:2 
EPIC-
Potsdam 
0.77 
(0.60-0.99) 
0.88 
(0.68-1.15) 
0.88 
(0.68-1.15) 
0.59 
(0.31-1.10) 
 KORA 
0.49 
(0.30-0.82) 
0.51 
(0.30-0.88) 
- - 
PC ae C38:0 
EPIC-
Potsdam 
0.69 
(0.54-0.90) 
0.78 
(0.59-1.02) 
0.78 
(0.59-1.02) 
0.68 
(0.34-1.37) 
 KORA 
0.64 
(0.40-1.02) 
0.64 
(0.39-1.05) 
- - 
PC ae C38:2 
EPIC-
Potsdam 
0.77 
(0.61-0.99) 
0.81 
(0.63-1.05) 
0.81 
(0.63-1.05) 
0.57 
(0.30-1.11) 
 KORA 
0.67 
(0.43-1.05) 
0.67 
(0.41-1.08) 
- - 
PC ae C40:1 
EPIC-
Potsdam 
0.71 
(0.55-0.90) 
0.76 
(0.59-0.99) 
0.76 
(0.59-0.99) 
0.69 
(0.36-1.33) 
 KORA 
0.67 
(0.42-1.05) 
0.72 
(0.45-1.17) 
-  
PC ae C40:2 
EPIC-
Potsdam 
0.78 
(0.60-1.00) 
0.89 
(0.68-1.15) 
0.89 
(0.68-1.15) 
0.99 
(0.53-1.85) 
 KORA 
0.81 
(0.51-1.28) 
0.6 
(0.36-1.00) 
- - 
PC ae C40:5 
EPIC-
Potsdam 
0.71 
(0.55-0.91) 
0.77 
(0.59-1.00) 
0.77 
(0.59-1.00) 
0.88 
(0.46-1.69) 
 KORA 
0.59 
(0.37-0.93) 
1.03 
(0.63-1.70) 
- - 
PC ae C40:6 
EPIC-
Potsdam 
0.65 
(0.50-0.84) 
0.71 
(0.54-0.94) 
0.71 
(0.54-0.94) 
0.73 
(0.42-1.30) 
 KORA 
0.67 
(0.43-1.05) 
0.75 
(0.48-1.19) 
- - 
PC ae C42:2 
EPIC-
Potsdam 
0.62 
(0.48-0.81) 
0.63 
(0.48-0.83) 
0.63 
(0.48-0.83) 
0.69 
(0.38-1.26) 
 KORA 
0.82 
(0.55-1.22) 
0.9 
(0.59-1.38) 
- - 
PC ae C42:3 
EPIC-
Potsdam 
0.67 
(0.52-0.86) 
0.64 
(0.49-0.84) 
0.64 
(0.49-0.84) 
0.66 
(0.37-1.18) 
 KORA 
0.67 
(0.41-1.07) 
0.73 
(0.44-1.19) 
- - 
lysoPC a 
C17:0 
EPIC-
Potsdam 
0.70 
(0.54-0.90) 
0.72 
(0.55-0.94) 
0.72 
(0.55-0.94) 
0.80 
(0.39-1.62) 
 KORA 
0.82 
(0.53-1.27) 
0.85 
(0.54-1.35) 
- - 
Abbreviations: PC, phosphatidylcholine; a, acyl;  e, alkyl 
  
 
 
Appendix 4 Results of subgroup analyses in women for metabolites showing significant associations with WG phenotype in women 
Metabolite Study 
Overall 
study 
population 
High 
physical 
activity 
≥1h/week 
Low  
physical 
activity 
<1h/week 
Abdominal 
obesity 
(WC ≥ 88m) 
No 
abdominal 
obesity 
(WC 
<88cm) 
Age  
≤ 55 years 
Age  
> 55 years 
Low  
alcohol 
consumption 
(<10g/d) 
High  
alcohol 
consumption 
(≥10g/d) 
  
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
Tryptophan 
EPIC-
Potsdam 
0.67 
(0.52-0.85) 
0.69 
(0.48-0.99) 
0.71 
(0.51-0.99) 
1.22 
(0.56-2.67) 
0.67 
(0.52-0.86) 
0.74 
(0.56-0.98) 
0.61 
(0.35-1.05) 
0.67 
(0.51-0.88) 
0.74 
(0.42-1.31) 
 KORA 
0.88 
(0.56-1.36) 
1.03 
(0.53-2.01) 
0.78 
(0.43-1.43) 
0.62 
(0.30-1.32) 
1.12 
(0.63-1.99) 
- - 
0.72 
(0.43-1.20) 
3.7 
(0.76-18.09) 
PC aa 
C32:3 
EPIC-
Potsdam 
0.69 
(0.54-0.88) 
0.89 
(0.63-1.27) 
0.61 
(0.44-0.86) 
0.80 
(0.35-1.85) 
0.72 
(0.56-0.93) 
0.72 
(0.53-0.96) 
0.78 
(0.47-1.28) 
0.73 
(0.56-0.95) 
0.69 
(0.35-1.34) 
 KORA 
0.69 
(0.43-1.11) 
0.81 
(0.46-1.43) 
0.38 
(0.17-0.89) 
0.99 
(0.50-1.95) 
0.23 
(0.08-0.62) 
- - 
0.49 
(0.27-0.91) 
0.66 
(0.28-1.56) 
PC aa 
C36:0 
EPIC-
Potsdam 
0.69 
(0.54-0.89) 
0.80 
(0.56-1.16) 
0.65 
(0.47-0.92) 
0.27 
(0.08-0.98) 
0.77 
(0.60-1.00) 
0.74 
(0.54-1.00) 
0.68 
(0.43-1.08) 
0.70 
(0.53-0.92) 
0.87 
(0.50-1.53) 
 KORA 
0.74 
(0.47-1.16) 
0.82 
(0.42-1.63) 
0.63 
(0.33-1.21) 
0.71 
(0.30-1.71) 
0.8 
(0.47-1.36) 
- - 
0.55 
(0.31-0.98) 
3.19 
(0.85-12.03) 
PC aa 
C38:0 
EPIC-
Potsdam 
0.67 
(0.52-0.86) 
0.69 
(0.47-1.00) 
0.69 
(0.49-0.95) 
0.27 
(0.08-0.93) 
0.72 
(0.56-0.93) 
0.67 
(0.49-0.91) 
0.72 
(0.47-1.10) 
0.66 
(0.50-0.86) 
0.87 
(0.49-1.55) 
 KORA 
0.78 
(0.50-1.22) 
0.8 
(0.40-1.58) 
0.72 
(0.38-1.37) 
0.76 
(0.32-1.79) 
0.86 
(0.50-1.46) 
- - 
0.71 
(0.42-1.2) 
2.47 
(0.57-10.76) 
PC aa 
C38:1 
EPIC-
Potsdam 
0.73 
(0.56-0.95) 
0.63 
(0.42-0.94) 
0.68 
(0.48-0.98) 
0.62 
(0.22-1.70) 
0.68 
(0.52-0.90) 
0.62 
(0.44-0.87) 
0.77 
(0.50-1.20) 
0.64 
(0.48-0.86) 
0.87 
(0.51-1.49) 
 
KORA 
0.59 
(0.37-0.95) 
0.85 
(0.42-1.70) 
0.36 
(0.17-0.75) 
0.53 
(0.22-1.25) 
0.62 
(0.35-1.12) 
- - 0.42 
(0.23-0.76) 
2.4 
(0.84-6.87) 
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Metabolite Study 
Overall 
study 
population 
High 
physical 
activity 
≥1h/week 
Low  
physical 
activity 
<1h/week 
Abdominal 
obesity 
(WC ≥ 88m) 
No 
abdominal 
obesity 
(WC 
<88cm) 
Age  
≤ 55 years 
Age  
> 55 years 
Low  
alcohol 
consumption 
(<10g/d) 
High  
alcohol 
consumption 
(≥10g/d) 
  
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
PC aa 
C42:2 
EPIC-
Potsdam 
0.64 
(0.49-0.85) 
0.64 
(0.43-0.96) 
0.58 
(0.39-0.85) 
0.33 
(0.10-1.12) 
0.66 
(0.50-0.87) 
0.57 
(0.40-0.81) 
0.74 
(0.48-1.15) 
0.57 
(0.42-0.78) 
0.91 
(0.51-1.62) 
 
KORA 
0.97  
(0.61-1.54) 
1.3 
(0.68-2.47) 
0.66 
(0.32-1.35) 
1.26 
(0.57-2.82) 
0.84 
(0.47-1.51) 
- - 
0.79 
(0.45-1.39) 
3.01 
(0.86-10.51) 
PC aa 
C42:5 
EPIC-
Potsdam 
0.75 
(0.58-0.99) 
0.81 
(0.56-1.18) 
0.66 
(0.45-0.96) 
0.49 
(0.13-1.83) 
0.76 
(0.58-0.99) 
0.77 
(0.55-1.06) 
0.69 
(0.43-1.09) 
0.71 
(0.53-0.96) 
0.88 
(0.47-1.64) 
 KORA 
0.62 
(0.38-0.99) 
0.49 
(0.21-1.12) 
0.64 
(0.35-1.18) 
0.54 
(0.21-1.37) 
0.6 
(0.33-1.10) - - 
0.57 
(0.32-1.00) 
0.5 
(0.15-1.66) 
PC ae 
C32:2 
EPIC-
Potsdam 
0.72 
(0.57-0.92) 
0.69 
(0.47-1.00) 
0.82 
(0.60-1.10) 
0.82 
(0.28-2.37) 
0.76 
(0.59-0.97) 
0.72 
(0.54-0.97) 
0.93 
(0.60-1.43) 
0.69 
(0.53-0.90) 
1.17 
(0.73-1.89) 
 KORA 
0.74 
(0.48-1.15) 
0.69 
(0.33-1.45) 
0.7 
(0.40-1.23) 
0.95 
(0.45-2.00) 
0.62 
(0.35-1.11) - - 
0.67 
(0.40-1.13) 
1.2 
(0.46-3.12) 
PC ae 
C34:0 
EPIC-
Potsdam 
0.73 
(0.57-0.94) 
0.67 
(0.48-0.95) 
0.83 
(0.33-2.11) 
0.78 
(0.61-1.01) 
0.76 
(0.56-1.03) 
0.87 
(0.55-1.38) 
0.87 
(0.55-1.38) 
0.79 
(0.61-1.02) 
0.76 
(0.39-1.48) 
 KORA 
0.70 
(0.45-1.10) 
0.75 
(0.34-1.66) 
0.7 
(0.40-1.21) 
1.07 
(0.53-2.15) 
0.5 
(0.26-0.96) - - 
0.65 
(0.39-1.09) 
1.12 
(0.40-3.13) 
PC ae 
C36:0 
EPIC-
Potsdam 
0.71 
(0.55-0.91) 
0.75 
(0.53-1.05) 
0.69 
(0.48-0.98) 
0.06 
(0.01-0.56) 
0.78 
(0.61-1.01) 
0.74 
(0.54-1.00) 
0.72 
(0.46-1.14) 
0.64 
(0.48-0.86) 
1.10 
(0.65-1.88) 
 KORA 
0.79 
(0.48-1.29) 
0.83 
(0.40-1.74) 
0.7 
(0.35-1.42) 
1.18 
(0.55-2.53) 
0.59 
(0.28-1.22) - - 
0.73 
(0.42-1.27) 
1.48 
(0.35-6.19) 
PC ae 
C36:1 
EPIC-
Potsdam 
0.80 
(0.63-1.03) 
1.08 
(0.74-1.57) 
0.66 
(0.47-0.92) 
1.73 
(0.66-4.58) 
0.77 
(0.60-0.99) 
0.71 
(0.52-0.97) 
1.08 
(0.68-1.71) 
0.82 
(0.63-1.06) 
0.83 
(0.44-1.57) 
 KORA 
0.52 
(0.32-0.84) 
0.54 
(0.24-1.20) 
0.52 
(0.28-0.98) 
0.84 
(0.36-1.99) 
0.37 
(0.18-0.76) 
- - 
0.55 
(0.32-0.95) 
0.65 
(0.15-2.81) 
PC ae 
C36:2 
EPIC-
Potsdam 
0.77 
(0.60-0.99) 
0.88 
(0.60-1.30) 
0.73 
(0.52-1.02) 
2.37 
(0.73-7.74) 
0.78 
(0.60-1.01) 
0.74 
(0.54-1.01) 
1.07 
(0.66-1.71) 
0.79 
(0.60-1.04) 
0.83 
(0.44-1.58) 
 KORA 0.49 0.62 0.42 1.03 0.31 - - 0.53 0.78 
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Metabolite Study 
Overall 
study 
population 
High 
physical 
activity 
≥1h/week 
Low  
physical 
activity 
<1h/week 
Abdominal 
obesity 
(WC ≥ 88m) 
No 
abdominal 
obesity 
(WC 
<88cm) 
Age  
≤ 55 years 
Age  
> 55 years 
Low  
alcohol 
consumption 
(<10g/d) 
High  
alcohol 
consumption 
(≥10g/d) 
  
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
(0.30-0.82) (0.28-1.35) (0.21-0.84) (0.41-2.59) (0.15-0.65) (0.30-0.93) (0.21-2.93) 
PC ae 
C38:0 
EPIC-
Potsdam 
0.69 
(0.54-0.90) 
0.85 
(0.60-1.21) 
0.56 
(0.38-0.82) 
0.49 
(0.16-1.46) 
0.73 
(0.57-0.95) 
0.73 
(0.53-1.00) 
0.71 
(0.46-1.10) 
0.73 
(0.56-0.96) 
0.72 
(0.38-1.38) 
 KORA 
0.64 
(0.40-1.02) 
0.82 
(0.43-1.58) 
0.49 
(0.24-1.00) 
0.55 
(0.24-1.29) 
0.69 
(0.39-1.22) 
- - 
0.45 
(0.25-0.81) 
1.67 
(0.57-4.88) 
PC ae 
C38:2 
EPIC-
Potsdam 
0.77 
(0.61-0.99) 
0.89 
(0.63-1.25) 
0.68 
(0.48-0.97) 
1.44 
(0.49-4.22) 
0.79 
(0.62-1.01) 
0.73 
(0.54-0.98) 
1.08 
(0.69-1.67) 
0.74 
(0.57-0.97) 
1.08 
(0.61-1.90) 
 KORA 
0.67 
(0.43-1.05) 
0.75 
(0.38-1.49) 
0.59 
(0.32-1.09) 
1.63 
(0.74-3.60) 
0.4 
(0.21-0.78) 
- - 
0.69 
(0.42-1.12) 
1.87 
(0.54-6.46) 
PC ae 
C40:1 
EPIC-
Potsdam 
0.71 
(0.55-0.90) 
0.85 
(0.60-1.20) 
0.62 
(0.43-0.88) 
0.60 
(0.21-1.71) 
0.75 
(0.59-0.97) 
0.70 
(0.52-0.95) 
0.85 
(0.54-1.34) 
0.73 
(0.56-0.95) 
0.85 
(0.48-1.52) 
 
KORA 
0.67 
(0.42-1.05) 
0.84 
(0.42-1.66) 
0.54 
(0.28-1.07) 
0.52 
(0.23-1.22) 
0.76 
(0.44-1.31) 
- - 0.5 
(0.29-0.88) 
2.34 
(0.72-7.65) 
PC ae 
C40:2 
EPIC-
Potsdam 
0.78 
 (0.60-1.0) 
0.88 
(0.59-1.30) 
0.80 
(0.57-1.12) 
1.23 
(0.59-2.58) 
0.77 
(0.59-1.01) 
0.86 
(0.63-1.16) 
0.82 
(0.51-1.31) 
0.81 
(0.62-1.06) 
0.94 
(0.52-1.69) 
 KORA 
0.81 
(0.51-1.28) 
0.72 
(0.34-1.52) 
0.53 
(0.30-0.97) 
0.97 
(0.42-2.25) 
0.47 
(0.26-0.87) - - 
0.68 
(0.41-1.13) 
0.5 
(0.11-2.13) 
PC ae 
C40:5 
EPIC-
Potsdam 
0.71 
(0.55-0.91) 
0.85 
(0.57-1.27) 
0.67 
(0.48-0.93) 
0.61 
(0.18-2.03) 
0.72 
(0.56-0.94) 
0.70 
(0.52-0.95) 
0.87 
(0.54-1.43) 
0.68 
(0.52-0.90) 
0.87 
(0.47-1.60) 
 KORA 
0.59 
(0.37-0.93) 
1.11 
(0.54-2.30) 
0.68 
(0.37-1.25) 
0.82 
(0.35-1.95) 
0.8 
(0.45-1.42) - - 
0.83 
(0.49-1.40) 
1.49 
(0.40-5.55) 
PC ae 
C40:6 
EPIC-
Potsdam 
0.65 
(0.50-0.84) 
0.72 
(0.48-1.07) 
0.63 
(0.44-0.89) 
0.60 
(0.24-1.49) 
0.67 
(0.51-0.88) 
0.67 
(0.49-0.93) 
0.68 
(0.43-1.07) 
0.68 
(0.51-0.89) 
0.68 
(0.36-1.29) 
 
KORA 
0.67 
(0.43-1.05) 
0.81 
(0.42-1.58) 
0.58 
(0.31-1.10) 
0.56 
(0.22-1.44) 
0.74 
(0.44-1.25) 
- - 0.63 
(0.38-1.06) 
1.4 
(0.43-4.56) 
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Metabolite Study 
Overall 
study 
population 
High 
physical 
activity 
≥1h/week 
Low  
physical 
activity 
<1h/week 
Abdominal 
obesity 
(WC ≥ 88m) 
No 
abdominal 
obesity 
(WC 
<88cm) 
Age  
≤ 55 years 
Age  
> 55 years 
Low  
alcohol 
consumption 
(<10g/d) 
High  
alcohol 
consumption 
(≥10g/d) 
  
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
PC ae 
C42:2 
EPIC-
Potsdam 
0.62 
(0.48-0.81) 
0.68 
(0.46-1.00) 
0.55 
(0.38-0.79) 
0.40 
(0.13-1.26) 
0.62 
(0.47-0.81) 
0.56 
(0.41-0.77) 
0.72 
(0.44-1.17) 
0.61 
(0.46-0.82) 
0.53 
(0.27-1.05) 
 KORA 
0.82 
(0.55-1.22) 
1.01 
(0.52-1.96) 
0.72 
(0.42-1.23) 
1.01 
(0.55-1.86) 
0.69 
(0.40-1.18) - - 
0.75 
(0.47-1.20) 
2.5 
(0.58-10.69) 
PC ae 
C42:3 
EPIC-
Potsdam 
0.67 
(0.52-0.86) 
0.71 
(0.49-1.03) 
0.57 
(0.39-0.81) 
0.55 
(0.17-1.77) 
0.64 
(0.49-0.83) 
0.61 
(0.45-0.82) 
0.78 
(0.48-1.27) 
0.63 
(0.48-0.83) 
0.60 
(0.32-1.14) 
 
KORA 
0.67 
(0.41-1.07) 
0.81 
(0.40-1.66) 
0.56 
(0.29-1.10) 
0.83 
(0.36-1.94) 
0.57 
(0.30-1.11) 
- - 0.55 
(0.31-0.98) 
3.77 
(0.70-20.29) 
lysoPC a 
C17:0 
EPIC-
Potsdam 
0.70 
(0.54-0.90) 
0.74 
(0.49-1.13) 
0.70 
(0.50-0.97) 
2.19 
(0.93-5.13) 
0.64 
(0.49-0.84) 
0.60 
(0.44-0.82) 
1.08 
(0.66-1.77) 
0.74 
(0.56-0.98) 
0.58 
(0.32-1.07) 
 KORA 
0.82 
(0.53-1.27) 
1.55 
(0.89-2.72) 
0.41 
(0.19-0.89) 
0.53 
(0.18-1.61) 
0.91 
(0.56-1.48) - - 
0.86 
(0.53-1.40) 
0.84 
(0.19-3.73) 
Abbreviations: PC, phosphatidylcholine; a, acyl; e, alkyl 
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Appendix 5 Values of I² as an index of present heterogeneity in the fixed-effects meta-
analyses for investigated endpoints in men and women 
 Men Women 
 WG  HG  WG  HG  
 I² I² I² I² 
Amino Acids     
Arginine 57% 0% 0% 26% 
Glutamine 62% 0% 43% 0% 
Glycine 0% 77% 72% 0% 
Histidine 73% 0% 0% 0% 
Methionine 65% 0% 71% 0% 
Ornithine 85% 0% 3% 0% 
Phenylalanine 0% 72% 0% 27% 
Proline 0% 0% 0% 0% 
Serine 69% 0% 77% 40% 
Threonine 0% 0% 77% 61% 
Tryptophan 55% 0% 12% 0% 
Tyrosine 59% 0% 0% 0% 
Valine 61% 59% 25% 17% 
Hexose     
H1 0% 0% 11% 0% 
Acylcarnitines     
C0 0% 0% 0% 0% 
C2 0% 0% 0% 0% 
C3 0% 55% 0% 0% 
C5-OH (C3-DC-M) 0% 0% 0% 0% 
C7-DC 0% 0% 3% 70% 
C9 0% 0% 0% 0% 
C10 0% 0% 0% 0% 
C10:2 0% 8% 0% 42% 
C14:1 0% 0% 0% 0% 
C14:2 0% 34% 0% 0% 
C16 86% 0% 0% 0% 
C18 10% 52% 0% 0% 
C18:1 64% 0% 0% 0% 
C18:2 63% 3% 0% 24% 
Diacyl-Phosphatidylcholines     
PC aa C28:1 0% 75% 87% 0% 
PC aa C30:0 0% 68% 0% 0% 
PC aa C32:0 54% 0% 0% 45% 
PC aa C32:1 71% 0% 0% 0% 
PC aa C32:2 0% 60% 56% 0% 
PC aa C32:3 81% 0% 0% 44% 
PC aa C34:1 79% 0% 0% 0% 
PC aa C34:2 75% 0% 40% 0% 
Table continued on the next page 
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 Men Women 
 WG  HG  WG  HG  
 I² I² I² I² 
PC aa C34:3 84% 0% 0% 0% 
PC aa C34:4 30% 59% 64% 9% 
PC aa C36:0 63% 0% 0% 82% 
PC aa C36:1 0% 0% 0% 0% 
PC aa C36:2 7% 0% 12% 0% 
PC aa C36:3 59% 0% 75% 0% 
PC aa C36:4 52% 0% 70% 0% 
PC aa C36:5 0% 40% 0% 38% 
PC aa C36:6 37% 63% 0% 0% 
PC aa C38:0 65% 0% 0% 84% 
PC aa C38:1 64% 0% 0% 0% 
PC aa C38:3 0% 0% 87% 0% 
PC aa C38:4 0% 0% 72% 0% 
PC aa C38:5 23% 0% 0% 0% 
PC aa C38:6 71% 0% 26% 65% 
PC aa C40:2 0% 0% 0% 0% 
PC aa C40:3 18% 51% 0% 3% 
PC aa C40:4 2% 0% 50% 0% 
PC aa C40:5 52% 0% 22% 0% 
PC aa C40:6 58% 0% 0% 47% 
PC aa C42:0 50% 0% 56% 46% 
PC aa C42:1 79% 21% 44% 23% 
PC aa C42:2 78% 0% 56% 82% 
PC aa C42:4 60% 0% 0% 60% 
PC aa C42:5 61% 0% 0% 0% 
PC aa C42:6 79% 0% 0% 0% 
Acyl-alkyl-Phosphatidylcholines    
PC ae C30:0 20% 71% 0% 0% 
PC ae C30:2 0% 0% 74% 0% 
PC ae C32:1 69% 0% 0% 75% 
PC ae C32:2 42% 0% 0% 85% 
PC ae C34:0 0% 61% 0% 0% 
PC ae C34:1 63% 24% 0% 43% 
PC ae C34:2 0% 28% 36% 89% 
PC ae C34:3 0% 0% 0% 91% 
PC ae C36:0 39% 0% 0% 0% 
PC ae C36:1 36% 65% 59% 0% 
PC ae C36:2 30% 0% 58% 27% 
PC ae C36:3 0% 0% 4% 86% 
PC ae C36:4 0% 0% 0% 3% 
PC ae C36:5 0% 0% 0% 65% 
PC ae C38:0 68% 0% 0% 71% 
PC ae C38:1 0% 0% 0% 0% 
Table continued on the next page 
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 Men Women 
 WG  HG  WG  HG  
 I² I² I² I² 
PC ae C38:2 77% 0% 0% 0% 
PC ae C38:3 2% 64% 84% 0% 
PC ae C38:4 0% 0% 21% 34% 
PC ae C38:5 0% 0% 0% 71% 
PC ae C38:6 0% 0% 0% 80% 
PC ae C40:1 67% 0% 0% 52% 
PC ae C40:2 0% 0% 6% 52% 
PC ae C40:3 32% 36% 21% 62% 
PC ae C40:4 46% 0% 0% 12% 
PC ae C40:5 47% 0% 0% 64% 
PC ae C40:6 77% 0% 0% 84% 
PC ae C42:1 14% 0% 0% 0% 
PC ae C42:2 61% 0% 20% 35% 
PC ae C42:3 63% 0% 0% 81% 
PC ae C42:4 0% 0% 0% 65% 
PC ae C42:5 57% 0% 0% 33% 
PC ae C44:3 82% 65% 0% 0% 
PC ae C44:4 0% 0% 0% 0% 
PC ae C44:5 66% 0% 0% 7% 
PC ae C44:6 77% 0% 41% 62% 
Lyso-Phosphatidylcholines     
lysoPC a C14:0 0% 42% 0% 61% 
lysoPC a C16:0 27% 0% 0% 0% 
lysoPC a C16:1 70% 42% 0% 0% 
lysoPC a C17:0 0% 25% 0% 0% 
lysoPC a C18:0 0% 0% 0% 0% 
lysoPC a C18:1 0% 0% 81% 0% 
lysoPC a C18:2 0% 0% 66% 0% 
lysoPC a C20:3 0% 64% 0% 0% 
lysoPC a C20:4 0% 0% 64% 0% 
lysoPC a C28:1 0% 0% 3% 0% 
Sphingomyelins     
SM C16:0 33% 0% 0% 80% 
SM C16:1 54% 0% 0% 81% 
SM C18:0 0% 0% 79% 46% 
SM C18:1 0% 0% 19% 65% 
SM C20:2 11% 0% 0% 69% 
SM C24:0 0% 56% 22% 0% 
SM C24:1 0% 0% 0% 54% 
SM C26:1 0% 0% 0% 73% 
SM (OH) C14:1 0% 59% 83% 20% 
SM (OH) C16:1 0% 0% 70% 38% 
SM (OH) C22:1 0% 67% 67% 0% 
Table continued on the next page 
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 Men Women 
 WG  HG  WG  HG  
 I² I² I² I² 
SM (OH) C22:2 0% 43% 76% 52% 
SM (OH) C24:1 0% 79% 0% 0% 
Abbreviations: PC, phosphatidylcholine; a, acyl; e, alkyl; SM, sphingomyelin 
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Appendix 6 Rotated Factor Pattern of 5 principal components in men 
Rotated factor pattern men 
  PComp1  PComp2  PComp3  PComp4  PComp5  
Amino Acids      
Arginine 4  9  14  63 * 5  
Glutamine -8  17  15  68 * 4  
Glycine -11  21  5  55  -6  
Histidine 14  9  7  76 * 7  
Methionine 11  2  -11  79 * -7  
Ornithine 1  7  -4  70 * 6  
Phenylalanine 19  4  7  75 * 10  
Proline 11  2  0  51  -16  
Serine -8  26  8  63 * 1  
Threonine 11  15  -5  65 * -16  
Tryptophan 14  13  10  77 * 0  
Tyrosine 20  -7  -4  67 * 1  
Valine 14  -2  3  72 * 3  
xLeucine 13  -4  0  77 * 3  
Hexose      
H1 23  4  1  26  8  
Acylcarnitines      
C0 27  -5  -5  39  35  
C2 24  7  1  -5  57  
C3 14  -8  3  46  16  
C5-DC (C6-OH) 2  4  17  3  63 * 
C5-OH (C3-DC-M) 9  -2  20  10  53  
C7-DC 2  4  8  -10  69 * 
C8:1 -6  11  -11  15  49  
C9 -5  12  31  -4  26  
C10 6  9  11  -9  45  
C10:2 3  5  12  5  54  
C14:1 21  13  25  -7  70 * 
C14:2 0  11  0  -9  76 * 
C16 40  9  13  8  55  
C16:2 4  13  2  -8  65 * 
C18 20  14  27  20  38  
C18:1 28  10  -1  6  63 * 
C18:2 -2  15  -13  19  61 * 
Diacyl-Phosphatidylcholines     
PC aa C28:1 36  18  68 * 2  4  
PC aa C30:0 74 * 6  33  -2  -8  
PC aa C32:0 73 * 27  27  9  8  
PC aa C32:1 82 * -5  -8  -5  4  
PC aa C32:2 75 * 4  12  7  -17  
PC aa C32:3 45  46  32  7  -12  
PC aa C34:1 84 * 10  11  7  13  
PC aa C34:2 52  24  21  35  -11  
PC aa C34:3 78 * 19  7  11  -9  
PC aa C34:4 83 * 13  7  11  -5  
PC aa C36:0 30  69 * 16  10  7  
PC aa C36:1 82 * 12  21  9  12  
PC aa C36:2 54  25  24  37  -6  
PC aa C36:3 75 * 12  22  28  0  
PC aa C36:4 68 * 17  11  27  17  
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Rotated factor pattern men 
  PComp1  PComp2  PComp3  PComp4  PComp5  
PC aa C36:5 53  45  -3  -12  14  
PC aa C36:6 64 * 50  2  -9  4  
PC aa C38:0 13  80 * 19  14  11  
PC aa C38:1 14  57  6  -6  6  
PC aa C38:3 71 * -3  20  19  22  
PC aa C38:4 62 * 11  9  24  29  
PC aa C38:5 76 * 38  6  6  23  
PC aa C38:6 51  55  2  -4  23  
PC aa C40:2 26  71 * -2  1  14  
PC aa C40:3 27  68 * 2  -1  15  
PC aa C40:4 74 * 0  7  18  26  
PC aa C40:5 81 * 12  2  10  27  
PC aa C40:6 55  39  -1  -4  25  
PC aa C42:0 -14  84 * 17  7  9  
PC aa C42:1 0  81 * 12  13  15  
PC aa C42:2 31  74 * 4  0  15  
PC aa C42:4 41  54  15  12  22  
PC aa C42:5 52  49  -6  -2  21  
PC aa C42:6 62 * 48  -1  -6  18  
Acyl-alkyl-Phosphatidylcholines     
PC ae C30:0 32  32  61 * 4  -27  
PC ae C30:1 16  17  34  -7  -6  
PC ae C30:2 21  29  45  1  3  
PC ae C32:1 37  53  43  12  -2  
PC ae C32:2 41  62 * 40  3  -2  
PC ae C34:0 49  34  58  0  -20  
PC ae C34:1 55  32  56  6  -15  
PC ae C34:2 7  43  46  26  -25  
PC ae C34:3 7  50  34  24  -7  
PC ae C36:0 52  54  14  1  12  
PC ae C36:1 47  29  64 * 1  -13  
PC ae C36:2 14  41  60  21  -32  
PC ae C36:3 17  45  40  29  -16  
PC ae C36:4 20  35  29  32  4  
PC ae C36:5 32  52  25  22  15  
PC ae C38:0 56  64 * 6  -1  8  
PC ae C38:1 31  40  41  1  5  
PC ae C38:2 38  52  43  20  -18  
PC ae C38:3 37  30  62 * 17  -16  
PC ae C38:4 18  39  54  34  -1  
PC ae C38:5 21  53  29  30  13  
PC ae C38:6 26  73 * 23  12  13  
PC ae C40:1 52  63 * 12  19  6  
PC ae C40:2 17  45  63 * -6  5  
PC ae C40:3 19  58  59  12  0  
PC ae C40:4 10  56  45  34  1  
PC ae C40:5 16  73 * 37  15  7  
PC ae C40:6 12  77 * 36  7  3  
PC ae C42:1 53  42  10  15  24  
PC ae C42:2 47  65 * 26  2  10  
PC ae C42:3 30  79 * 22  11  7  
PC ae C42:4 -12  57  39  26  4  
 
 Appendix 
 
 
124 
 
Rotated factor pattern men 
  PComp1  PComp2  PComp3  PComp4  PComp5  
PC ae C42:5 -11  70 * 31  22  8  
PC ae C44:3 24  53  20  8  16  
PC ae C44:4 -4  48  33  19  3  
PC ae C44:5 -13  50  28  22  12  
PC ae C44:6 -20  69 * 19  22  11  
Lyso-Phosphatidylcholines     
lysoPC a C14:0 48  -6  20  18  -5  
lysoPC a C16:0 44  16  15  41  16  
lysoPC a C16:1 75 * 1  -7  13  10  
lysoPC a C17:0 3  23  44  21  -19  
lysoPC a C18:0 26  22  16  42  11  
lysoPC a C18:1 44  19  9  29  4  
lysoPC a C18:2 1  22  12  41  -13  
lysoPC a C20:3 49  -3  9  35  3  
lysoPC a C20:4 30  16  5  35  14  
lysoPC a C28:1 22  18  48  4  -6  
Sphingomyelins      
SM (OH) C14:1 0  18  85 * 1  -1  
SM (OH) C16:1 -7  14  89 * 1  7  
SM (OH) C22:1 8  8  84 * 8  20  
SM (OH) C22:2 -1  24  84 * 4  15  
SM (OH) C24:1 0  0  80 * 3  25  
SM C16:0 7  29  75 * 14  32  
SM C16:1 15  26  66 * 13  38  
SM C18:0 6  2  73 * 4  38  
SM C18:1 4  11  68 * 9  34  
SM C20:2 -8  38  15  -3  4  
SM C24:0 20  3  62 * 12  43  
SM C24:1 4  30  53  7  40  
SM C26:0 2  6  69 * -5  29  
SM C26:1 7  22  51  -4  41  
Factor loadings are multiplied by 100 and rounded.  
Values greater 0.6 are marked with '*’ 
Abbreviations: PC, phosphatidylcholine; a, acyl; e, alkyl; SM, sphingomyelin 
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Appendix 7 Rotated Factor Pattern of 4 principal components in women 
Rotated factor pattern women 
  PComp1 
 
PComp2 
 
PComp3 
 
PComp4  
Amino Acids     
Arginine 15  1  14  66 * 
Glutamine 26  -1  11  66 * 
Glycine 23  -16  12  31  
Histidine 18  15  -7  60 * 
Methionine 19  5  -16  75 * 
Ornithine 7  -5  16  68 * 
Phenylalanine 13  14  2  74 * 
Proline 0  3  -2  67 * 
Serine 41  -15  4  55  
Threonine 28  11  -21  51  
Tryptophan 27  16  -6  74 * 
Tyroysine 0  12  3  68 * 
Valine -5  16  -2  70 * 
xLeucine -2  10  -4  72 * 
Hexose     
H1 -4  24  12  27 
 Acylcarnitines    
C0 -6  13  29  43  
C2 8  5  44  -19  
C3 -13  12  23  54 
C5-DC (C6-OH) 1  -2  54  11 
C5-OH (C3-DC-M) -9  3  51  20 
C7-DC -1  -12  61 * -1 
C8:1 -4  -8  32  16 
C9 3  3  45  17 
C10 2  0  48  -6 
C10:2 -6  -8  52  19 
C14:1 8  13  70 * -8 
C14:2 0  -15  64 * -11 
C16 6  26  57  4 
C16:2 -4  -12  56  4 
C18 19  8  45  18 
C18:1 11  5  53  -5 
C18:2 10  -20  50  10 
Diacyl-Phosphatidylcholines     
PC aa C28:1 25  48  50  15  
PC aa C30:0 12  77 * 7  12  
PC aa C32:0 39  75 * 5  6  
PC aa C32:1 -7  80 * -8  6  
PC aa C32:2 6  74 * -11  12  
PC aa C32:3 37  59  15  20  
PC aa C34:1 14  84 * -1  5  
PC aa C34:2 34  60 * -14  15  
PC aa C34:3 19  75 * -10  22  
PC aa C34:4 9  85 * -12  6  
PC aa C36:0 67 * 28  9  0  
PC aa C36:1 13  74 * 21  22  
PC aa C36:2 34  55  10  31  
PC aa C36:3 18  78 * -3  22  
PC aa C36:4 23  72 * -7  -2  
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PC aa C36:5 24  55  7  -10  
PC aa C36:6 29  72 * 2  -2  
PC aa C38:0 76 * 21  15  1  
PC aa C38:1 50  1  10  -3  
PC aa C38:3 -1  73 * 28  16  
PC aa C38:4 20  65 * 22  4  
PC aa C38:5 31  74 * 21  2  
PC aa C38:6 39  55  11  -13  
PC aa C40:2 52  19  10  7  
PC aa C40:3 55  26  14  9  
PC aa C40:4 8  73 * 23  13  
PC aa C40:5 9  68 * 31  10  
PC aa C40:6 23  51  28  -3  
PC aa C42:0 83 * -11  14  5  
PC aa C42:1 81 * -3  14  9  
PC aa C42:2 64 * 19  14  5  
PC aa C42:4 57  41  17  5  
PC aa C42:5 44  48  7  -5  
PC aa C42:6 40  56  17  3  
Acyl-alkyl-Phosphatidylcholines    
PC ae C30:0 45  44  9  17  
PC ae C30:1 26  11  20  3  
PC ae C30:2 36  22  41  15  
PC ae C32:1 71 * 40  5  8  
PC ae C32:2 71 * 39  17  8  
PC ae C34:0 40  65 * 14  9  
PC ae C34:1 46  66 * 9  9  
PC ae C34:2 57  33  -3  14  
PC ae C34:3 68 * 22  -3  9  
PC ae C36:0 53  39  10  8  
PC ae C36:1 34  63 * 26  11  
PC ae C36:2 54  39  10  23  
PC ae C36:3 58  37  -2  18  
PC ae C36:4 52  39  2  3  
PC ae C36:5 63 * 40  9  -3  
PC ae C38:0 52  57  9  5  
PC ae C38:1 36  37  30  9  
PC ae C38:2 57  43  8  28  
PC ae C38:3 37  61 * 20  18  
PC ae C38:4 63 * 42  13  8  
PC ae C38:5 68 * 33  12  3  
PC ae C38:6 69 * 38  15  -4  
PC ae C40:1 62 * 50  7  20  
PC ae C40:2 50  37  43  1  
PC ae C40:3 71 * 28  30  20  
PC ae C40:4 78 * 21  9  17  
PC ae C40:5 82 * 24  22  8  
PC ae C40:6 77 * 27  24  0  
PC ae C42:1 48  44  19  18  
PC ae C42:2 61 * 38  27  18  
PC ae C42:3 78 * 19  14  20  
PC ae C42:4 76 * -4  6  19  
PC ae C42:5 85 * -5  8  10  
PC ae C44:3 57  14  16  20  
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Factor loadings are multiplied by 100 and rounded.  
Values greater 0.6 are marked with '*’ 
Abbreviations: PC, phosphatidylcholine; a, acyl; e, alkyl; SM, sphingomyelin 
 
  
PC ae C44:4 63 * 0  9  16  
PC ae C44:5 73 * -7  8  9  
PC ae C44:6 82 * -13  10  9  
Lyso-Phosphatidylcholines     
lysoPC a C14:0 -11  46  6  37  
lysoPC a C16:0 7  33  19  52  
lysoPC a C16:1 -6  49  10  42  
lysoPC a C17:0 23  12  28  40  
lysoPC a C18:0 15  16  31  48  
lysoPC a C18:1 20  17  10  51  
lysoPC a C18:2 25  -10  -2  54  
lysoPC a C20:3 -7  42  8  45  
lysoPC a C20:4 20  20  10  34  
lysoPC a C28:1 31  22  28  17  
Sphingomyelins     
SM (OH) C14:1 32  22  62 * 11  
SM (OH) C16:1 32  17  69 * 7  
SM (OH) C22:1 21  36  67 * 10  
SM (OH) C22:2 35  26  68 * 6  
SM (OH) C24:1 18  19  71 * 4  
SM C16:0 45  19  67 * 12  
SM C16:1 30  28  69 * 12  
SM C18:0 18  23  73 * -1  
SM C18:1 23  20  69 * 4  
SM C20:2 23  -1  23  12  
SM C24:0 16  37  61 * 7  
SM C24:1 42  14  49  -3  
SM C26:0 21  12  65 * 1  
SM C26:1 28  12  63 * -9  
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Appendix 8 Pearson correlation coefficients for Absolute IDQ p150 metabolites with sex 
hormones estradiol and testosterone stratified by sex in EPIC-Potsdam 
 Men Women 
 Estradiol Testosterone Estradiol Testosterone 
 (n=261) (n=317) (n=438) (n=189) 
 r p r p r p r p 
Amino Acids         
Arginine -0.0002 0.9972 -0.0690 0.2209 0.0015 0.9759 0.0397 0.5879 
Glutamine -0.0705 0.2564 -0.0114 0.8394 0.0636 0.184 0.0478 0.5134 
Glycine 0.0481 0.439 0.0088 0.8757 0.0029 0.9524 -0.0069 0.9249 
Histidine -0.0485 0.4349 -0.0960 0.088 -0.0135 0.7778 0.0966 0.1863 
Methionine -0.0682 0.2721 -0.0664 0.2385 0.0177 0.7119 0.0754 0.3025 
Ornithine -0.0490 0.4306 -0.0540 0.3376 -0.0588 0.2197 0.0031 0.9662 
Phenylalanine -0.0374 0.5478 -0.1527 0.0065 -0.0440 0.3584 0.1094 0.134 
Proline 0.0187 0.7643 -0.1167 0.0379 -0.0011 0.9809 -0.0115 0.875 
Serine -0.0203 0.7437 0.0416 0.46 0.0059 0.9027 0.1121 0.1245 
Threonine -0.0732 0.2383 0.0167 0.7671 0.0663 0.1661 0.1180 0.1058 
Tryptophan -0.1049 0.0907 -0.0624 0.268 0.0045 0.9252 0.0825 0.2593 
Tyrosine -0.0649 0.2963 -0.0991 0.078 -0.0084 0.8606 0.0469 0.522 
Valine -0.0622 0.3172 -0.1628 0.0037 -0.0943 0.0485 -0.0159 0.8279 
xLeucine -0.0661 0.2874 -0.1789 0.0014 -0.0414 0.3872 -0.0297 0.6851 
Hexose         
H1 -0.0455 0.4638 -0.1078 0.0552 -0.0249 0.6033 -0.0546 0.4553 
Acylcarnitines         
C0 0.0605 0.3304 -0.0444 0.4308 -0.0296 0.5371 0.0099 0.8923 
C2 0.0361 0.5621 -0.0130 0.8174 -0.0058 0.9045 0.0130 0.8588 
C3 -0.0773 0.2134 -0.1280 0.0227 -0.0626 0.1912 0.0099 0.8927 
C5-DC (C6-OH) 0.0113 0.8561 0.0235 0.6775 0.0175 0.7149 0.1229 0.092 
C5-OH(C3-DCM) 0.0181 0.7715 -0.0126 0.8226 -0.0251 0.6011 0.0511 0.4854 
C7-DC 0.0251 0.686 0.0467 0.4077 0.0868 0.0697 0.0759 0.2995 
C8:1 0.0177 0.7765 0.0079 0.8892 -0.1090 0.0226 0.0396 0.5883 
C9 0.0942 0.1292 0.0559 0.3214 0.0195 0.6834 0.0378 0.606 
C10 0.0646 0.2988 0.1294 0.0212 0.0429 0.3705 0.0924 0.206 
C16 0.0251 0.6868 -0.0521 0.3549 0.0471 0.3253 0.0662 0.3656 
C18 0.0395 0.5252 0.0307 0.5861 0.0857 0.0732 0.1575 0.0305 
C10:2 0.0623 0.3159 -0.0265 0.6381 0.0226 0.6368 0.0527 0.4717 
C14:1 -0.0080 0.8975 0.0162 0.7737 0.0061 0.8989 0.0245 0.7384 
C14:2 0.0386 0.5351 0.0753 0.1813 -0.0124 0.7955 0.0428 0.5589 
C16:2 0.1088 0.0793 -0.0024 0.9666 0.0756 0.1144 0.0694 0.3427 
C18:1 0.0071 0.909 0.0256 0.6497 0.0381 0.4259 0.0555 0.4485 
C18:2 -0.0026 0.9673 -0.0216 0.7014 0.0261 0.5853 0.1223 0.0936 
Diacyl-Phosphatidylcholines       
PC aa C28:1 0.0731 0.2394 -0.0295 0.6011 -0.0525 0.2733 0.0805 0.2711 
PC aa C30:0 -0.0370 0.5522 -0.0662 0.2397 -0.0646 0.1773 0.0403 0.582 
PC aa C32:0 -0.0175 0.7787 -0.0436 0.4393 -0.0782 0.102 0.0802 0.2724 
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 Men Women 
 Estradiol Testosterone Estradiol Testosterone 
 (n=261) (n=317) (n=438) (n=189) 
 r p r p r p r p 
PC aa C32:1 -0.0055 0.93 -0.0556 0.3239 -0.0544 0.2558 0.0633 0.3866 
PC aa C32:2 -0.0073 0.9063 -0.1103 0.0499 -0.0742 0.1209 -0.0041 0.9556 
PC aa C32:3 -0.0015 0.9804 -0.0096 0.8644 -0.0872 0.0682 -0.0054 0.9414 
PC aa C34:1 -0.0107 0.8636 -0.0221 0.6951 -0.0368 0.442 0.0676 0.3556 
PC aa C34:2 0.0011 0.9864 -0.0366 0.5165 -0.0786 0.1004 0.0379 0.6044 
PC aa C34:3 -0.0013 0.9834 -0.0493 0.3813 -0.0669 0.1619 -0.0077 0.9158 
PC aa C34:4 -0.0343 0.5813 -0.1671 0.0028 -0.0725 0.1296 -0.0024 0.9741 
PC aa C36:0 0.0432 0.4871 0.0244 0.6658 0.0413 0.3889 0.1281 0.0791 
PC aa C36:1 -0.0305 0.6235 -0.0001 0.9989 -0.0060 0.9 0.0768 0.2936 
PC aa C36:2 -0.0391 0.5293 -0.0239 0.6712 -0.0151 0.7535 0.0966 0.1862 
PC aa C36:3 -0.0101 0.8714 -0.0596 0.2904 -0.0908 0.0577 0.0413 0.5722 
PC aa C36:4 -0.0468 0.4519 -0.1457 0.0094 -0.0646 0.177 0.0595 0.4161 
PC aa C36:5 0.0169 0.786 -0.0908 0.1066 0.0135 0.7785 -0.0911 0.2127 
PC aa C36:6 0.0322 0.6045 -0.1283 0.0223 -0.0172 0.7202 -0.0122 0.8673 
PC aa C38:0 0.0239 0.7004 0.0659 0.2423 0.0178 0.7107 0.1208 0.0978 
PC aa C38:1 0.0663 0.2861 0.0350 0.5343 0.1014 0.0339 -0.0075 0.9187 
PC aa C38:3 -0.0360 0.5632 -0.1298 0.0208 -0.0989 0.0385 0.0464 0.5257 
PC aa C38:4 -0.0961 0.1215 -0.1552 0.0056 -0.0293 0.5413 0.1004 0.1695 
PC aa C38:5 -0.0207 0.7394 -0.1236 0.0278 0.0265 0.5797 0.0046 0.9505 
PC aa C38:6 0.0629 0.3116 -0.1054 0.0608 0.0189 0.6936 0.0582 0.4263 
PC aa C40:2 -0.0082 0.8953 0.0087 0.8771 -0.0304 0.5252 -0.0363 0.6196 
PC aa C40:3 0.0343 0.5817 0.0162 0.7743 -0.0102 0.8316 -0.0105 0.8861 
PC aa C40:4 -0.0460 0.4591 -0.0916 0.1036 -0.0261 0.5861 0.0541 0.4598 
PC aa C40:5 -0.0126 0.8397 -0.1175 0.0366 0.0172 0.7198 0.0181 0.8045 
PC aa C40:6 0.0237 0.7037 -0.1267 0.024 0.0076 0.874 0.0764 0.2964 
PC aa C42:0 -0.0359 0.5637 0.0463 0.4113 0.0563 0.2396 0.0613 0.4025 
PC aa C42:1 0.0028 0.9637 0.0116 0.8376 0.0380 0.4272 0.1111 0.1281 
PC aa C42:2 -0.0180 0.7721 -0.0450 0.4251 -0.0115 0.8099 -0.0478 0.5139 
PC aa C42:4 -0.0422 0.4971 0.0319 0.571 -0.0401 0.4025 0.0425 0.5619 
PC aa C42:5 0.0584 0.3471 -0.0145 0.7971 0.0184 0.701 -0.0128 0.8616 
PC aa C42:6 0.0098 0.8749 -0.0297 0.5987 0.0157 0.744 -0.0604 0.4091 
Acyl-alkyl-Phosphatidylcholines      
PC ae C30:0 -0.0032 0.9587 0.0173 0.7597 0.0216 0.6522 0.0705 0.3351 
PC ae C30:1 -0.1057 0.0884 -0.0160 0.7769 -0.0643 0.1794 -0.0041 0.9559 
PC ae C30:2 -0.0704 0.2568 -0.0086 0.8783 -0.0486 0.31 0.1031 0.1581 
PC ae C32:1 0.0149 0.8102 0.1360 0.0154 0.0272 0.5702 0.0421 0.5654 
PC ae C32:2 0.0524 0.3994 0.0996 0.0767 0.0251 0.5998 0.1066 0.1445 
PC ae C34:0 0.0359 0.5641 0.0369 0.5127 -0.0092 0.8472 0.0565 0.4396 
PC ae C34:1 0.0183 0.7684 0.0887 0.115 -0.0098 0.8381 0.0565 0.4397 
PC ae C34:2 -0.0126 0.8398 0.1153 0.0402 -0.0054 0.9099 0.0417 0.5693 
PC ae C34:3 0.0337 0.5882 0.1451 0.0097 0.0145 0.763 0.0243 0.7396 
PC ae C36:0 -0.0189 0.7615 0.0106 0.8514 0.0569 0.2347 0.0879 0.2289 
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 Men Women 
 Estradiol Testosterone Estradiol Testosterone 
 (n=261) (n=317) (n=438) (n=189) 
 r p r p r p r p 
PC ae C36:1 0.0830 0.1815 0.0486 0.389 -0.0112 0.8157 0.0536 0.4637 
PC ae C36:2 0.0767 0.2166 0.0962 0.0874 0.0039 0.9358 0.0334 0.6487 
PC ae C36:3 -0.0128 0.8374 0.1194 0.0337 -0.0206 0.6672 0.0595 0.4158 
PC ae C36:4 -0.0480 0.4401 0.0027 0.9623 -0.0318 0.5069 0.1188 0.1034 
PC ae C36:5 0.0374 0.5472 0.0481 0.3938 -0.0017 0.9712 0.1075 0.141 
PC ae C38:0 0.0418 0.5013 -0.0492 0.3824 0.0246 0.607 0.0327 0.6549 
PC ae C38:1 0.0165 0.7913 0.0519 0.3573 0.0085 0.8585 0.0542 0.4588 
PC ae C38:2 0.0060 0.9232 0.0991 0.0782 0.0095 0.8422 0.0310 0.6722 
PC ae C38:3 0.0431 0.4882 0.0267 0.6355 -0.0416 0.3852 0.0159 0.8283 
PC ae C38:4 -0.0323 0.6039 0.0331 0.557 0.0183 0.7021 0.0776 0.2883 
PC ae C38:5 -0.0509 0.4132 0.0485 0.3892 0.0062 0.8973 0.1000 0.1709 
PC ae C38:6 0.0420 0.4991 0.0297 0.5989 0.0202 0.6733 0.0909 0.2135 
PC ae C40:1 -0.0664 0.2849 -0.0439 0.4357 0.0085 0.8592 0.0930 0.203 
PC ae C40:2 0.0699 0.2603 0.0479 0.3958 0.0128 0.7889 0.0203 0.7819 
PC ae C40:3 0.0022 0.9719 0.0866 0.1237 0.0530 0.2682 0.0400 0.5848 
PC ae C40:4 -0.0432 0.4876 0.0769 0.1719 0.0723 0.1307 0.0825 0.2594 
PC ae C40:5 -0.0329 0.5972 0.0590 0.295 0.0605 0.2064 0.0269 0.7135 
PC ae C40:6 0.0637 0.3052 0.0526 0.3507 0.0681 0.1548 0.0618 0.3986 
PC ae C42:1 -0.1190 0.0548 -0.0447 0.4275 -0.0111 0.8169 0.1341 0.0658 
PC ae C42:2 0.0396 0.5239 0.0029 0.9592 0.0823 0.0855 0.0702 0.3372 
PC ae C42:3 -0.0063 0.9192 0.0442 0.4327 0.0632 0.187 0.0889 0.2238 
PC ae C42:4 -0.0688 0.2685 0.1087 0.0533 0.0645 0.1777 0.0135 0.8542 
PC ae C42:5 -0.0517 0.4057 0.0808 0.1512 0.0692 0.1485 0.0487 0.5062 
PC ae C44:3 -0.0554 0.3723 -0.0194 0.7314 0.0330 0.4911 0.1556 0.0325 
PC ae C44:4 -0.0714 0.2503 0.1251 0.0259 0.0441 0.3574 0.0107 0.8834 
PC ae C44:5 -0.0837 0.1776 0.1122 0.046 0.0490 0.3058 0.0295 0.6873 
PC ae C44:6 -0.0595 0.3383 0.0744 0.1865 0.0326 0.4965 0.0631 0.3882 
Lyso-Phosphatidylcholines       
lysoPC a C14:0 -0.0757 0.2232 -0.1317 0.019 -0.0304 0.5264 -0.0208 0.7765 
lysoPC a C16:0 -0.0493 0.428 -0.1282 0.0224 -0.0636 0.1841 0.0857 0.241 
lysoPC a C16:1 -0.0149 0.8103 -0.0985 0.0799 -0.0284 0.5537 0.0422 0.5645 
lysoPC a C17:0 0.0512 0.4101 -0.0191 0.7347 0.0121 0.8008 0.0125 0.865 
lysoPC a C18:0 -0.0698 0.261 -0.0883 0.1168 -0.0161 0.7367 0.1158 0.1126 
lysoPC a C18:1 -0.0747 0.2291 -0.0066 0.9071 0.0217 0.65 0.0622 0.3955 
lysoPC a C18:2 -0.0654 0.2927 -0.0269 0.6334 0.0346 0.4697 0.0654 0.3713 
lysoPC a C20:3 -0.1070 0.0846 -0.1583 0.0047 -0.0647 0.1763 0.0722 0.3236 
lysoPC a C20:4 -0.1171 0.0588 -0.1425 0.0111 -0.0077 0.8732 0.1094 0.1341 
lysoPC a C28:1 -0.1333 0.0313 -0.0315 0.5768 -0.0216 0.6516 0.1016 0.1643 
Sphingomyelins         
SM C16:0 -0.0586 0.3456 0.0941 0.0945 0.0040 0.9333 0.0696 0.3415 
SM C16:1 -0.0090 0.8855 0.0376 0.5051 -0.0422 0.3788 0.0055 0.9399 
SM C18:0 -0.0445 0.474 0.0115 0.8391 -0.0384 0.4226 0.0823 0.2601 
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 Men Women 
 Estradiol Testosterone Estradiol Testosterone 
 (n=261) (n=317) (n=438) (n=189) 
 r p r p r p r p 
SM C18:1 -0.0314 0.6131 0.0128 0.8204 -0.0381 0.4261 0.0682 0.351 
SM C20:2 0.0318 0.609 0.0417 0.4598 -0.0241 0.615 -0.0230 0.7531 
SM C24:0 -0.1170 0.059 -0.0311 0.5817 -0.0859 0.0725 0.0058 0.937 
SM C24:1 -0.0407 0.5127 0.0977 0.0823 -0.0414 0.3879 0.0115 0.8751 
SM C26:0 -0.0531 0.3928 0.0627 0.2658 0.0404 0.3986 0.0195 0.7904 
SM C26:1 -0.0707 0.2551 0.0237 0.6739 -0.0282 0.5556 -0.0052 0.9438 
SM (OH) C14:1 0.0953 0.1247 0.0966 0.086 0.0003 0.9959 0.0711 0.331 
SM (OH) C16:1 0.0354 0.5691 0.0889 0.1142 0.0068 0.8865 0.0826 0.2583 
SM (OH) C22:1 -0.0560 0.3676 0.0317 0.5739 -0.0520 0.2775 0.0203 0.7819 
SM (OH) C22:2 0.0137 0.8255 0.0866 0.1238 -0.0308 0.5199 0.0009 0.9905 
SM (OH) C24:1 -0.0542 0.3831 0.0027 0.9622 -0.0185 0.6999 0.0345 0.6377 
Abbreviations: PC, phosphatidylcholine; a, acyl; e, alkyl; SM, sphingomyelin 
